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Amyotrophic lateral sclerosis (ALS) is a major neurodegenerative disease caused by 
the death of motor neurons leading to paralysis. Mechanisms underlying the 
pathogenesis of the disease remain unknown but with the identification of causative 
genes from ALS patients, some processes have been linked to the disease. One of 
these genes is VAPB, a highly conserved protein involved in lipid transfer, vesicle 
metabolism and synaptic morphology. We modeled in Drosophila the disease-linked 
P56S mutation (DVAP-P58S) and observed with the expression of this allele 
neurodegeneration in the eye and loss of motor performance. These phenotypes 
provide an excellent opportunity to use fly’s genetics to find novel genetic interactors 
of DVAP and understand ALS pathomechanism. Therefore, we carried out a large 
scale genetic screen by crossing the ALS model with a collection of P-element 
overexpression lines. After the analysis of 1183 lines, we obtained 71 modifier lines 
that suppress DVAP-induced neurodegeneration and 14 lines that enhance this 
phenotype, decreasing furthermore the eye size and viability of the offspring. To 
confirm that the effect of modifier lines was caused by a specific gene, we validated 
them with independent alleles of those genes. Using different sources, we were able 
to confirm the effect of 63 of the 85 modifiers, providing a strong confirmation of 
their effect. When we studied the effect of the modifier genes co-expressed with 
DVAP-P58S in the nervous system, we detected that 46 lines presented the same 
modifying effect in adult viability and 58 in the motor performance of the adult 
offspring. Considering the stronger readouts, we obtained 42 genes as novel high 
confidence DVAP genetic interactors. To understand furthermore the way they are 
affecting DVAP neurodegeneration, we carried out a series of bioinformatic analyses 
using Drosophila and human databases. Lipid droplets, vesicle metabolism and cell 
proliferation appear as the most important categories found in the screen, all 
processes conserved when analysed with human orthologs of the modifiers. Further 
characterisation of the endocytosis-linked modifier Rab5 and the predicted DVAP-
interactors Rab7 and Rab11, showed that the suppression effect is not only 
confirmed in vivo but is also conserved in human tissue from ALS patients. These 
data validate our genetic screen and at the same time open novel opportunities to 
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1.1 Amyotrophic lateral sclerosis and motor neuron diseases 
 
Amyotrophic lateral sclerosis (ALS) is a progressive adult-onset disorder, 
characterized by the selective death of upper and lower motor neurons leading to 
paralysis and muscle atrophy (Pasinelli & Brown, 2006). Most clinical symptoms 
appear when axons show retraction and denervation, effect slowered through 
subsequent lateral sprouting and reinnervation. After the failure of this last response, 
neurons die leading to development of the disease (Robberecht & Philips, 2013). 
ALS is the most common motor neuron disease and one of the major 
neurodegenerative diseases alongside Alzheimer’s disease and Parkinson’s disease, 
with an incidence rate of 1-2 per 100,000 people affected per year and a uniform 
distribution in Europe of 2.16 per 100,000 persons (Kiernan et al., 2011). 
 
 The overall population-based lifetime risk of ALS is 1:400 for women and 
1:350 for men. The peak age at onset is 58–63 years for sporadic disease and 47–52 
years for familial disease (Kiernan et al., 2011). In most cases, respiratory failure 
causes the death of patients usually within 5 years after the onset of clinical 
symptoms (Pasinelli & Brown, 2006). These include limb spasticity, fasciculation 
and weakness, slow and distorted speech caused by bulbar dysfunction, and defects 
in bulbar lower motor neurons, leading to tongue wasting and dysphagia (Kiernan et 
al., 2011). Evaluations of all these symptoms are required to distinguish between 
different ALS types and other pathologies with similar symptoms as 
endochrinopathies, infections and intoxication (Kunst, 2004). 
 
 Studies of familial cases of ALS (fALS) have identified thirty genetic loci as 
causative to the disease (Figure 1), including among others, mutations in the genes 
VAPB, ALS2, TARDBP and SOD1 (Nishimura et al., 1994; Hadano et al., 2001; 
Neumann et al., 2006; Rosen et al., 1993). Mutations in these genes share the same 
pathological features as sporadic ALS (sALS), which represent 90% of the cases 
(Chen et al., 2010) (Figure 1). The diversity of gene functions means that different 
processes have been implicated in the pathogenesis of ALS, including apoptosis, 








Figure 1. ALS causative genes. (A) Timeline of gene discoveries in familial and 
sporadic ALS. Values represent the proportion of ALS explained by each gene in 
populations of European ancestry. In the charts at the right, percentages represent the 
amount of cases explained by known genetic mutations. Taken from Renton et al., 
2013. (B) Genes thought to cause or increase risk of ALS and their location in the 






Rothstein, 2001). However, even considering all these functions, the molecular 
mechanism underlying this disease remains elusive. The study of these individual 
pathways and the search and characterisation of new causative genes are the best 
way to move forward in the comprehension of the disease. 
 
1.2 ALS causatives genes  
 
1.2.1 Cu/Zn-superoxide dismutase (SOD1) 
 
Twenty years ago, Rosen et al. (Rosen et al., 1993) linked for the first time genetic 
mutations with ALS. Thirteen different families showed different mutations in the 
gene that encodes the cytoplasmic copper/zinc-binding superoxide dismutase SOD1, 
an enzyme that catalyses the conversion of the toxic O2
- 
anions into O2 and H2O2. 
Being the first gene associated with the disease, several studies in patients have 
found more than 100 mutations throughout the years, but only a subset of these 
mutations shows a link to a pathogenic effect of the protein (Andersen et al., 1996). 
Also, these mutations, which account for over 10% of all the familial cases of the 
disease (Chio et al., 2008), exhibit a broad range of phenotypes and penetrance. 
These effects stretch from the one caused by the aggressive A4V allele that leads to 
death in less than one year from the symptom onset, to the milder D90A form, which 
causes respiratory failure only after 10 years of the onset (Andersen et al., 1996). 
 
 SOD1 is an important protein in the respiratory metabolism, involved in free 
radical scavenging. However, pathogenesis caused by the mutation does not seem to 
be associated with a loss-of-function mechanism, but more likely to an increase in 
the aggregation and misfolding of the protein (Robberecht & Philips, 2013). Most 
SOD1 mutations are missense and not truncations, suggesting that most of the 
protein length must be present in the cell to trigger a pathogenic effect. Misfolded 
SOD1 proteins carrying these mutations escape from ubiquitylation process and 
affect proteasomal pathway and autophagy clearance pathways (Bendotti et al., 
2012; Chen et al., 2012). 
 
17 
 Misfolded protein aggregates cause failure of several cellular processes and 
trigger ER stress response and apoptotic signals (Pasinelli & Brown, 2006). 
Processes related to SOD1 toxicity include axonal transport and cytoskeleton defects 
(Williamson & Cleveland, 1999; Farah et al., 2003), DNA/RNA metabolism 
(Pasinelli & Brown, 2006) and mitochondrion dysfunction (Pasinelli et al., 2004). 
However, all these processes seem to be related to protein stability and aggregation 
more than to the original function of the enzyme and its lack of function in the 
affected cell (Pasinelli & Brown, 2006). The relevance of the aggregation in the 
death of cells has led to several studies to propose SOD1 as a potential prion-like 
protein. In this hypothesis, a misfolded version of SOD1 would seed the 
transformation of wild-type SOD1 into fibrils that can be then transmitted to other 
cells. These fibrillar species represent a toxic state of the protein that would lead to 
cellular death, developing the whole pathology (Chia et al., 2010; Grad et al., 2011). 
These novel features, far from elucidating the complex genetics of SOD1 mutations, 
open extra questions in terms of cross-seeding process, exportation of the toxic 
aggregates to other cell types and discrimination between toxic and wild type forms 
of the protein (Polymenidou & Cleveland, 2011). 
 
 Different animal models have been generated to understand SOD1-induced 
pathogenesis, but none of them has completely clarified the picture. Studies with the 
first SOD1 transgenic mouse elucidated relevant interactions and cellular 
mechanisms (Pasinelli et al., 2004) but the model has failed as a target of proposed 
human therapies (Ludolph et al., 2010). Wang et al. observed that overexpression of 
wild-type version of SOD1 accelerated the disease onset and pathogenesis in mice 
expressing a mutant form of the protein (Wang et al., 2009).  They suggest that 
wild-type SOD1 may be recruited to toxic aggregates caused by the mutant version. 
Other rodent models however, have not improved these aspects (Turner & Talbot, 
2008) and currently, SOD1-ALS is treated independently of other types of ALS, 
mainly for its absence of TDP43-related phenotypes (Renton et al., 2013). Watson et 
al. generated the first Drosophila model for SOD1 and observed motor defects, 
upregulation of the heat shock protein 70 and reduction of synaptic transmission. 
These phenotypes are also present when the wild type form of the protein is 
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overexpressed (Watson et al., 2008). However, no effect was observed in motor 
neuron survival and life span. Expression of three different ALS-related SOD1-
mutations in C. elegans also showed aggregates formation and mild cellular 
dysfunction. Interestingly, this toxicity was enhanced when proteins that destabilize 
the cellular folding machinery were co-expressed. This indicates that SOD1 toxicity 
may not be completely dependent of its own misfolding activity but also depends on 
genetic interactions with other cellular pathways (Gidalevitz et al., 2009). 
 
1.2.2 Transactive response DNA-binding protein (TDP-43) and 
Fused in sarcoma (FUS) 
 
RNA processing dysfunction appeared to be a cause of ALS pathogenesis when the 
Transactive response DNA-binding protein (TARDBP, TDP-43) was found to be a 
major component of ALS-associated protein aggregates in neurons (Neumann et al., 
2006). Mutations in this gene account for 4% of ALS familial cases (Sreedharan et 
al., 2008) and since the original discovery in 2006, several other mutations have been 
linked to sporadic cases of ALS and FrontoTemporal dementia (FTD). TDP-43 is a 
protein involved in RNA processing that normally presents a nuclear localisation but 
shuttles to cytoplasmic protein aggregates where then blocks mRNA translation as a 
response to starvation or oxidative stress (Dewey et al., 2011). In ALS patients, the 
protein is located mostly in stress granules, which are cytoplasmic aggregates 
composed by proteins and inactive mRNA and induced by cellular stress. TDP-43 
translocation to these structures potentially initiates neurodegenerative effects in 
neurons and glia (Ferraiuolo et al., 2011). 
 
 One hypothesis that explains TDP-43 toxicity highlights the exact amount of 
protein needed for the normal function of TDP-43. ALS-linked mutations enhance 
the aggregation ability of the protein, increasing toxic aggregation and formation of 
stress granules that includes also the wild-type form of the protein in a gain-of-
function mechanism. This translates at the same time, in the decrease of the TDP-43 
amount available in the nucleus, implying a loss of TDP-43 normal function as an 
RNA processing protein (Johnson et al., 2009; Blokhuis et al., 2013) This two-step 
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gain-of-function/loss-of-function mechanism may be related to functions of other 
proteins and has been proposed as a central explanation for ALS pathomechanism 
(Robberecht & Philips, 2013). 
 
 The discovery of Fused in Sarcoma (FUS) as an ALS causative gene also 
fortified the role of RNA metabolism in the disease (Vance et al., 2009; 
Kwiatkowski et al., 2009). This protein, just as TDP-43, is involved in 
transcriptional regulation and RNA processing. FUS ALS-linked mutations generally 
alter the nuclear localisation of the protein, inducing the formation of FUS 
aggregates in the cytoplasm (Dormann et al., 2010). Just as in the case of TDP-43, 
the mechanism underlying the disease is not known and it can be due to a 
combination of loss of FUS nuclear function and gain of toxic function in the 
cytoplasm. 
 
 Compared to SOD1, TDP-43 animal models have been more successful 
mirroring hallmarks of the disease, but they still do not provide a complete picture of 
the disease mechanism. Neuromuscular phenotypes and motor dysfunction have been 
observed in Drosophila, zebrafish and mice models (Feiguin et al., 2009; Laird et al., 
2010; Kraemer et al., 2010). In rodent models toxicity phenotypes have been 
detected with the overexpression of mutants and wild type versions of the protein, 
implying that TDP-43 pathogenesis may be dosage dependent (Stallings et al., 2010). 
In zebrafish and fly models however, mutant TDP-43 overexpression causes a 
greater degeneration than the wild type version (Liachko et al., 2010; Laird et al., 
2010). An interesting result was observed in a conditional rat model that presented 
motor performance dysfunction when TDP-43 was overexpressed. The observed 
paralysis was however, suppressed in the same animal when the overexpression was 
transiently removed, result that can give insights into a potential reversible 
pathogenic effect of the protein (Huang et al., 2012). 
 
 The association of TDP-43 and RNA metabolism with the disease changed the 
initial idea of a disease based exclusively on protein dysfunction. At the same time 
this protein linked even more ALS and FTD as similar genetic diseases. The 
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connection between the two diseases and the relevance of RNA processing as an 
associated pathway in the diseases were supported later on with the identification of 
novel mutations in other RNA metabolism-related genes such as C9orf72 
(Robberecht & Phillips, 2013). 
 
1.2.3 Chromosome 9 open reading frame 72 (C9orf72) 
 
An important shift in the research of the ALS occurred a couple of years ago when 
two different groups reported that in the genetic locus C9orf72, a GGGGCC 
hexanucleotide repeat expansion was the cause of the ALS and FTD cases linked to 
the chromosomal region 9p21 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). 
This breakthrough constituted the first time that a repeat expansion is linked to ALS 
but more importantly, this expansion appeared to be the most frequent cause of the 
disease. Only considering the familial cases, expansions in C9orf72 now account for 
up to 48% of the ALS cases (Woollacott & Mead, 2014). Interestingly, expansions in 
this gene are also linked to 25% of the familial FTD cases, explaining genetically the 
overlap between these two diseases (Majounie et al., 2012). 
 
 The increasing relevance of this protein in the disease has not been translated 
yet to a definitive pathomechanism. C9orf72 function is not clear yet, but in silico 
research suggested that it may be related to Differentially Expressed in Normal and 
Neoplasia (DENN), a GDP/GTP exchange factor (GEF) protein that regulates Rab-
GTPases activation and vesicular trafficking (Levine et al., 2013). Patients with 
ALS-carrying expansions in the gene show RNA foci, also found in TDP43-linked 
patients. RNAi foci suggest a link to RNA metabolism disruption and sequestering of 
RNA binding proteins (DeJesus-Hernandez et al., 2011) but the mechanism in which 
hexanucleotide are toxic in neurons still has not been completely understood. 
Recently however, the link between C9orf72 and endocytic transport was confirmed 
in vivo, suggesting that the role of this protein in RNA metabolism and protein 
degradation may be an important pathway in ALS pathogenesis (Farg et al., 2014)   
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 A current hypothesis for hexanucleotide toxicity involves the disorganised 
recruitment of splicing factors during the C9orf72 mRNA production, which 
translates in a loss-of-function mechanism. The presence of RNA G-quadruplexes, 
guanine-rich nucleic acids sequences that form four-stranded structures (Bugaut and 
Balasubramanian, 2012), alters the RNA splicing and disrupts the production of one 
of the three mature transcripts for this gene. At the same time, this expansion can 
generate toxic insoluble dipeptide repeats that may affect in a direct form the cellular 
metabolism in a gain-of-function mechanism (Fratta et al., 2012; Robberecht & 
Philips, 2013). This hypothesis implies two different mechanisms for the C9orf72-
linked toxicity, with loss- and gain-of-function mechanisms. These are not mutually 
exclusive but still unclear whether both of them contribute to the degeneration and 
how they are connected to other ALS-linked mutations.  
 
 Considering the recent discovery of C9orf72 as an ALS causative gene, big 
efforts have been made to construct animal models and characterise the effect of the 
hexanucleotide repeat expansion.  So far, studies have shown that loss-of-function 
of C9orf72 is linked with motor deficits in zebrafish (Ciura et al., 2013) but also that 
a decrease of 70% of its transcription is not enough to produce a phenotypic effect in 
mice (Lagier-Tourenne et al., 2013). Even though there is not a Drosophila 
homologue for C9orf72, strong structural homology can be found with other DENN-
like proteins (Stepto et al., 2014). Additionally, studies have related overexpression 
of G4C2 hexanucleotide repeats with neurodegeneration in Drosophila eye and motor 
neurons (Xu et al., 2013). The confirmation of these results in Zebrafish, where 
RNAi foci were also found (Lee et al., 2013) supports the idea of animal modeling. 
However the lack of strong evidence suggests a long period before complete 
characterization of the C9orf72 pathomechanism.  
 
1.2.4 Alsin (ALS2) 
 
ALS2 is one of the three genes causative of a juvenile form of ALS (altogether with 
SETX and SPG11) and also the only one where recessive loss-of-function mutations 
are responsible for the disease. Mutations in this gene, identified originally in a 
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Tunisian family in 2001 (Hadano et al., 2001), are also associated with other MNDs 
but they represent less than 1% of known ALS cases (Hadano et al., 2007). ALS2 
protein has multiple domains associated with regulation of small GTPases, including 
Rac, Rho and Rab families. Small GTPases function as molecular switches, changing 
from a GTP-bound active state to an inactive GDP-bound state. This GTP-depending 
control is regulated also by the guanine nucleotide exchange factor (GEF) and 
GTPase activating protein (GAP) proteins, which improve the GTP binding and 
hydrolysis respectively (Zhang et al., 2007). In vitro, ALS2 shows a GEF activity on 
Rab5, through its VPS9-containing C-terminal domain. The presence of the vacuolar 
protein sorting 9 (VPS9) domain suggests an involvement of ALS2 in membrane 
dynamics and cytoskeletal structure of the cell (Hadano et al., 2007).  
 
 ALS2 is also related to ALS because of its interaction with SOD1. ALS2 binds 
mutant but not wild type forms of SOD1, through its RhoGEF domain (Kanekura et 
al., 2004). Morever, ALS2 suppress SOD1-induced toxicity in a mouse model, 
activating Rac1 and the PI3K/Akt prosurvival pathway (Kanekura et al., 2005). A 
parallel work confirmed this finding reporting an exacerbation of motor dysfunction 
in a SOD1 mutant by loss of ALS2 function (Hadano et al., 2010).  
 
1.2.5. Other causative genes 
 
A constantly increasing number of at least 30 genetic loci have been associated with 
ALS so far (Robberecht & Philips, 2013). Some of these loci have not been 
completely validated and others have been strongly linked with other similar 
syndromes. Nevertheless, detailed study of each of these genes can potentially 
provide important clues and connections to understand the disease mechanism. 
 
 Found originally in Japanese families (Maruyama et al., 2010), mutations in 
Optineurin (OPTN) were also associated with other disorders not closely linked to 
ALS such as primary open angle glaucoma and Paget’s disease of bone (Rezaie et 
al., 2002; Albagha et al., 2010). The molecular function of OPTN is related to 
protein secretion, membrane trafficking and cell division. The recent association of 
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the gene with ALS and the low frequency in the total of familial cases (lower than 
1%) translate in a lower interest in the characterisation of OPTN pathomechanism at 
the moment. 
 
 Other gene found mutated in only 1% of the familial ALS cases is the Valosin-
containing protein (VCP). Connected to the disease for the first time in 2010 
(Johnson et al., 2010), mutations in VCP were previously linked with FTD (Watts et 
al., 2004) supporting furthermore the similarities between this disease and ALS. 
These mutations seem to affect the respiratory metabolism and levels of ATP 
produced due to mitochondrial uncoupling (Bartolome et al., 2013). The mechanism 
recapitulates deficiencies observed with SOD1 mutations, indicating that different 
causative genes can be involved in converging pathways. Interestingly, the discovery 
of VCP mutations in 2010 was the first obtained using exome sequencing of affected 
patients, a technique that will help to study known and novel mutations in families 
without abundant availability of genetic data (Renton et al., 2013).  
 
 UBQLN2 and SQSTM1 that encode Ubiquilin 2 and p62 respectively, are two 
genetic loci associated with protein degradation, which were recently linked to less 
than 1% of patients with the disease (Deng et al., 2011; Gal et al., 2009). P62 directs 
and ubiquilin transports polyubiquitinated proteins to the protein degradation 
systems ubiquitin-proteasome and autophagy. In this way, p62 and ubiquilin link 
these two systems and accentuate the relevance of this pathway in the disease 
pathogenesis (Ling et al., 2013). Protein aggregation and accumulation appear as an 
important cause of neurodegeneration for most ALS-linked mutations. Therefore, the 
presence of UBQLN2 and SQSTM1 in protein inclusions found in ALS patients 
provides extra evidence for that mechanism (Ling et al., 2013). Whether protein 
aggregation is an initial trigger or a consequence of toxicity caused by other proteins 
is not completely understood although. 
 
 Finally, an important group of genes is associated with cellular transport 
defects, a cause also related to the most studied loci (Ferraiuolo et al., 2011). Only 
two years ago, mutations in Profilin 1 (PFN1) were found in several ALS kindred 
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(Wu et al., 2012). This gene plays an important role in cytoskeletal architecture, 
functioning as an actin-monomer binding protein (Witke, 2004). PFN1 also interacts 
with VCP, the spinal muscular atrophy causative gene SMN, and Huntingtin, the 
causative of Huntington’s disease. This suggests that cytoskeleton regulation can be 
a misregulated pathway shared between different disorders (Wu et al., 2012). 
Mutations in Dynactin (DCTN), Neurofilament heavy polypeptide (NEFH), 
phosphoinositide phosphatase (FIG4), Charged multivesicular body protein 2b 
(CHMP2B) and peripherin (PRPH) have all been linked to ALS (Munch et al., 2004; 
Figlewicz et al., 1994; Chow et al., 2009; Parkinson et al., 2006; Gros-Louis et al., 
2004). These genes are connected to both axonal and vesicular transport in neurons. 
However, despite the fact that all of them could potentially be part of a crucial 
mechanism to explain the disease, these genes have been less studied than the 
previously mentioned causative loci. The lack of patients carrying a mutation in this 
group of genes has been associated with a lower relevance in the whole picture of 
ALS mechanism. This tendency can be risky if we consider that they may possess an 
equally high importance in the disease pathogenesis and their underestimation in 
favour of the most studied genes can lead to an incomplete map of the disease. 
Commonalities between the previously mentioned neurodegenerative disorders could 
be explained by similar pathomechanisms, where all these described causative genes 
should play an important role. A similar situation is observed with mutations in the 
protein VAPB, a transport-related protein that will be the central focus of this study. 
 
1.3 VAP proteins 
 
Vesicle-associated membrane protein (VAMP) associated protein, VAP, is another 
important ALS-linked protein. A mutation in this gene was first isolated from an 
ALS Brazilian kindred and therefore, research with animal models and patients have 
increased in the last decade. VAP relevance in several key cellular processes has 
transformed this protein in a crucial player in different mechanisms associated with 




1.3.1 VAP primary organization exhibits three conserved domains 
 
First isolated from Aplysia californica (Skehel et al., 1995), VAP-33 was proposed 
to be a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor) associated protein. These proteins are relevant in synaptic fusion (Lev et 
al., 2008) and autophagic degradation and regulation (Furuta et al., 2010).  
 
 After being identified in Aplysia, VAP genes were found in humans (Weir et 
al., 1998), mice (Nishimura et al., 1999), Drosophila (Pennetta et al., 2002), yeast 
(Loewen et al., 2003) and C. elegans (Tsuda et al., 2008). This highly conserved 
gene has two isoforms in mammals, VAPA and VAPB. A third one, VAPC, was found 
to be a shorter splicing variant of VAPB without known data of expression or 
function (Nishimura et al., 1999). VAP proteins are ubiquitously expressed in 
tissues, organs and cell types with a higher expression in the nervous system (Skehel 
et al., 2000). In the human nervous system, five splice variants of VAPB have been 
found but the alternative versions are barely detected and quickly degraded through 
the proteasomal system (Nachreiner et al., 2010).  
 
 VAP proteins share highly conserved sequences and three relevant domains 
(Figure 2). Facing the cytoplasm, the N-terminal region exhibits a sequence that is 
highly similar functionally and structurally to C. elegans Major Sperm Protein 
(MSP) (Kuwabara, 2003). MSP is a dimeric protein that forms non-polar 
cytoskeletan filaments and mediates amoeboid motility. The dimerization of 
recombinant MSP domain observed in VAPB suggests that this domain may 
contribute to VAP oligomerisation (Lev et al., 2008). Inside this MSP domain, there 
is a FFAT (diphenylalanine in an acidic tract) binding site formed by the consensus 
aminoacid sequence EFFDAxE. FFAT works as a targeting signal motif and 
localises proteins to the cytosolic side of the ER and nuclear membranes (Kaiser et 
al., 2005). FFAT binding site is highly conserved among VAP proteins but not in 
MSP proteins, indicating that this sequence activity is important for VAPB biological 











Figure 2. VAP proteins sequence and conserved domains. (A) Predicted domains 
in VAP proteins: major sperm protein (yellow), coil-coiled (brown) and 
transmembrane domains (blue). The high degree of homology in the VAP consensus 
(pale green box) and transmembrane (pale blue box) sequences are specified for 
different species. The three ALS-linked mutations (gray box) are presented in these 
conserved sequences. (B) Alignment of the sequences from human VAPB (hVAPB) 
protein and its Drosophila orthologue DVAP. Asterisks indicate an identity match; 
colons indicate conservation between amino acids with strongly similar properties 
and periods indicate a conserved substitution between amino acids with weakly 
similar properties. Red boxes highlight the amino acid residues changed by the ALS8 




 The central part of the protein shows a variable coiled-coil domain (CCD) that 
is also present in other VAMPs and SNARE proteins (Nishimura et al., 1999). 
VAPA and VAPB form homo- and hetero-dimers mediated by both the CCD and the 
dimerization site located in the C-terminal transmembrane region of the protein. The 
similarity of VAP protein in the transmembrane region also is less conserved from 
yeast to humans compared to the MSP domain. The GxxxG dimerisation site is 
present from humans down to C. elegans and the lack of this sequence in the yeast 
VAP homolog explains its failure to form dimers (Russ & Engelman, 2000).    
 
 Different studies have found that VAP proteins localize in the ER and several 
other intracellular membrane such as endosome, Golgi, neuromuscular junction and 
plasma membrane (Lev et al., 2008). ER membranes can reach mostly every 
intracellular organelle through membrane conctact sites or ER junctions, explaining 
in this way the multiple localisation of VAP proteins (Levine and Loewen, 2006). 
Through these junctions, VAPB can regulate not only ER structure but also calcium 
homeostasis at the mitochondria and lipid transfer at the Golgi (De Vos et al., 2012; 
Peretti et al., 2008). VAPB mutations that lead protein aggregation disrupt the 
normal VAPB localization. The formation of aggregates in immobile ER clusters  
(Teuling et al., 2007) and in non-ER compartments (Kanekura et al., 2006) explains 
the toxicity and associate neurodegeneration of this structural change of the protein.  
 
1.3.2 VAP functions affect several cellular processes 
 
VAP proteins are linked with several important cellular processes including lipid 
transfer, vesicular trafficking, synaptic regulation, calcium metabolism and ER 
morphology (Amarilio et al., 2005; Teuling et al., 2007; Soussan et al., 1999; Skehel 
et al., 2000; Kuijpers et al., 2013).  A relation between VAP proteins and lipid 
transfer was originally observed in the yeast homologue SCS2. Opi1p, a 
transcriptional regulator of phospholipid biosynthesis, binds SCS2 through its FFAT 
domain. This binding was proposed as a common ER targeting mechanism for lipid-
related proteins containing FFAT motif (Loewen et al., 2003). Following this, 
different groups reported interactions between VAP and the FFAT motif-containing 
28 
proteins Oxysterol-binding protein (OSBP), ceramide transport protein (CERT) and 
phosphatidylinositol transfer protein (Nir2) (Wyles et al., 2002; Kawano et al., 2006; 
Amarilio et al., 2005). Last year, we characterised the interaction between the 
Drosophila VAPB homologue and the phosphoinositide phosphatase Sac1 (Forrest et 
al., 2013).  Phosphoinositides (PI) are lipids that localise in specific cellular 
organelles according to their reversible phosphorylation state. Each one of these lipid 
pools can bind specifically different effector proteins regulating their intracellular 
concentrations (Blagoveshchenskaya & Mayinger, 2008). Sac1 is an evolutionarily 
conserved protein that mainly dephosphorylates PI4P pools, affecting actin 
organization and sphingomyelin synthesis (Foti et al., 2001; Brice et al., 2009). 
Drosophila DVAP is necessary to regulate phophoinositide levels through its 
interaction with Sac1, and the lack of this complex affects synaptic structure and 
causes neurodegeneration (Forrest et al., 2013). OSBP and CERT interacts in the ER 
with VAPB through their pleckstrin homology domain (PH), and with the Golgi-
specific PI4P pool through their FFAT motif. Disruption of the Sac1/DVAP complex 
could potentially alter not only phosphoinositide metabolism but also sphingolipid 
and sterol metabolism, regulated by CERT and OSBP proteins respectively 
(Raychaudhuri & Prinz, 2010, Forrest et al., 2013).  
 
 Calcium homeostasis is another process regulated by VAPB. Wild type version 
of the protein interacts with the tyrosine phosphatase-interacting protein 51 
(PTPIP51), an outer mitochondrial protein implicated in cell morphology and 
apoptosis (De Vos et al., 2012). The mutant version of VAPB found in patients with 
ALS (VAPB-P56S) does not show interaction with PTPIP51, increasing the 
mitochondrial calcium uptake obtained from ER reservoirs. VAPB-P56S also 
disrupts Ca
++ 
concentrations by the disruption of the mitochondrial Rho GTPase-1 
Miro1/kinesin-1 complex. Affected binding affinity of Miro1 for tubulin leads to 
failure of anterograde axonal mitochondria transport, a phenotype also observed in 
the ALS-linked mutations of SOD1 (Morotz et al., 2012). Calcium homoeostasis has 
been underlined as a possible explanation of the selective neuronal vulnerability. 
Specifically, motor neurons are more susceptible to calcium-overload due to limited 
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expression of the calcium-regulator glutamate receptor 2 (GluR2) (Van Damme et 
al., 2007) and reduced calcium-buffering capacity (Vanselow & Keller, 2000). 
 
 Most VAP interactors are located at the ER, a fact that underlines the relevance 
of the protein in this organelle’s function. ER-Golgi recycling protein YIF1A is a 
VAPB interactor that regulates intracellular trafficking into dendrites and ER 
morphology (Kuijpers et al., 2013). Mutant VAPB disrupts this regulation and 
affects the localisation of both proteins. Alteration of the ER structure was also 
shown to be a consequence of VAPB-P56S-mediated aggregates that affect wild type 
VAPB availability and its interaction with other ER proteins (Teuling et al., 2007; 
Fasana et al., 2010). Increase of VAPB-associated inclusions was observed by down-
regulating the ATPase VCP, another ALS-linked protein (Johnson et al., 2010) and 
reduction of non-aggregated VAPB levels is one of the features shared with SOD1 
mutant cells, another aggregation-prone ALS-causative protein (Teuling et al., 
2007). 
 
 Recently, VAPB was also linked to cell growth and cancer. When primary and 
metastatic breast tumor were analysed, VAPB appears overexpressed and this 
increase in mRNA levels correlates with a lower survival in patients with breast 
cancer (Rao et al., 2012). Authors not only observed cell growth or inhibition with 
VAPB up- or down-regulation respectively, but also showed that modulation of AKT 
mediates this growth regulation. AKT forms part of a pathway altogether with 
mTOR and PI3K, which regulates phosphoinositide metabolism, autophagy and cell 
survival (Bitting & Armstrong, 2013; Fruman & Rommel, 2014). As mentioned 
before, VAPB is tightly associated with phosphoinositide metabolism; therefore, this 
study can present a still unknown relevance of VAPB in cell growth and cancer. 
 
1.3.3 VAP MSP domain is cleaved and secreted  
 
A recent hypothesis for VAP function suggests that the N-terminal MSP domain is 
secreted to regulate energy metabolism in muscles (Tsuda et al., 2008; Han et al., 
2012; Han et al., 2013). This highly conserved domain has been deeply studied in C. 
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elegans where it works as signaling molecule that controls oocyte maturation and 
fertility (Miller et al., 2003). In Drosophila, Tsuda et al. showed that the DVAP-
MSP domain is cleaved and secreted to bind postsynaptic Eph receptors. The ALS-
linked DVAP mutation disrupts the cleavage of the domain and triggers the protein 
accumulation (Tsuda et al., 2008). The same group later proved that the secreted 
MSP domain binds to Roundabout and Lar-like protein-tyrosine phosphatase 
receptors in muscles. These growth cone guidance pathways regulate actin 
remodeling and mitochondrial localisation via Arp2/3 complex. Therefore, secretion 
of DVAP-MSP domain can support energy production and ALS-linked VAP mutants 
can affect mitochondrial metabolism deregulating localisation and function of the 
protein (Han et al., 2012). 
 
 Recently, the same authors proposed that an up-regulation of the FoxO 
pathway could compensate the metabolic dysfunction caused by the lack of VAPB-
MSP domain secretion (Han et al., 2013). DAF-16, the C. elegans FoxO homolog, 
presents an up-regulation when secreted MSP is low. This transcription factor 
activates ATP and triacylglycerol production in muscles, increasing lifespan and 
compensating VAPB-associated energy metabolism defects. DAF-16 acts 
downstream of Arp2/3 complex, therefore the up-regulation of the transcription 
factor and its fat-related downstream targets could explain the observed lipid 
accumulation in muscles and the recovery of mutants phenotypes observed in their 
previous work. 
 
 Lipid accumulation is an important aspect observed in VAPB related 
phenotypes. However, these previous works have not elucidated completely the 
implication of MSP domain secretion with lipid metabolism. Other lipid-related 
VAPB interactors may play an important role in the final mutant phenotype in a 





1.3.4 VAP interacting proteins include lipid- and synapsis-related 
proteins 
 
The structure of VAP proteins and the presence of conserved domains facilitate an 
important number of interactions with other proteins. Mostly, these have been found 
in high-throughput approaches aimed at finding VAPB physical interactors in 
different organisms. However, VAPB genetic interactors have been not extensively 
characterized so far. In S. cerevisiae, different studies have found physical interactors 
of the yeast VAP homologue, Scs2p, including the proteins Num1, Rpn10 and the 
lipid-related proteins Stt4, Osh1, Osh2 and Erg2, 9 and 11 (Kagiwada & Zen, 2003; 
Chao et al., 2009; Wilson et al., 2011; Manford et al., 2012). Most interactors 
originally were linked to the group of SNARE proteins, triggered by the initial 
finding that VAPB interacts with the synaptic SNARE VAMP (Lev et al., 2008). 
Therefore, other proteins related to synaptic vesicles were found as VAPB interactors 
such as Rbet1, Rsec22, tSNARe, NSF and SNAP (Weir et al., 1998). 
 
 However, the most characterised VAPB interactions are the ones with proteins 
containing the FFAT-motif. The interaction in yeast between Sc2 and Opi1p, a 
transcriptional regulator of phospholipid synthesis, was the first link between VAP 
proteins and lipids (Lowren et al., 2003). Later, this was supported by the 
confirmation of the interaction of VAP proteins and the previously discussed lipid-
related proteins OSBP, CERT and Nir2. 
 
 Other studies have found genetic interactors in genes related to processes 
including autophagy, vesicle and nuclear migration, GTP exchange and lipid 
metabolism (Costanzo et al., 2010; Schuldiner et al., 2005; Aguilar et al., 2010). 
According to the Biological General Repository for Interaction Datasets, BioGrid 
(Chatr-aryamontri et al., 2012) 313 unique interactions have been found only in yeast 
and some of these proteins have been confirmed in more complex organisms. The 
same database informs of 49 interactions found in Drosophila and humans, which 
confirm the same protein functions previously described in yeast (Table 1). These 
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interactions represent a central core of the known VAP functions and could provide 
insights into the potential mechanisms in which the protein associates to 
pathogenesis in ALS.  
 
1.4 VAP mutations cause ALS 
 
Initially, VAPB was found to be an ALS causative gene with the discovery of a 
Brazilian family carrying the substitution Pro56Ser in the gene (Nishimura et al., 
2004a). This mutation causes a predicted structural change of the MSP domain and 
disrupts the seven-strand β-sandwich conformation present in the wild type form of 
the protein. This change transforms the protein to an insoluble state (Shi et al., 2010) 
with an enhanced oligomerisation conformation (Kim et al., 2010). Also, the 
substitution converts the MSP domain to a highly helical conformation in a 
membrane environment that potentially can explain ER rearrangements (Qin et al., 
2013).  
 
 Later studies indicated that the P56S mutation was not the only way in which 
VAPB was associated with the disease, as it was shown that VAPB expression is 
down-regulated in spinal cord tissue and pyramid tract of sporadic ALS patients 
(Anagnostou et al., 2010) and SOD1 mutants mice (Teuling et al., 2007). More 
recently, other VAPB mutations have been found in ALS patients, supporting 
furthermore the link between the protein and the disease’s pathomechanism. A 
threonine to isoleucine substitution in VAPB position 46 was found in a 73 year old 
British ALS patient who presented classical signs of the disease. Located in the MSP 
domain, this mutation presented a pathogenesis index even larger than the previously 
characterized P56S mutation (Chen et al., 2010). As observed in P56S expressing 
cells, T46I mutation triggered protein aggregation that also included the wild type 
form of the protein. Protein aggregation caused cell death, ubiquitin-labeled 
inclusions and a disruption of UPR system activation via IRE1. Interestingly, they 
showed a non-cell autonomous effect of VAPB toxicity and aggregation in neighbor 
cells, which supports the idea of ALS as a disease that is not exclusive to motor 
neurons. All these phenotypes were confirmed in a Drosophila model that expressed  
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Interactor Organism Experimental 
Evidence 
Reference Throughput 
HNRNPC H. sapiens Co-fractionation Havugimana et al., 2012 HT 
INSIG1 H. sapiens Affinity Capture-
Western 
Gong et al., 2006 LT 
MPST H. sapiens Co-fractionation Havugimana et al., 2012 HT 
MTNR1A H. sapiens Affinity Capture-MS Daulat et al., 2007 LT 
NRF1 H. sapiens Co-localization Satoh et al., 2013 HT 
OSBPL9 H. sapiens Affinity Capture-MS Sowa et al., 2009 HT 
OXCT1 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
PITRM1 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
PRKACA H. sapiens Affinity Capture-MS Varjosalo et al., 2013 HT 
PRKACB H. sapiens Affinity Capture-MS Varjosalo et al., 2013 HT 
S100A16 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
SCAF4 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
SEC22B H. sapiens Co-fractionation Havugimana et al., 2012 HT 
SEPT9 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
STX1A H. sapiens Reconstituted 
Complex 
Li et al., 2003 LT 
STX1B H. sapiens Reconstituted 
Complex 
Li et al., 2003 LT 
STX2 H. sapiens Reconstituted 
Complex 
Li et al., 2003 LT 
STX4 H. sapiens Reconstituted 
Complex 
Li et al., 2003 LT 
STX5 H. sapiens Reconstituted 
Complex 
Li et al., 2003 LT 
TJP1 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
UBC H. sapiens Affinity Capture-MS Danielsen et al., 2011 HT 
UBL4A H. sapiens Affinity Capture-MS Xu et al., 2012 HT 
UQCRFS1 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
USP20 H. sapiens Affinity Capture-MS Sowa et al., 2009 HT 
VAMP1 H. sapiens Reconstituted 
Complex 
Nishimura et al., 1999 LT 
VAMP2 H. sapiens Reconstituted 
Complex 
Nishimura et al., 1999 LT 
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Table 1. VAP physical interactors found in Drosophila and human-based 
experiments. According to BioGrid, forty nine unique proteins have physical 
interaction confirmed through different approaches. These proteins are related to 
vesicle recycling, synaptic structure and lipid metabolism, among other cellular 
functions. HT: High throughput experiments; LT: Low throughput. 
 
VAPA H. sapiens Reconstituted 
Complex 
Nishimura et al., 1999 LT 
VCL H. sapiens Co-fractionation Havugimana et al., 2012 HT 
VDAC3 H. sapiens Co-fractionation Havugimana et al., 2012 HT 
VHL H. sapiens Reconstituted 
Complex 
Lai et al., 2012 LT 
VKORC1 H. sapiens Two-hybrid Schaafhausen et al., 2011 LT 
EPHA4 M. musculus Affinity Capture-
Western 
Tsuda et al., 2008 LT 
CG1513 D. melanogaster Two-hybrid Giot et al., 2003 HT 
CG2064 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG4729 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG5742 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG8188 D. melanogaster Affinity Capture-
Western 
Tsuda et al., 2008 LT 
CG8765 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG9205 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG9723 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG13220 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CG33523 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
CCT2 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
DL D. melanogaster Two-hybrid Formstecher et al., 2005 HT 
MRG15 D. melanogaster Affinity Capture-MS Guruharsha et al., 2011 HT 
NF-YA D. melanogaster Two-hybrid Giot et al., 2003 HT 
RAB7 D. melanogaster LC-MS/MS McCray et al., 2010 LT 
REL D. melanogaster Affinity Capture-MS Fukuyama et al., 2013 HT 
SAC1 D. melanogaster Two-hybrid Giot et al., 2003 HT 
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the corresponding mutation DVAP-T48I. Additionally, disruption of ER protein 
distribution, heat shock response and neurodegeneration in the eye were observed in 
the fly model (Chen et al., 2010). 
 
 Two years later, a novel mutation was found in a Dutch familial ALS patient. 
In contrast to the previous substitutions, the mutation V234I was located in an 
evolutionary conserved sequence in the VAPB transmembrane domain (van 
Blitterswijk et al., 2012b). The pathogenicity of the mutation calculated in-silico is 
similarly high to the one found in T46I, mainly due to the structural change predicted 
in the transmembrane domain of the protein. Interestingly, this fALS patient also 
carries the expansion in the C9orf72 gene, which supports the oligogenic origin of 
the disease (van Blitterswijk et al., 2012a). Only some months ago our group 
reported a characterisation of this mutation in a Drosophila model (Sanhueza et al., 
2013). Surprisingly, the synaptic and microtubule phenotypes observed in this model 
go in the opposite direction to the ones observed with the two previous VAPB 
mutations. However, aggregate formation, abnormal locomotion behavior and up-
regulation of HSP stress response were observed, all phenotypes present with the 
previous mutations. The fact that overexpression of wild-type alleles of DVAP also 
produces similar phenotypes than those observed with DVAP-V260I implies that the 
overexpression of the protein is enough to cause neurodegeneration and that a gain-
of-function mechanism may be involved in VAPB-induced ALS (Sanhueza et al., 
2013). 
 
 These three mutations have been characterised and neurodegenerative 
phenotypes were found reminiscent to those observed in ALS-linked phenotypes. 
However, VAPB mutations are sometimes treated as a rare cause of ALS without a 
strong number of cases from different origins, despite the presence of European and 
Japanese patients with the VAPB-P56S mutations (Millecamps et al., 2010; Funke et 
al., 2010). Recent reviews of the molecular causes of ALS (Renton et al., 2013; 
Robberecht & Philips, 2013; Al-Chalabi & Hardiman, 2013) underestimate the 
relevance of VAPB based on the lack of novel mutations and on studies that found 
less pathogenic VAPB alleles in ALS patients (Ingre et al., 2013; Conforti et al., 
36 
2006; van Blitterswijk et al., 2012b). However, these reviews avoid important facts 
that strongly link VAPB with ALS pathology including the lower VAPB levels in 
ALS patients and the neurodegeneration observed in the previously described VAPB 
models (Anagnostou et al., 2010; Chai et al., 2008). Additionally, we cannot discard 
that the decrease in protein levels may be caused by unknown mutations in VAPB 
regulatory regions that may lead to pathogenic forms difficult to find by studies that 
search mutations in gene exons. Finally, the association of VAPB mutants with 
defects in protein clearance links this gene with a group of other ALS causative 
genes and suggests that further studies of this pathway and VAPB can provide 
important insights into the disease pathogenesis (Ling et al., 2013) 
 
1.5 Drosophila is a powerful animal model 
 
In the last century, the fruit fly played a pivotal role in crucially advancing areas of 
biology. Landmark studies in Drosophila include the initial work of Thomas Hunt 
Morgan studying the chromosomal theory of inheritance, advances in learning 
(Quinn et al., 1974), visual system (Pak et al., 1970) and embryonic development 
(Nüsslein-Volhard & Wieschaus, 1980). In the last two decades however, the use of 
Drosophila as an animal model to study human diseases has increased enormously 
(Bilen & Bonini, 2005). Despite the significant evolutionary distance between fruit 
flies and humans, their genomes share a considerable similarity. Half of the 
Drosophila genes show a significant homology to human genes and furthermore, 
77% of human genes associated with diseases have an ortholog in the fruit fly (Reiter 
et al., 2001). 
 
 Normally, the easier a genetic model is to work with, the worse it is to mimic 
human characteristics (St Johnston, 2002). In that regard, Drosophila exhibits one of 
the best balances between these two aspects. Also, with an important repertoire of 
genetic techniques, it is fair to consider Drosophila as an important animal model. 
Fruit fly’s low cost, simple maintenance, short generation time and well-known 
anatomy are vital advantages of Drosophila compared to major organisms and a 
central reason to use it for large-scale studies (St Johnston, 2002; Bellen et al., 2004; 
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Bilen & Bonini, 2005). On the other hand, the use of Drosophila as animal model 
implies some drawbacks as well. Fruit flies need constant stock maintenance at 
controlled temperatures compared to unicellular models that can be frozen and 
revived afterwards (St Johnston, 2002). Drosophila also lacks some organs and 
tissues present in humans, which affects the modeling of some human diseases 
(Razell et al., 2011). Finally, developmental difference between flies and human 
nervous systems is large enough to make difficult the study of some cognitive and 
behavioral hallmarks of neurodegenerative diseases (Prubing et al., 2013).  
 
 Genetic simplicity is another key aspect of Drosophila advantages. In the last 
two decades, a strong effort from the Drosophila community has generated a 
valuable number of stock collections that cover most its genome. P-element 
insertions, deletions, RNAi and overexpression lines are all publicly available and 
are the basis of a productive scientific communication between Drosophilists 
(Drysdale & FlyBase Consortium, 2008; Bellen et al., 2004; Dietzl et al., 2007; 
Cook et al., 2012). These stock lines are constantly studied, mapped and conserved 
to help the Drosophila community. The genetic simplicity of Drosophila also is 
useful as there are less evolutionary duplication events that in other animal models. 
This makes more challenging the study of a gene function in animals with more than 
one copy for that gene (O'Kane, 2003; O'Sullivan et al., 2012). 
 
 Finally, the evolutionary distance between Drosophila and humans can be 
evaded with the insertion of human genes into the fly’s genome. Mechanisms 
involved in human diseases can be confirmed with this approach using Drosophila 
genetic tools repertoire. Also, it can be useful to express human genes without 
orthologs in the Drosophila genome as an alternative way to use the previously listed 
advantages of this organism. The exploitation of this idea has led to several models 
of human diseases that successfully provide crucial data (Chai et al., 2008; Li et al., 





1.6 Other neurodegenerative disease models 
 
Fly models have been successfully constructed for the most relevant human 
neurodegenerative diseases. Polyglutamine diseases include a group of at least 9 
different diseases that share the expansion of a CAG repeat in their genes (Gusella & 
MacDonald, 2000). The study of one of these diseases, spinocerebellar ataxia type 1 
(SCA1) was enormously benefited by the generation of a Drosophila model 
expressing the full-length human SCA1 gene. A genetic screen looking at modifiers 
of the SCA1-induced neurodegenerative phenotype led to understand the 
participation of protein misfolding and clearance along with aberrations in RNA 
processing as main aspects of disease pathogenesis (Fernandez-Funez et al., 2000). 
Subsequent reports have deepened the understanding of these mechanisms and 
supported the relevance of flies as an SCA1 model (Chen et al., 2003; Lam et al., 
2006; Park et al., 2013). Similar results were observed with the models for SCA2 
and SCA3, where the expression of either full-length, truncated or expanded versions 
of these proteins in Drosophila lead to neurodegeneration and protein aggregation 
(Warrick et al., 2005; Warrick et al., 1998; Satterfield et al., 2002). 
 
 Another polyglutamine-caused disorder is Huntington’s disease (HD). 
Expression of the N-terminal portion of the causative gene htt in Drosophila was 
linked to progressive neurodegeneration. As observed in humans, the pathogenicity 
was proportional to the length of polyQ repeats (Jackson et al., 1998). Further studies 
proved that expression of the full-length version of the protein in Drosophila nervous 
system generated neurodegeneration due to an increased release of neurotransmitter. 
This finding indicates a possible pathomechanism for HD (Ross et al., 2014; Rozas 
et al., 2011). Other two models based on the truncated version of htt showed that the 
pathomechanism was explained in part by transcriptional deregulation and fast 
axonal transport (Steffan et al., 2001; Lee et al., 2004). Furthermore, Drosophila 
models were used to identify chemicals with potential pharmaceutical effects 
(Auluck & Bonini, 2002; Miller et al., 2012). 
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 Parkinson disease is a more common disorder affecting 2.5 per 100.000 
persons (Savica et al., 2013). Feany and Bender were able to express in Drosophila 
the human α-synuclein, one of the causative genes of the disease (Feany & Bender, 
2000). This model presented adult onset neurodegeneration, protein accumulation 
and motor dysfunction, as observed in humans. Models based on another causative 
gene, parkin, presented oxidative stress sensitivity and abnormal wing phenotypes 
(Greene et al., 2003; Pesah et al., 2004). Recently, specific dopaminergic neurons 
were identified in Drosophila’s mushroom bodies as the cause of locomotor deficits 
(Riemensperger et al., 2013).  
 
 However, the most common neurodegenerative disease is Alzheimer’ disease. 
The main mechanism associated with the disease is the cleavage of the amyloid 
precursor protein (APP) by the -secretase, encoded by the presenilin 1 and 2 genes 
(PS1 and PS2). This cleavage releases the Aβ40 and Aβ42 products found in protein 
aggregates (Huang & Mucke, 2012). Mutations in the APP, PS1 and PS2 genes are 
associated with familial cases of the disease (Vassar et al., 2014). All the 
components of the APP cleavage machinery are not present in Drosophila genome 
and the APP protein does not present the Aβ domain. Despite that, fly models for the 
disease have provided important insights into the disease pathomechanism, such as 
the link of cell death and cell-cell adhesion (Ye et al., 1999; Fossgreen et al., 1998). 
When the human APP is coexpressed with the -secretase precursor in flies, Aβ40 
and Aβ42 are produced causing neurodegeneration (Greeve et al., 2004). 
Neurodegeneration also is observed in fly models expressing mutant forms of Tau, 
another Alzheimer’s disease-associated protein (Nishimura et al., 2004b; Wittmann 
et al., 2001). 
 
1.7 Genetic screens using fly models 
 
The genetic power of Drosophila as animal model has been a key aspect of its 
success in the identification of novel gene functions using genetic screens. From 
mutagenesis analyses based on ethylmethane sulphonate (EMS) and P-transposable 
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elements, to more specific approaches including transgenic and clonal screens, these 
studies are a strong way to use the power of Drosophila.  
 
 Traditional studies were based on the generation of mutant lines using EMS, 
which causes specifically point mutations in the genome. The first ground-breaking 
study of this kind was the screen designed by the Nobel Prize recipients Christiane 
Nusslein-Volhard and Eric Wieschaus (Nüsslein-Volhard & Wieschaus, 1980). In 
this screen were identified mutants that affected embryonic positional information. It 
became one of the first screens that used the embryo as model to find genes in a 
single process (St Johnston, 2002). In this work, authors were able to define three 
different segmentation processes and associate them with most of the genes that 
control them such Hedgehog, Fused, Wingless, Cubitus interruptus, patched and 
other 10 central genes.  
 
 A further step forward in the searching for novel gene functions was reported 
in the characterisation of sevenless, a gene that controls cell fate in photoreceptor 
cells. Most loss-of-function mutations are recessive and only one copy is enough to 
show a wild type phenotype. However, when additionally another gene from the 
same process is already mutated, the single copy of the original gene may not be 
enough and a phenotype may be detected. Changes in gene dosage are used in this 
way to find novel genes that modify the mutant phenotype of a known protein. The 
screen that found downstream targets of sevenless had extra advantages compared to 
previous screens, especially the possibility to screen the offspring directly after the 
original cross and not to wait for homozygous mutant flies as in the previous screens 
(idea known as a F1 screen, Figure 3) (Simon et al., 1992; Simon, 1994).  
 
 Another way to analyse recessive mutations that show phenotype in 
homozygous cells are the screens based on mitotic clones. This technique involves 
the use of the yeast recombinase Flp and transgenic lines with specific sites of 
recombination (Flp recombinase target, FRT). With these elements, recombination 
occurs in homologous chromosomes that after segregating in mitosis, produce cells 
with the desired mutation in homozygosis. This technique also is a F1 screen, which  
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Figure 3. Schemes of classic genetic screens in Drosophila. (A) Mutagenesis-
based screen published by Nüsslein-Volhard & Wieschaus, which found for the first 
time mutations that affect patterning of the embryo. Male flies are fed EMS to induce 
mutations. As the mutations are induced in mature spermatids, each F1 male inherits 
a mutagenized chromosome (red) carrying a different spectrum of mutations. Single 
F1 males that carry a mutagenized chromosome are then backcrossed to balancer 
stock to generate F2 males and females that carry the same mutagenized 
chromosome. (B) Scheme for the screen for enhancers of sev, published by Simon et 
al. Males that are hemizygous for sev
d2
 were mutagenized with X-rays and crossed to 
sev
d2
 homozygous females that carry a temperature-sensitive allele of sev as a 
transgene inserted on TM3. The F1 TM3 flies were then screened for a reduction in 
the number of R7 photoreceptor cells in the eye. Taken from St Johnston, 2002. 
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provides the advantage of a faster search for new functions. Originally used for the 
search of tumour related genes (Xu et al., 1995), the clonal analysis has been 
optimized in following studies that direct the recombination in specific tissues (Chou 
& Perrimon, 1996; Newsome et al., 2000) or others that improve the recombination 
efficiency removing non-recombinant cells (Stowers & Schwarz, 1999). 
 
 To address the situation of a lack of phenotype in several genes when presented 
as loss-of-function, an effective type of screen was designed by Pernille Rørth 
(Rørth, 1996) using the modular expression technique UAS-Gal4 (Brand & 
Perrimon, 1993). With the creation of transgenic lines carrying upstream activating 
sequences in a target gene, Rørth was able to upregulate several genes and observe a 
specific phenotype or the modulation of a previous one. This was exemplified by the 
phenotype observed with the misexpression of Ras GAP in the eye. Proposed as the 
best way to screen genes, due to the possibility to observe effects in previously silent 
genes, misexpression screens have been successfully performed throughout the last 
decade to understand different processes (Franciscovich et al., 2008; Paik et al., 
2012; Stofanko et al., 2008; Ambegaokar & Jackson, 2011). The generation of novel 
collection of transgenic misexpressing lines constantly improves these screens 
(Staudt et al., 2005; Bellen et al., 2004; Beinert et al., 2004; Bellen et al., 2011). 
 
 From these screens, the eye appears as the most popular way to find genetic 
modifiers of an existing process or mutant phenotype. The non-essential condition of 
this organ and the easy readout that is associated with it allow testing in the eye 
lethal genes in a quick manner. More importantly, genes that do not present a known 
eye-specific function can still be tested if they show a specific rough phenotype in 
the eye (St Johnston, 2002). Drosophila eye is composed of approximately 750 
ommatidia, a unit that clusters differentiated eye cells. When a protein produces a 
toxic effect, the severity of its associated degeneration can be observed in different 
degrees, according to the number of ommatidia damaged (Thomas & Wassarman, 
1999). Several studies have successfully used eye screens to find genetic modifiers 
that alter this degree of degeneration (Bonini, 1999; Fernandez-Funez et al., 2000; 
Barrett et al., 1997). 
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 Finally, another effective way to test modification phenotypes is behavioural 
performance analysis, specially testing motor performance changes in model flies. 
Feany’s work modeling Parkinson in Drosophila used the motor performance 
measurement to detect late-onset loss of dopaminergic neurons (Feany & Bender, 
2000). Later, similar assays were reported for other neurodegenerative diseases 
including SCA1 and HD, where novel genetic interactors of the causative genes 
Ataxin 1 and huntingtin respectively, were found to affect Drosophila’s behaviour 
(Branco et al., 2008; Kaltenbach et al., 2007). In the study of ALS, behaviour has 
been tested in fly models for two genes. Li reported a TDP-43 model that presented 
late-onset motor defects with the overexpression of the human form of the protein in 
Drosophila (Li et al., 2010). This same gene and technique were the center of 
multisystemic works that discovered Taf15 and ataxin-2 as TDP-43 genetic 
interactors (Couthouis et al., 2011; Elden et al., 2010). SOD1 mutants also present 
motor performance defects first described by Watson et al. (Watson et al., 2008) and 
confirmed by a different model recently (Bahadorani et al., 2013). However, for 
SOD1 and other causative genes, no further characterisations have been made linking 
disease-related mutations with relevant hallmarks of the diseases like motor defects. 
The potential use of this analysis, together with other gene discovery tools could lead 
to an incremental understanding of the disease pathomechanism. 
 
1.8 Experimental aims 
 
The lack of understanding of VAP biology and its relation with ALS pathogenesis 
are the driving forces to start this study.  A gain of knowledge regarding 
interactions and phenotypes of this protein will significantly improve our 
comprehension of the mechanism behind motor neuron death. Drosophila as a 
simple animal model gives us the chance to perform genome-wide projects that are 
basically impossible in other systems. Curiously, the search for genetic interactors is 
something not performed yet for VAPB and ALS. Therefore, we plan to perform a 
high-scale genetic screen to find modifiers of DVAP-P58S-associated 
neurodegeneration, and discover potential pathways and mechanisms currently 
hidden in the study of this protein. For that purpose, we aim to characterise and 
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optimise the ALS Drosophila model based on DVAP-P58S to then carry out a 
misexpression screen to find potential DVAP genetic modifiers. The confirmation 
and further characterisation of these novel interactors will not only increase DVAP 
spectrum of mechanisms inside the cell, but also will potentially allow us to identify 
future therapeutic targets for the VAPB-linked ALS. 
 
Aim 1. Characterisation and optimisation of the ALS model. Before start a 
genome-wide screen, it is mandatory to characterise the phenotypes associated with 
DVAP mutants and pinpoint the exact conditions to perform following experiments 
in an optimal way. For this purpose, we plan to study the expression of DVAP 
mutants in different tissues and temperatures, and test our parameters in small-scale 
pilot experiments. 
 
Aim 2. Perform a primary screen based on the expression of DVAP-P58S in the 
eye. Using changes in the fly’s eye phenotype as a quick and reliable readout, we 
plan to analyse more than one thousand misexpression lines to search for genes that 
modify DVAP-P58S phenotype. The selection and further confirmation of these 
genetic interactors will be the central part of this study and the genes discovered at 
this stage should provide us novel information about the role of DVAP in the cell. 
 
Aim 3. Perform a secondary screen based on the expression of DVAP-P58S in 
the whole nervous system.  After filtering positive interactors with our previous 
aim, we plan to study the behaviour of these modifiers in the Drosophila nervous 
system under the control of the elav-GAL4 driver. Analysing different paradigms, we 
will be able to confirm results informed previously. Importantly, we will observe the 
behaviour of these interactions in assays that resemble relevant human hallmarks of 
the disease such as the loss of motor performance.  
 
Aim 4. Bioinformatic studies of the DVAP-neurodegeneration modifiers. 
Currently, an important area of scientific research involves the data prediction and 
organization of the available information. We plan to use different approaches to 
obtain further information, with our set of novel interactors as the starting point. 
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These analyses will not only allow us to understand previously reported information 
but also, will unveil relevant functions and pathways associated now to DVAP-
linked neurodegeneration. 
 
Aim 5. Characterisation of functional pathways enriched in the genetic screen. 
From the myriad of novel DVAP-interactors found in the previous stages, some will 
highlight due to their known connection to DVAP and their integration with other 
modifiers. We propose the characterisation of some of these modifiers with the 
purpose to validate our list of modifiers but also to provide a potential link of DVAP 
with important cellular functions. The study through immunohistochemical assays 
and furthermore, the translation of our results to human samples will accomplish 


















































2.1.1 Primary antibodies used for immunohistochemistry 
Antibody Source 
Guinea Pig α-DVAP Giusy Pennetta 
Rabbit α-Rab5 Giusy Pennetta 
Rabbit α-human RAB5A Novus Biologicals 
Chicken α-Syx7 David Bilder 
Table 2. Primary antibodies 
 
2.1.2 Secondary antibodies used for immunohistochemistry 
Antibody Source 
Goat α-guinea pig FITC Jackson Immunoresearch 
Goat α-rabbit Cy3 Jackson Immunoresearch 
Table 3. Secondary antibodies 
 
2.2 Fly genetics 
 
2.2.1 Drosophila stocks 
 
Stocks were maintained on standard cornmeal food at room temperature. Flies were 
raised at specific temperatures according the experiment. Four groups of stocks were 
used in this study: general Drosophila stocks, 1183 misexpression stocks tested in 
the genetic screen (Bloomington Drosophila Stock Center, BDSC), RNAi stocks 
used to validate positive results from the screen (BDSC and Vienna Drosophila 
resource center, VDRC) and transgenic lines used for the same purpose, obtained 






Line Source Description 
yw Bloomington Drosophila 
Stock center 
Wild type line 
Canton S Bloomington Drosophila 
Stock center 
Wild type line 
elav
c155
-GAL4 Bloomington Drosophila 
Stock center 
Nervous system expression 
driver 
GMR-GAL4 Bloomington Drosophila 
Stock center 
Eye expression driver 
eyeless-GAL4 Bloomington Drosophila 
Stock center 
Eye expression driver 
BG57-GAL4 Bloomington Drosophila 
Stock center 
Muscle expression driver 
UAS-DVAP-P58S Chai et al., 2008 Transgenic DVAP allele 
UAS-DVAP-T48I Chen et al., 2010 Transgenic DVAP allele 
ey-GAL4, UAS-DVAP-
P58S/CyO-GFP 
Giusy Pennetta Recombinant line 
elav-GAL4; UAS-DVAP-
P58S/CyO-GFP 
This study Recombinant line 
UAS-mCD8:GFP Bloomington Drosophila 
Stock center 
GFP control line 
Δ2-3 Robertson et al., 1988 Transposase source line 
Lpin/CyO-GFP Andrew Jarman CyO-GFP Balancer line 
UAS-Sac1 Giusy Pennetta Sac1 overexpression 
Stt4RNAi Khuong et al., 2010 Stt4 RNAi line 
FwdRNAi Yavari et al., 2010 Fwd RNAi line 
UAS-DIAP1 Bloomington Drosophila 
Stock center 
Inhibitor of Apoptosis 1 
Jnk-DN Bloomington Drosophila 
Stock center 
Basket dominant negative 
UAS-Puc Bloomington Drosophila 
Stock center 
Puc overexpression 
UAS-DIAP2 Ribeiro et al., 2007 DIAP2 overexpression 
49 
Line Source Description 
UAS-Ric Harrison et al., 2005 Ric overexpression 
UAS-Sir2 Burnett et al., 2012 Sir2 overexpression 
UAS-Rho Strisovsky et al., 2009 Rho overexpression 
Klar
1
 Elhanany-Tamir et al., 2012 Klar loss of function 
DAP160∆1/CyO-GFP Koh et al., 2007 DAP160 loss of function 
UAS-Drp(I) McPhee et al., 2010 Draper overexpression 
UAS-Rab7
WT
-Flag McCray et al., 2010 Rab7 WT overexpression 
UAS-Rab7
Q67L
-Flag McCray et al., 2010 Rab7 constitutively active 
UAS-Rab7
T22N
-Flag McCray et al., 2010 Rab7 dominant negative 
UAS-Rab7
L129
-Flag McCray et al., 2010 Rab7 CMT mutation 
UAS-Rab11-GFP Bloomington Drosophila 
Stock center 
Rab11 WT overexpression 
Table 4. General Stocks and Drosophila tools used in this study. 
 
2.2.2 Genetic screen 
 
Virgins females from the recombinant line ey-Gal4,DVAP-P58S/CyO-GFP (“tester 
line”) were crossed with males from misexpression stocks. Embryos from these 
crosses were collected at RT for 48 hours. Parents were transferred and embryos 
were heat-shocked at 30ºC to maximize the expression of the Gal4 activator. This 
temperature was maintained in a termoregulated water bath, in which the food vials 
showed better condition, humidity levels and larger offspring, in comparison to an air 
incubator at the same temperature. The offspring was sorted by phenotype, counted 
and their eyes were photographed using a Nikon D5100 camera attached to a SZX9 
Nikon stereomicroscope. The lines showing a modifying activity compared to 





2.2.3 P-Element excision  
 
To confirm that the modifying effect was due to the P-element insertion, we excised 
the P-element from the original misexpression stocks and tested if this revertant line 
loses its effect over ey-GAL4,DVAP-P58S. As a transposase source, we used the 
P{∆2-3} line  (w-; Sp/CyO; P{ry+∆2-3}(99B), Dr/TM6B,Tb) (Robertson et al., 
1988), which increases the mobilisation frequency of other elements but remains 
stable itself. P-elements inserted in the second chromosome were excised following 
this genetic scheme: 
 
P: ♂     P (EP) ;  +         x        ♀          Sp   ;  ∆ 2-3, Dr 
        P (EP)   +                             CyO    TM6B,Tb 
     ↙ 
F1:     ♂       P (EP)  ;  ∆ 2-3, Dr          x    ♀    L, Pin     
               CyO          +          CyO-GFP 
      ↙ 
F2:        ♂   P (∆EP)      x          ♀       +        
                   CyO-GFP               CyO   
      ↙ 
F3:    $    P (∆EP)  
      CyO 
 
 Virgin ∆2-3 females were crossed with males from the original P-element 
modifier line. Males with the markers Curly (on the chromosome CyO) and drop 
(Dr) were selected from the offspring. One hundred males were individually crossed 
with virgin CyO-GFP females. From the offspring of those crosses, the revertant 
male was selected for the lack of eye colour and presence of GFP signal. The stock 
was constructed after crossing that male with virgins CyO and selecting for the lack 
of GFP marker. This revertant was tested against ey-GAL4,DVAP-P58S to confirm 







2.2.4 Viability assay 
 
To investigate the effect of DVAP mutant in the adult viability, we analysed the 
number of eclosed flies expressing DVAP-P58S under the control of the pan-neural 
driver elav
C155
-GAL4. Crosses between elav;DVAP-P58S virgin females and males 
from lines with potential modification effect were performed in the same way as 
previously detailed. All the eclosed flies were sorted in two groups: flies co-
expressing DVAP mutant allele and the target studied gene (flies without the CyO 
chromosome, CyO
+
) and flies expressing exclusively the target gene (CyO flies). If 
the co-expression of both genes is not toxic for flies, we could assume that the 
amount of flies that would come out from both phenotypes is the same. Therefore, 
the ratio between observed (CyO
+
) and expected (CyO) flies would be 1.0 for non-
toxic co-expression. A value lower than 1.0, indicated a toxicity effect. Modification 
ratios were then compared to the ratio observed for the tester line (elav-GAL4/+; 
DVAP-P58S/+). The modification effect was plotted and statistically analysed using 
unpaired, two-tailed Student’s T-test. 
 
P: ♂       P (EP)        x        ♀    elav-Gal4 ; DVAP-P58S 
            P (EP)                      elav-Gal4     Cyo 
 
F1:    Co-expressing flies:  elav-Gal4 ; DVAP-P58S   ♀ 
                 (Cyo
+
)   +      P(EP) 
   
           elav-Gal4 ; DVAP-P58S   ♂ 
                   Y      P(EP) 
 
  Non-DVAP flies:  elav-Gal4 ;  P(EP)    ♀ 
                   (Cyo)  +       Cyo 
 
           elav-Gal4 ;  P(EP)   ♂ 
               Y       Cyo 
 
2.2.5 Motor performance assay 
 
Motor performance of the DVAP-mediated toxicity modifier lines was tested using 
the climbing assay (Branco et al., 2008). Misexpression stocks were crossed with 
elav;DVAP-P58S flies virgin females at 28ºC. A set of 10 age-matched adult females 
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was raised at the same temperature and every 2 days was tested to score how many 
flies could climb 8 cm high in an empty vial in 15 seconds. After this period, flies 
were tapped to the bottom and the trial was repeated ten times to calculate the 
average. These averages were plotted and statistically analysed using Two-way 
ANOVA with Bonferroni as Post-Hoc test to compare samples with control flies 
performance. Flies were transferred to a new vial every two days to avoid death of 
flies or loss of mobility due to sticky food.  
 
2.3 Drosophila eye structure 
 
2.3.1 Light microscopy images and modification levels 
 
To characterise the eye morphology of the different lines, two-dimensional images 
were obtained using a Nikon D5100 Camera attached to a SZX9 Nikon 
stereomicroscope. To quantify the eye surface area of flies, images were analysed 
with ImageJ software. The percentage of modification was calculated to reflect the 
difference of area between stocks and controls. If we assume that level of 
modification occurs between the tester line ey-Gal4,DVAP-P58S/+ (T, 0%) and the 
control ey-Gal4/+ as maximum level of eye size (C,100%), we can calculate the 
specific modification ratio of each stock (S) as: (AreaS - AreaT) / (AreaC - AreaT). 
A perfect suppressor will show the same area of the control (Ratio=1), a no-effect 
stock will show the same area of the tester line (Ratio=0) and an enhancer line will 
show smaller area than positive control (Ratio ≤ 0). The same principle was used for 
enhancement assays at 28ºC, where the percentage of decrease from the tester line 
was calculated for each stock as: 1 - (AreaS /AreaT). All these values were then 




To analyse the internal eye structure of adult flies, 10 heads were fixed overnight 
using a mix of formaldehyde, ethanol and acetic acid (10:85:5). After dehydration, 
the samples were embedded in paraffin and sliced to obtain thin sections. These 
53 
sections were stained with hematoxylin-eosin and then visualised on a 
stereomicroscope. 
 
2.3.3 Scanning electron microscopy 
 
Fly heads were fixed with 3% glutaraldehyde in 0.1M sodium cacodylate buffer pH 
7.4 for at least 3 hours. After wash with the same buffer for 1 hour, the heads were 
incubated in 1% osmium tetroxide for 2 hours and then dehydrated in 50%, 70%, 
90% and 100% acetone for 10 minutes each. Finally, samples are sputter coated with 
20nm gold/palladium (60/40) to be visualised with a Hitachi 4700 FESEM.  
 
2.4 Plasmid rescue 
 
DNA was extracted from 15 adult flies using the alkaline method (Roberts, 1986). 
Flies were smashed in 1% SDS buffer and incubated for 30 min at 65ºC, followed by 
DNA extraction using 8M potassium acetate and precipitation with isopropanol. 
Genomic DNA was digested using 10U EcoRI and checked in a 1% agarose gel with 
ethidium bromide. Completely digested DNA was ligated overnight at 15ºC using T4 
DNA ligase, extracted with phenol-chloroform-isoamyl alcohol (25:24:1) and 
precipitated with 3M sodium acetate solution. 
 
 Circular DNA obtained was transformed into XL10 Gold Ultracompetent e. 
coli cells (Agilent), following a heat pulse of 42ºC for 45 s. Transformants were 
selected by Kanamycin resistance over LB plates (30ng/mL) and positive colonies 
were rescued and grown overnight in LB-Kanamycin media. Plasmidial DNA was 
extracted from these cultures using standard alkaline lysis method (Russell & 
Sambrook, 2001), linearised by digestion with EcoRI and analysed in a 1% agarose 
gel. The plasmid size was calculated by comparison with the DNA 1kb ladder 
(Invitrogen) and compared with the expected genomic region of the P element 
insertion of each stock. This region comprises the EcoRI 3’ end fragment from the 
EP cassette (Rørth, 1996) plus the genomic sequence downstream of the insertion 
site, reported in FlyBase for each line. This DNA sequence was virtually digested 
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using NEB Cutter 2.0 (New England Biolabs website) and the resulting fragments 
compared with the one observed from the linearised plasmid.  
 
2.5 Statistical analysis 
 
Statistical analysis was performed and graphs were generated using GraphPad Prism 
5.0. For experiments with more than two samples, a one-way ANOVA test was 
applied. Tukey’s multiple comparison test was then used as a post hoc-test when a 
significant difference was found in the ANOVA test. For experiments with only two 
samples a two-tailed un-paired Student’s t-test was applied. For the climbing assay 
data, two-way ANOVA and Bonferroni as post-hoc test were used to compare 
difference between time points and genotypes with the motor performance of each 
line. Finally, one-sample t-test was used to compare the observed value of a sample 






To classify the modifiers found in the screen, we used the Protein Analysis Through 
Evolutionary Relationships system, PANTHER (Thomas et al., 2003). The protein 
and gene classification performed by this system is both human curated and 
bioinformatically sorted. Data obtained include Family and Subfamily levels from 
PANTHER classification, GeneOntology terms and the closer human ortholog, if 
available.  
 
2.6.2 DIOPT  
 
The search of human orthologs for the Drosophila DVAP genetic interactors was 
performed with the DRSC Integrative Ortholog Prediction Tool (DIOPT). This tool 
developed by the Drosophila RNAi screening center at the Harvard medical school 
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(Hu et al., 2011) uses ten different algorithms to find orthologs for one specific gene. 
The number of positive results for one ortholog is associated with a score, reflecting 
the strength of the result as well. With this tool, we tried to avoid conflicting results 




The Database for Annotation, Visualization and Integrated Discovery, DAVID, was 
used to identify enriched Gene Ontology terms from the genes found in the screen. 
For a large number of input genes, DAVID provides number of genes linked to a 
specific function, related genes and groups to each function and a statistical 
representation of the significance of the enrichment (Huang et al., 2008). 
Connections are discovered using a knowledge database that recalls information 
from public genomic resources, including NCBI, SWISS-PROT, GO, OMIM, 
PubMed and others. For the representation we selected non-redundant Gene 




The set of modifier genes was further analysed to search for previously reported 
functional links. GeneMANIA (Warde-Farley et al., 2010) finds genes that are 
related to the input using a large set of functional association data. These specifically 
include physical interaction, co-expression and co-localisation data. We searched for 
connection between the 85 modifiers, without predicting related nodes. Interactions 
and categories were graphed in a network using the GeneMANIA plug-in for the 
bioinformatical tool Cytoscape 3.1.0. Genes were also ranked according their false 
discovery rate (FDR) corrected, enrichment Benjamin-Hochberg test. Weighting 








In order to predict other proteins that may be involved in the DVAP-modifiers 
network, we used the database STRING (Jensen et al., 2009). Similar to the way 
GeneMANIA connect nodes, STRING uses previously reported data and predicts 
other relevant proteins in the input network. An interaction network was created with 
all the modifier lines plus DVAP using Drosophila datasets. Parameters were 
calculated automatically and 20 predicted interactors plus 10 white nodes were added 
using a medium confidence of 0.25. 
 
2.6.6 Ingenuity pathway analysis 
 
To explore if the relation of modifiers observed with the Drosophila data was 
conserved in human data and proteins, we searched biological connection of the 
human orthologs of our data set using Ingenuity Pathway Analysis, IPA (Ingenuity 
systems, Quiagen). Most relevant functional categories and canonical pathways were 
selected using an adjusted Benjamin-Hochberg test, with a significance level of 
P<0.05. They were classified according to their functional category and enrichment 
level. Modifiers were also connected using a network analysis, including only input 
modifier genes plus VAPB. Finally, an expanded VAPB interaction network was 
built connecting the whole modifier list to VAPB using the “Shortest path” method 
from IPA, which includes predicted interactors of these proteins. 
 
2.7 Dissection and antibody staining of Drosophila eye imaginal discs 
 
Eye imaginal discs were extracted from wandering third-instar larvae expressing 
DVAP-P58S and its control. Collected larvae were washed in PBS and cut in the 
middle. Anterior half was turned inside out pushing the head end in on itself, 
exposing the imaginal discs still attached to cuticle. Samples were transferred to an 
eppendorf tube and fixed with Bouin’s fixative (15:5:1 saturated picric acid: 37% 
formaldehyde: glacial acetic acid) for ten minutes. After several washes with 0.1% 
solution of phosphate buffered Triton (PBT), samples were blocked with 10% 
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normal goat serum (NGS) for 2h at room temperature. Staining with primary 
antibodies was performed overnight at 4ºC at a concentration of 1:1000 in a solution 
of 5% NGS. After 8 rinses of 15 min with PBT, samples were incubated for 2h at 
room temperature with the secondary antibodies at a concentration of 1:500 in a 5% 
NGS solution. Excess of antibody was then removed washing 8 times for 15 min 
with PBT. Eye imaginal discs were carefully separated from the remaining tissue 
using fine tipped tweezers and a syringe needle. Finally, samples were transferred to 
a microscope slide with drops of Vectashield, covered and sealed using nails varnish 
to avoid drying out. 
 
2.8 Immunohistochemistry on post-mortem human spinal cord 
tissue 
 
Human tissue was obtained from the MRC Edinburgh Brain Bank with full ethical 
approval for research studies. Human spinal cord tissue fixed in 10% neutral-
buffered formalin was processed into paraffin. 7 µm sections were cut and de-
paraffinised with xylene before being rehydrated through graded ethanol solutions. 
Sections were pre-treated using heat-induced epitope retrieval with Novocastra pH6 
retrieval buffer in a decloaking chamber by heating to 125°C for 10sec, cooling to 
90°C before washing in running tap water. Slides were then stained on a Leica 
Vision Biosystems Bond robot using the refine polymer detection kit (Leica) as 
follows. Endogenous peroxidase was blocked with 3% hydrogen peroxide in TBST 
for 10 min. Sections were incubated with rabbit anti-Rab5 (1:250, Bethyl 
laboratories) primary antibody in 0.1% TBST for 2 hours at 25°C and then incubated 
with anti-rabbit HRP polymer for 15 minutes at 25°C. Staining was visualized using 
3,3’-diaminobenzidine as chromogen. Tissue was finally subjected to haematoxylin 



















Chapter 3:  ALS model: 
















3.1 Introduction  
 
These initial experiments were designed to explore the effect of the expression of 
DVAP alleles in the eye and nervous system of flies. Having performed so, we tried 
to find the best condition to observe clear degenerative phenotypes and optimize the 
use of this ALS model as a way to search for DVAP-interactor genes in a genome-
wide screen. 
 
3.2 DVAP mutant alleles cause neurodegeneration in the Drosophila 
eye 
 
The biology of VAPB has been systematically studied since its original 
characterisation in Aplysia (Skehel et al., 1995). Functional homologues found in 
Drosophila, mice and humans improved the understanding of this protein and its 
relation with synaptic vesicles. However a major turning point occurred with its 
linkage to ALS in patients from a Brazilian family (Nishimura et al., 2004a). Since 
then, the causative mutation has been modeled in different organisms and the relation 
between structural changes in the protein and neurodegenerative phenotypes has 
been strengthened. One of these models was developed by our group (Chai et al., 
2008) using the expression of the Drosophila homolog of the human Pro56Ser 
mutation, DVAP-P58S. Expression of the causative allele in flies has been shown to 
cause altered synaptic remodeling, decrease in viability and recapitulation of other 
ALS hallmarks. This Drosophila ALS model will be the pivot of this project and as a 
first step, we have determined the best combination of parameters to perform a 
genome wide genetic screen.  
 
 DVAP-P58S expression in the eye was previously associated with roughness 
and reduction in size (Forrest et al., 2013). These same phenotypes were also 
observed with the expression of another ALS-linked mutation, DVAP-T48I (Chen et 
al., 2010). The aim of this chapter was to report the characterization of DVAP 
expression in the eye and analyse neurodegenerative phenotypes associated with 
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different alleles, GAL4-drivers and temperature. The optimal combination of these 
variables was used to carry out the screen. 
 
3.3 UAS-GAL4 system can direct DVAP expression specifically in 
the eye 
 
In Drosophila, to drive the expression of a transgene in a tissue- and time-specific 
manner, the best available tool is the UAS-GAL4 system designed by Andrea Brand 
and Norbert Perrimon (Brand & Perrimon, 1993). With this technique, the level of 
expression and activity of the GAL4 protein and consequently, the expression of the 
transgene, can be modulated by changing the temperature at which flies are raised. 
This system is based on two components: the yeast transcriptional activator GAL4, 
which is expressed under the control of tissue specific promoters, and the target gene 
that possess in its regulatory region GAL4 binding sites (Upstream activator 
sequences, UAS) that activate the expression of this gene in the tissues where the 
GAL4 activator is present. In this way, the target transgene will be expressed 
exclusively in the tissue where the GAL4 was transcribed. The discovery and 
construction of different tissue-specific GAL4 lines (“driver” lines) and the 
increasing availability of transgenic UAS alleles, allow a myriad of possibilities to 
study Drosophila genes in an efficient and clean way (St Johnston, 2002) 
 
 To examine DVAP-associated neurodegeneration specifically in the eye, we 
explored the use of the two eye specific drivers: eyeless-GAL4 and GMR-GAL4. 
Eyeless-GAL4 is a transgenic line based on the eyeless gene (ey), which encodes the 
homolog to the mouse transcription factor Pax6. Initially, ey is expressed in the 
embryonic ventral nerve cord and in some regions of the brain. In the larval stages it 
is expressed in eye imaginal discs and only in the third larval stage, the expression is 
restricted to undifferentiated cells from imaginal discs, becoming the master gene for 
the Drosophila eye development (Halder et al., 1995). The ey-GAL4 driver was 
originally reported as a way to express specifically a target gene in the eye imaginal 
disc. Then, it has become a relevant tool for the study of lethal genes without 
affecting massively the offspring viability (Tseng & Hariharan, 2002). However, a 
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low level of expression in other tissues has been observed in previous studies as well 
(Callaerts et al., 2001). 
 
 Glass multimer reporter or GMR-GAL4 driver was constructed to drive the 
expression in the developing eye (Freeman, 1996). Opposite to ey, which is 
expressed in the region anterior to the morphogenic furrow area of undifferentiated 
cells (Halder et al., 1995), GMR is expressed in the posterior area, where ommatidia 
cells are starting to differentiate. Nevertheless, both genes have shown expression in 
tissues outside this area. Both drivers are widely used as tools to perform genetic 
screens in the eye (Tseng & Hariharan, 2002; Fernandez-Funez et al., 2000). We 
decided to test whether any of them could be used to drive the expression of DVAP 
alleles in the eye to perform a genetic screen. 
 
3.4 Expression of DVAP-P58S under the control of ey-GAL4 driver 
presents a consistent degenerative phenotype 
 
Light microscopy images of flies expressing both DVAP mutant alleles under GMR-
GAL4 control at 30ºC revealed degeneration in the eye, but unfortunately a similar 
phenotype was also observed in the control cross carrying one copy of the driver 
(Figure 4A). With the same driver, a slight rough eye phenotype was observed in 
mutants but not in control flies when they were raised at 28˚C. However, the mutant 
phenotype was too weak to be used for a screen and when raised at lower 
temperatures, the phenotype vanished. The degenerative effect of the driver by its 
own was confirmed using paraffin eye sections stained with hematoxylin and eosin 
(HE) at 30ºC (Figure 4B). Toxicity caused by GMR-GAL4 on its own has been 
previously reported (Kramer & Staveley, 2003), so the use of this driver has been 
useful only for genes with a strong phenotype that is not masked by the one of the 
driver. 
 
 Conversely, using ey-GAL4 driver, a robust and specific phenotype was 
observed in mutant transgenic lines when compared to controls.  Although a 
reduction in eye size was already evident for both transgenic lines at 28˚C, a stronger  
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Figure 4. Expression of DVAP mutant alleles under the control of GMR-GAL4. 
(A) Representative light microscope images of eyes from control (GMR-GAL4/+), 
GMR/DVAP-P58S and GMR/DVAP-T48I adult flies raised at 28, 29 and 30ºC.                    
(B) Paraffin sections of heads from adult flies from these phenotypes raised at 30ºC. 
Roughness in the eye is present not only in flies carrying the mutant alleles but also 
in controls expressing the driver by its own. 
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effect was observed at 30˚C (Figure 5A). Under the microscope, eyes of flies DVAP-
P58S/ey-GAL4 looked smaller than DVAP-T48I/ey-GAL4 ones. This 
neurodegeneration was confirmed with the analysis of HE stained sections (Figure 
5B). At 30ºC, eyes of adult flies expressing DVAP-P58S looked comparatively 
smaller and showed fusion and disorganisation of ommatidia as well. This was also 
previously reported in detail using scanning electronic microscopy images and 
paraffin eye sections (Andrea Chai thesis). These phenotypic changes can be 
analysed and as previously reported, they represent an interesting readout for a 
genetic screen (Branco et al., 2008; Fernandez-Funez et al., 2000).  
 
 Eye size differences were easily noticeable but there was variability at different 
temperatures. The model selected for the genetic screen must show a consistent 
phenotype but also display a low variability for data reproducibility. To address this 
issue, we quantified the eye size area of the previous crosses. At least 20 eyes were 
photographed from independent adult flies using a light microscope. These were 
processed with the software ImageJ to quantify their eye surface area and then 
statistically analysed with Graphpad Prism. 
 
 The difference between mutant alleles and control areas was larger at 30ºC 
(Figure 6A), and less clear at 29ºC and 28ºC (Figure 6B and C, respectively). 
Another relevant difference was the larger variability in the area of eyes from flies 
carrying the DVAP-T48I allele compared to those with DVAP-P58S. This was clearly 
noticeable at 30ºC, where the former presents individuals with wild-type size eyes 
and others with almost no eyes. DVAP-P58S flies on the other hand, present a more 
consistent and narrow data distribution, clustering near the mean value. This crucial 
parameter for reproducibility of a screen, plus the higher reduction of eye size 
compared to controls, led us to select the expression of DVAP-P58S driven by ey-





Figure 5. Expression of DVAP mutant alleles under the control of ey-GAL4. (A) 
Representative light microscope images of eyes from control (ey-GAL4/+), 
ey/DVAP-P58S and ey/DVAP-T48I adult flies raised at 28, 29 and 30ºC. (B) Paraffin 
sections of heads from adult flies from these phenotypes raised at 30ºC. A significant 












Figure 6. Quantification of the eye surface area of flies carrying DVAP mutant 
alleles. Scatter plot displaying eye size area of CTRL (ey-GAL4/+), ey/DVAP-T48I 
(ey-GAL4,DVAP-T48I/+), ey/DVAP-P58S (ey-GAL4/DVAP-P58S) and recombinant 
ey,DVAP-P58S (ey-GAL4,DVAP-P58S/+) adult flies raised at 30ºC (A), 29ºC (B) 
and 28ºC (C). Each point corresponds to the measurement of an individual eye and 
the red line display the average of the population. When raised at 30ºC, the 
expression of DVAP-P58S in the eye presents a significant and consistent decrease 
in surface area. The same output is also observed in the recombinant line ey,DVAP-








3.5 Recombinant ey-GAL4,DVAP-P58S works consistently as a 
useful ALS model 
 
To achieve the DVAP-P58S expression, the UAS version of the allele must be 
present at the same time with the ey-GAL4 driver. This can be established either by 
crossing two parental lines each of them carrying one of the two elements, or by the 
construction of a recombinant line carrying both elements on the same chromosome. 
All these lines were available in our lab and we searched for differences in 
neurodegeneration induced by these two genetic possibilities. Quantification of eye 
surface area of flies obtained from a cross between ey-GAL4 males and UAS-
DVAP-P58S virgin females (ey-GAL4/DVAP-P58S) showed no significant 
differences when compared to eyes from flies obtained by crossing of the 
recombinant line and a wild type line (ey-GAL4,DVAP-P58S/+) (Figure 6A). 
Moreover, these two crosses presented the same narrow distribution at three different 
tested temperatures. Thus, the recombinant line ey-GAL4,DVAP-P58S represents a 
more convenient line as it provides the option to add a third element in the offspring 
(i.e. Misexpression EP line) to test its effect in the DVAP-P58S-expressing eye. This 
line was maintained throughout the screen, based on the solid results observed in 
these analyses. 
 
3.6 Expression of DVAP-P58S in the whole nervous system causes 
lethality at 30ºC 
 
After dissecting the DVAP-P58S-induced neurodegeneration in the eye, we studied 
the effect of the expression of this allele in the whole nervous system and compared 
the phenotype of the Drosophila model with some classical hallmarks of the disease 
in humans. ALS is a neurodegenerative disease that affects the motor system; 
therefore, expression in the whole Drosophila nervous system represents a closer 





 A different GAL4 driver was selected for nervous system expression. Elav-
GAL4 is based on the gene embryonic lethal abnormal vision, which codifies for a 
RNA-binding protein expressed in all neurons (pan-neural expression, Yannoni & 
White, 1997). This protein is required for maintenance and differentiation of the 
nervous system as it regulates splicing forms of different central genes like ewg, nrg 
and armadillo. Although DVAP protein is ubiquitously expressed, by using elav-
GAL4 we can regulate and mimic its deregulation in the nervous system. 
 
 As a first step we wanted to assess whether DVAP expression alters the 
viability of adult flies. Previous reports have shown that expression of DVAP-P58S 
forms intracellular protein aggregates containing both mutant and wild type versions 
of the protein (Teuling et al., 2007). This phenotype is central in several 
neurodegenerative diseases (Vabulas et al., 2010) and is related to cell death and 
decrease in the number of viable organisms. To study the effect of DVAP expression 
on the viability of adult flies, we expressed mutant DVAP alleles under the control of 
elav-GAL4. Flies failed to eclose when the mutant alleles DVAP-P58S and DVAP-
T48I were expressed at 30ºC (Figure 7A). Another line expressing low levels of the 
wild type form of the protein (DVAP-WT) showed a decrease in viability but not as 
severe as observed with mutant levels. When the expression of the alleles was 
reduced by decreasing the temperature, adult flies expressing the mutant alleles were 
able to eclose, but at a reduced ratio compared to controls and the DVAP-WT line. In 
the case of DVAP-P58S, the number of adult flies was almost 70% of the expected 
number observed in controls at 27ºC. These flies carry the mutant DVAP allele but 
still eclose as normal flies. This indicates that a progressive neurodegenerative effect 
can be observed after the flies eclose and not exclusively a defect at developmental 
level is presented. This was an important aspect of the next analysis, where mutant 








Figure 7. Expression of DVAP mutant alleles in Drosophila nervous system is 
toxic. (A) Viability ratios expressed as the number of observed adults females from 
control (in blue, elav-GAL4/+;+/+), elav;DVAP-P58S (red, elav-GAL4/+; DVAP-
P58S/+), elav;DVAP-T48I (green, elav-GAL4/+; DVAP-T48I/+), and elav;DVAP-
WT (black, elav-GAL4/DVAP-WT; +/+) flies raised at 27, 28, 29 and 30ºC. Number 
of females counted is displayed at the bottom of each bar. (B-E) Motor performance 
assay in DVAP-expressing adult flies. Flies expressing DVAP mutant alleles in the 
nervous system (red and green) lose progressively motor performance after eclosion. 
Compared to control flies (blue) elav;DVAP-P58S flies show a dramatic phenotype 
even before ten days after eclosion when raised at 28ºC. Each point represent the 
average of 10 repetitions of the percentage of flies able to reach 8 cm in 15 seconds 
(n=10). *** P < 0.001, ** P < 0.01 (Two-way ANOVA). 
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3.7 Motor performance progressively deteriorates with the 
expression of DVAP-P58S in the nervous system 
 
A central hallmark of ALS observed in patients is the progressive loss of motor 
performance, which finally leads to paralysis of vital organs such as heart and lungs 
(Pasinelli & Brown, 2006). This symptom is related to the progressive death of 
motor neurons through a mechanism not completely understood yet. If DVAP is an 
ALS causative gene and causes neurodegeneration, will be likely affecting motor 
performance in ALS models such as Drosophila. This has not been tested yet in this 
model, but has been consistently proved in other screens for neurodegenerative 
diseases, as a powerful tool to determine neuronal death (Branco et al., 2008; 
Kaltenbach et al., 2007). 
 
 To analyse this, we tested both DVAP mutant alleles at different temperatures 
to determine which level of expression would exhibit a specific and consistent 
phenotype. Males overexpressing DVAP were crossed with elav-GAL4 virgin 
females and the offspring was collected and raised at different temperatures: 25, 27, 
28 and 29 ºC. The different amount of DVAP expressed in the nervous system can 
alter the level and speed of neurodegeneration in adult flies. Therefore, we tried this 
range of temperatures to increase the possibility to obtain a clear phenotype. 
 
 Only female individuals were selected, as they show different climbing speed 
than males, likely due to their different size. Also, only virgin females were chosen 
due to two important observations: eggs inside non-virgin females may affect their 
weight and motor performance, and collection of virgin females in one day provides 
a narrow difference in age between the different individuals from the same group. 
 
 The tested females were kept at the specific temperature and every three days 
were tested to quantify the proportion of flies that were able to climb 8 cm in 15 s, 
inside a clear polyethylene tube. The number of flies who reached this height was 
counted, flies were tapped to the bottom and the measurement was repeated ten 
times. The flies were then transferred to a new vial of food and kept at the original 
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temperature until the time curve was complete. Every day before recording data, a 
trial run of ten non-recorded repetitions was performed to stabilise flies behaviour 
and climbing ability. 
 
 All DVAP lines showed normal motor performance in the first three days 
compared to controls; however they progressively started to lose this ability, 
implying that this phenotype had a neurodegenerative and not only a developmental 
origin (Figure 7B). Flies expressing DVAP-P58S in the nervous system showed a 
worse motor performance than other alleles at all temperatures tested, with an 
average of ten days before losing climbing capability. At 25ºC, flies expressing 
elav;DVAP-P58S showed wild-type level of climbing ability during the first nine 
days before losing it progressively ten days after. At this point, wild-type controls 
and overexpression of DVAP-WT exhibit an almost perfect motor performance. 
When the temperature was increased, the lack of motor performance in DVAP-P58S 
appeared even earlier, probably due to an increase in the toxic accumulation of this 
mutant protein in the nervous system. When tested at 29ºC, maximum temperature at 
which flies can eclose, the motor performance of individuals expressing DVAP-P58S 
was drastically lost before ten days, while flies expressing the other two DVAP 
alleles still performed at a climbing ratio over the 50%. 
 
 With these results, we showed for the first time the use of this important assay 
that can link expression of DVAP mutants and neurodegeneration. DVAP-P58S-
expressing flies mimic a central hallmark of the disease in humans and this validates 
even more the model as a relevant tool to study ALS. Considering that we plan to use 
this test to analyse several lines as part of our screen, it could be desirable to express 
DVAP at high temperatures to follow a shorter time curve that could supply data in a 
consistent way but in a shorter period of time. On the other hand, it is desirable to 
have a progressive decline in motor performance, which might bring less consistency 
and more variability as a negative effect. After several steps of optimisation, we 
decided to perform the climbing assay at 28ºC and in a time window between 4 and 
12 days. A significant suppression or enhancement of DVAP-P58S-associated 
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toxicity can be tested in this time frame and could represent a critical way to filter 
possible candidates.  
 
3.8 DVAP genetic modifiers can be found using the expression of its 
mutant allele in the eye 
 
We showed that the DVAP-P58S allele causes neurodegeneration in the eye as well 
as in the rest of the nervous system, and that driven under specific conditions, a 
consistent phenotype can be obtained. This phenotype could be the key to start the 
search of modifiers of DVAP-linked toxicity and at the same time, determine 
potential novel interactions of DVAP with ALS-related proteins. Before deciding to 
start this genome-wide search, we wanted to determine whether the ALS model can 
be used for that purpose, studying the genetic interaction of DVAP with pathways 
that other studies suggested could be involved in its toxicity. For this aim, we 
planned to study changes in DVAP-mediated toxicity under the effect of alleles of 
genes related to phosphoinositide metabolism and components of the JNK Pathway. 
 
 Phosphoinositides (PI) are membrane-related lipids involved in regulation and 
movement of different effector proteins. This function is crucial inside the cell and 
controls several pathways, based on the concentration of different versions of these 
lipids. The specific phosphorylation of 3 different positions in the molecule can form 
seven altered molecules that differ in concentration and localisation inside the cell. 
These small pools can relocate and concentrate diverse proteins to achieve their 
function in that specific area. For this reason, not only is relevant the PI 
concentration, but also the phosphatases and kinases that reversibly transform these 
molecules (Blagoveshchenskaya & Mayinger, 2008; Nakatsu et al., 2012). 
 
 Sac1 (Suppressor of Actin 1) is a phosphoinositide phosphatase that preferably 
dephosphorylates PI4P pools, but also can catalyse the conversion of PI3P and 
PI3,5P2. Previously, this protein has been listed as a DVAP physical interactor (Giot 
et al., 2003). This large-scale yeast two-hybrid result was recently confirmed by our 
group (Forrest et al., 2013), identifying at the same time that the transmembrane 
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domain of DVAP was necessary for this interaction. To understand the biological 
relevance of this physical interaction and concurrently, test our previously optimised 
ALS model, we analysed the effect of Sac1 alleles in the DVAP-linked 
neurodegeneration.  
 
 The co-expression of UAS-Sac1 in flies expressing DVAP-P58S under the 
control of ey-GAL4 suppresses the neurodegeneration in the eye (Figure 8). The eye 
size increased to an almost wild-type level. Additionally, ommatidia organization 
presented a normal organization compared to the roughness of the flies expressing 
DVAP-P58S, as observed in scanning electronic microscopy and paraffin sections of 
fly heads (Figure 8). This result suggests that the increase of PI or the decrease of 
PI4P could ameliorate the DVAP-P58S linked toxicity. If any of these is true, we 
should observe a suppression of the neurodegeneration by decreasing the formation 
of PI4P molecules. To confirm this, we co-expressed altogether with DVAP-P58S 
two loss-of-function alleles of the Drosophila PI4P kinases, Fwd and PI4KIIIα. As 
expected, we confirmed the result detected with the overexpression of Sac1 and 
reduction of kinases levels produced a normal eye structure, even when co-expressed 
with DVAP-P58S. These results (Figure 8) suggest the novel idea that accumulation 
of PI4P may be involved in DVAP toxicity, but more importantly for this project, 
reveal that changes in levels of DVAP genetic interactors can alter DVAP-P58S 
phenotype. The results also validate the expression of this allele under the control of 
ey-GAL4 as a useful model to search for genetic modifiers of its toxicity.  
 
 With the idea of confirming this last point and obtain novel data associated 
with DVAP mechanism, we studied components of another pathway related to PIs. 
In 2003, Wei et al. showed that Sac1 regulates apoptosis via JNK pathway. The Jun-
N-terminal kinase (JNK) is a stress-activated kinase that is conserved throughout the 
evolution and is the central step of a cascade system that responds to environmental 
stress stimuli. Even though in mammals each step of this system associates to a large 
family of genes that codifies different kinases, in Drosophila there is only one JNK 
protein (Basket) and two JNK Kinases (Hemipterous and dMKK4). These proteins 






Figure 8. DVAP-P58S-linked neurodegeneration is suppressed by 
downregulating PI4P formation. (A) Stereo microscope images, (B) frontal 
sections and (C,D) scanning electron micrographs of controls (ey-Gal4/+), ey,DVAP-
P58S (ey-GAL4,DVAP-P58S/+;+/+), ey,DVAP-P58S;UAS-Sac1 (ey-GAL4,DVAP-
P58S/+;UAS-Sac1/+), ey,DVAP-P58S/PI4KIIIaRNAi (ey-GAL4,DVAP-
P58S/PI4KIIIaRNAi;+/+) and ey,DVAP-P58S;FwdRNAi (ey-GAL4,DVAP-
P58S/FwdRNAi;+/+) adult fly eyes. Wild type structure of the control eye is affected 
as ey,DVAP-P58S eyes are smaller, with missing bristles and occasionally fused 
ommatidia. The ey,DVAP-P58S-mediated neurodegeneration is rescued by 
upregulating Sac1 phosphatase or by downregulating either PI4KIIIa or Fwd kinases. 
(E) Quantification of the eye surface area of these genotypes. Scale Bar = 50 um in 
























responses such as apoptosis, autophagy, cell proliferation and growth (Biteau et al., 
2011). Sac1 was linked to this pathway as a cooperative protein for the JNK 
suppressor Puckered, regulating negatively the pathway (Wei et al., 2003). They also 
suggested that this repression is mediated by the alteration of PI pools through the 
regulation of the cytoskeleton. To analyse whether this PI pool alteration also links 
the JNK pathway and DVAP toxicity, we crossed flies expressing different 
components of the JNK pathway with our ALS model. Interestingly, we did not find 
any modification of the DVAP neurodegeneration by downregulating the central 
component Jnk (Basket), or overexpressing the repressor Puc (Figure 9). However, 
we observed a strong suppressive effect when we tested the Inhibitor of apoptosis 
gene, DIAP1. This protein is required for survival of somatic cells in Drosophila 
embryos, inactivating different caspases that execute apoptosis via autoubiquitylation 
and proteasomal degradation (Hawkins et al., 1999). Our data suggest that the 
suppression of DVAP toxicity by DIAP1 is directed through a JNK-independent 
mechanism, possibly by blocking apoptosis effectors located downstream of DVAP.  
 
 In both validation assays, we observed a decrease in the toxic effect of the 
UAS-DVAP-P58S construct. It can be thought that this effect was due to a dilution 
of GAL4 when we crossed the construct with a different one. To discard this idea, 
we crossed DVAP-P58S flies with a line expressing a GFP construct (UAS-
mCD8:GFP). We observed the same phenotype of DVAP-P58S by its own (Figure 
10), indicating that the suppression effects previously showed are not due to a 
dilution effect from a non-interacting protein, validating at the same time these 
results. 
 
 Considering the previous data, we successfully tested the interaction of 
different alleles with the DVAP mutant allele. The clear neurodegeneration observed 
with the expression of this protein in the eye is a strong approach to analyse genetic 
interactions with those proteins involved in DVAP-toxicity mechanism. This idea 
will be the central part of this project, as we aim to search for novel modifiers of 




Figure 9. JNK Pathway components do not modify DVAP-linked 
neurodegeneration. (A) The JNK pathway, composed of three consecutive kinases 
that activate different apoptosis effectors. Puc is a direct repressor of the pathways 
and DIAP1 can also suppress apoptosis at other levels. The balance of these activities 
is important for cell growth and development. (B) Light microscopy images of 
control flies (ey-GAL4/+;+/+) and flies co-expressing in the eye DVAP-P58S and 
different JNK pathway mutant lines: ey,DVAP-P58S (ey-GAL4,DVAP-P58S/+;+/+), 
ey,DVAP-P58S;JNK-DN (ey-GAL4,DVAP-P58S/+;JNK-DN/+), ey,DVAP-P58S 
ey,DVAP-P58S/UAS-Puc (ey-GAL4,DVAP-P58S/UAS-Puc;+/+) and ey,DVAP-
P58S/UAS-Diap1 (ey-GAL4,DVAP-P58S/UAS-Diap1;+/+). Suppression is only 
observed with the overexpression of DIAP1, suggesting that the DVAP toxicity does 
not go through JNK pathway. (C) Quantification of eye surface area of the previous 
crosses. Only ey,DVAP-P58S/UAS-DIAP1 presented a comparable eye size with 
control (ey-Gal4/+) and significantly different from the ALS model (ey-Gal4,DVAP-






Figure 10. Expression of a GFP construct does not affect DVAP-P58S 
phenotype. (A) Light microscopy images of Controls (ey-Gal4/+), ey,DVAP-P58S 
(ey-GAL4,DVAP-P58S/+), and ey,DVAP-P58S/GFP (ey-GAL4,DVAP-P58S/UAS-
GFP) eyes. (B) Quantification of the eye surface area in flies of the indicated 
genotypes. DVAP-P58S expression in the eye displays same phenotype over a wild 
type chromosome or when co-expressed with the GFP construct. This confirms the 
lack of a GAL4 dilution effect in DVAP-P58S phenotype when another transgene is 



















Chapter 4: Genetic screen to 


















After optimising and validating the expression of DVAP-P58S in the eye as a proper 
model to study ALS, we performed a functional screen to discover genetic modifiers 
of the neurodegeneration associated with DVAP mutant allele. The lines that showed 
a significant modification level were then tested in a series of validation analyses that 
confirmed their effect in DVAP-P58S toxicity.  
 
4.2 Genetic screening as a powerful approach to study ALS 
 
Historically, the use of Drosophila has provided several crucial findings in the 
genetic field. In comparison with other models, probably the most practical 
advantage of the fruit fly is its genetic flexibility, which can lead to strong findings 
without redundancies or complications linked to higher organisms. This aspect has 
been successfully exploited throughout the years with designs of genetic functional 
screens, which stand out as a powerful approach successfully tested in other 
neurodegenerative diseases such as ataxias, Huntington’s disease and tauopathies 
(Fernandez-Funez et al., 2000; Kaltenbach et al., 2007; Shulman & Feany, 2003). 
Nevertheless, this idea has never been used to find unbiased functional interactors of 
ALS-causative genes. 
 
 Over the last years, other non-functional and biased screens have been 
performed with ALS-linked genes (Couthouis et al., 2011; Yang et al., 2013; Zhan et 
al., 2013). However, the strong characterisation performed in our model and the 
supporting evidence of it as a useful model for the study of the disease, directed us to 
start this functional screen. This characterisation has unveiled interesting processes 
and phenotypes associated with DVAP-P58S neurodegeneration. Among these 
parameters, neurodegeneration in the eye highlights as an easy and fast readout, not 
only for the consistent smaller eye compared to controls, but also for a clear 
disorganisation of the internal structure. This phenotype constitutes a good approach 
to test a high number of lines without excessive amount of resources involved in 
determining whether a modification effect is present. 
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4.3 Overexpression-based screens are an improved approach to find 
genetic interactions 
 
As an initial step, it was crucial to decide which type of line will be tested. 
Successful screens have mostly been performed based on three different Drosophila 
stocks: lines that misexpress transgenic constructs, loss-of-function lines of 
individual genes through expression of specific RNAi, and deletions of a genomic 
region using previously mapped stocks. Even considering the high availability of 
tools for the two loss-of-function techniques, these present important drawbacks and 
fewer advantages that the overexpression approach. 
 
 The expression of RNAi lines can be conveniently controlled. In the last years, 
different groups and stock centers have constructed RNAi lines for most Drosophila 
genes, turning this technique into a strong approach for genetic studies. However, an 
important problem with the expression of these constructs is the probability of non-
specific down-regulation of other genes. This off-target suppression affects the effect 
in the expected gene, and is necessary the use of additional RNAi lines to confirm a 
phenotype (Ma et al., 2006; Mohr et al., 2010). This is not ideal in a large scale 
screen, when the same resources could be used to investigate an additional gene and 
not a different allele for the first one. Additionally, RNAi-based results depend on 
the strength of the construct on the target gene. Therefore, different misleading 
phenotypes can be observed if the used RNAi line has a partial knock-out effect, 
compared to a complete loss of function allele. This also implies an extra detail in the 
background of the screen and the rate of false discovery that can affect the outcome 
of an RNAi screen (Mohr et al., 2010).  
 
 On the other hand, the search of modification using deletion stocks can provide 
important data in a faster way. A deletion line is constructed after the removal of a 
genomic region that includes a variable number of genes. A phenotype observed 
crossing the studied model with one of the deletion stocks may be caused by any of 
the missing genes in that specific line or even by two genes simultaneously. This is a 
main drawback of this technique for large scale studies, as it is necessary to 
81 
determine which of these genes is affected. This process may require several other 
stocks, resulting in a similar problem as the RNAi approach. Additionally, these 
techniques need a genetic background sensible enough to observe minor phenotypic 
differences, issue that can be difficult after handle an important number of stocks 
(Rørth, 1996).  
 
 The third technique, the use of missexpression lines, is our preferred choice for 
this study. Introduced for the first time in 1996 for the detection of tissue-specific 
phenotypes (Rørth, 1996), this genetic approach became the best way to find genetic 
modifiers as it was able to detect an important number of dominant interactions that 
were overlooked with the loss-of-function screens. This first generation of 
misexpression screen was based on the UAS-GAL4 system and random insertions of 
a P-element carrying a promoter with the potential to overexpress neighbor genes. 
 
 The P-transposable element inserted in the middle of a gene still worked as a 
loss-of-function insertion, disrupting the expression of the original gene. However if 
the P-element was inserted upstream of an open reading frame, the GAL4-responsive 
Upstream Activator Sequence enhances the transcription of the neighbour gene, 
resulting in lines that overexpresses their target. This concept was successfully 
proved originally by Rørth and later, expanded with the creation of other optimised 
P-elements (Staudt et al., 2005), building an important collection of misexpression 
stocks. These collections gathered a number of advantages that supported the system 
as an advanced screen approach: the detection of genes with phenotypes overlooked 
by previous screens (crucial point considering that two thirds of Drosophila genes do 
not posses a clear loss of function phenotypes), the tissue and temperature specific 
overexpression controlled by the UAS-GAL4 system, and the modular idea of the 






4.4 DVAP-P58S expression in the eye at 30ºC favours the finding of 
suppressor lines 
 
Temperature and tissue specific expression, parameters relevant in the UAS-GAL4 
system, were tested in the optimisation presented in our previous chapter. 
Temperature increase enhances the GAL4 transactivator activity in the target tissue 
and thus, increases the expression of the transgene under the control of the UAS-
GAL4 binding sequences (Duffy, 2002).  
 
 We observed a spectrum of phenotypes over 25ºC, but we decided to express 
the target genes at 30ºC, which constitutes a strong phenotype. The reason for 
selecting this temperature was that in this condition a more severe neurodegenerative 
phenotype is observed in the eye. This phenotype is characterized by disorganised 
ommatidia, loss and supernumerary bristles and a significant reduction in size 
(Forrest et al., 2013). This phenotype allowed us an easy and quick readout, relevant 
decision for a large scale screen considering resources and time scales.  
 
 This strong phenotype sets a threshold where the probability to find modifiers 
that suppress this neurodegeneration is higher than the ones that enhance it even 
more. This selection is desirable because, even although all modifiers are potentially 
useful, suppression of the phenotype can give us stronger clues for possible 
mitigation of ALS pathology. On the other hand, we consider that a possible 
enhancer line will show a narrower modification effect compared to the suppressors, 
basically because the eye in our model is already severely damaged. To address this 
problem we plan to double check potential enhancer lines repeating the cross at 
28ºC, a lower temperature where the eye size of the model is less affected and a 
potential enhancer line will show a bigger difference than at 30ºC. Additionally, 
another parameter was observed and consequently considered as a complement of 
the eye structure readout. Eyeless-GAL4 driver shows a leaky expression outside the 
eye (Callaerts et al., 2001). This may translate into a toxic effect in the rest of the 
nervous system and leads to a decrease in viability of crosses carrying the DVAP-
P58S allele. The viability ratio of ey-GAL4,DVAP-P58S/+ is lower than 1.0, but in 
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crosses with potential enhancers this ratio was even less, in addition to a smaller eye 
size. Reduction in eye size observed altogether with a decrease in viability gave us a 
stronger indication of a potential enhancement of the DVAP-P58S toxicity. With 
these parameters we expect to cover in a fast way, both directions of toxicity 
modification in flies expressing DVAP-P58S in the eye.  
 
4.5 Potential misexpression insertion stocks tested in the genetic 
screen 
 
The important amount of research and collaborative efforts achieved with 
Drosophila explain another central advantage of this model: the high number of 
stocks and genetic tools available for the community. Beside the already mentioned 
RNAi lines and deletion stock collections, an important number of P-element lines 
are publicly available in Drosophila stock centers. Bloomington Drosophila Stock 
Center at Indiana University is the largest one, offering different services, genetic 
tools and stocks. Their Potential Misexpression collection, comprising 5340 lines 
(34% of the Drosophila genome) include different lines carrying a P-element that 
potentially can overexpress or down-regulate a specific gene. Throughout the years, 
this list has been curated to remove redundant lines and characterised to add relevant 
information, such as genes affected, exact genetic location of the insertion and 
references associated. This information, available in FlyBase (Drysdale & FlyBase 
consortium, 2008), will be key in this study to filter and select the best lines that 
potentially can overexpress a specific target.  
 
 The Potential Misexpression collection comprises six groups of stocks carrying 
a different transgene each. The consortium in charge of the Gene disruption project, 
led by the Rubin, Bellen and Spradling groups, has mostly constructed these 
collections in the last two decades (Bellen et al., 2004). These collections, illustrated 
in Figure 11, differ in structure and final phenotype observed. Three of them (P{EP}, 
P{EPgy2} and P{Mae-UAS.6.11}) carry an independent promoter next to the UAS 
sequence in the construct. The promoter increases the chances of a potential 





Figure 11. Drosophila misexpression stocks used in this study. (A) Schemes of 
the three stock collections available in Bloomington Drosophila Stock Center used in 
this study. All of them carry a GAL4-binding UAS site (red) and a promoter (blue) to 
start the transcription of neighbour genes. (B) Genomic map of the region where is 
inserted the line DIAP2G2326.  The element insertion (blue triangle), in a correct 
direction and location at the regulatory region of the gene, ensures an increased 
transcription of the target gene. (C) Stocks used in this study. In green are 
highlighted the collections used, from the second and third chromosome. Available 
lines not included in the analysed category include lines with a potential loss-of-
function effect and redundant lines already tested. A total of 1183 lines were 
screened. (D) General scheme of the genetic screen. Female virgins expressing 
DVAP-P58S in the eye were crossed with males from the misexpression collection 
and their offspring can present either no effect in the ALS model phenotype or a 




(Figure 11A). The constructs can start the transcription of a neighbour gene if they 
are inserted in the correct orientation within 2kb upstream of a transcription unit 
(Figure 11B) (Bellen et al., 2004). These parameters were used to filter the original 
collection and discard lines that were less likely to overexpress the target gene. 
 
 Stocks not considered included lines with insertion in the middle or the 3’ end 
of a gene, stocks in which the direction of transcription of the transgenic promoter 
was in the opposite direction than the orientation of the target gene, and stocks 
inserted in a genomic region without close neighbour genes. In addition, when more 
than one stock was available to target one gene, the best located insertion according 
to the previous parameters was selected for analysis.  
 
 As a long-term project, in our group we believe that the best way to understand 
completely DVAP mechanisms and toxicity is to screen the whole genome and 
analyse all the possible available overexpression stocks. In this study, we presented 
the first step to this aim, with the analysis of 1183 potential overexpression lines 
available in BDSC (Figure 11C). These lines include all the available lines inserted 
in the second chromosome, curated to test potential overexpression stocks from the 
previously mentioned three collections. Additionally, we tested all the potential 
overexpression stocks from the P{EP}collection in the third chromosome, an extra 
set of 363 lines.  
 
 These stocks were carefully tested and repeated three times when results 
showed either significant or inconclusive modification. In this way, the first stage of 
the screen consisted of a cross of female virgins ey-Gal4,DVAP-P58S with males of 
misexpression stocks received from BDSC, to analyse the offspring and quantify 
their eye size in order to select modifiers (Figure 11D). This stage, the most time-
consuming part of the study, included an estimated amount of over 1500 crosses, 
before the next steps of validations and further characterisation discussed later. A 
flow chart detaling this stage and posterior experiments performed to reach a final 






Figure 12. Flow chart of the genetic screen. Flow chart illustrating pipeline of 
DVAP-P58S-modifiers identification. Starting from an initial set of 1183 
misexpression collection, we obtained a set of 42 high confidence modifiers of 






4.6 Ninety seven lines were identified as modifiers of DVAP-P58S-
induced neurodegeneration in the eye 
 
In order to carry out the screen, the methodology was highly coordinated. A constant 
collection of ey-GAL4,DVAP-P58S female virgins allowed to perform up to 50 
crosses per week. 10-12 female virgins were crossed to 8-10 males from each 
misexpression line and were left at room temperature for 48 hours before transferring 
the vials to a 30ºC water bath. A duplicate vial was used to increase the offspring 
number and reduce the chance of failed crosses. Offspring was then collected and 
analysed under the microscope to look for phenotypic differences between each cross 
and the respective control. Pictures of female flies were taken to quantify the average 
eye area surface of each cross using ImageJ. Crosses without a clear change in eye 
size were also captured but not quantified. Crosses with potential modification effect 
were confirmed through this quantitative analysis and the stock was crossed again 
two more times to confirm the phenotype and then kept for further studies. Stocks 
that failed to modify the phenotype were discarded. Throughout this process, the 
stocks were treated blindly and identified only by their stock number and not by their 
gene name, to avoid introducing any bias in data processing. 
 
 Lines with suppressor modifier effect (reduced DVAP-P58S-linked 
neurodegeneration in the eye with an increase in its area, from now on 
“Suppressors”) were detected and later confirmed through quantification (Figure 13). 
For lines with an enhancement effect (lines that increased DVAP-P58S toxicity 
reducing even more the eye size, from now on “Enhancers”) the detection was less 
straightforward, as previously discussed, with an already small, damaged eye in the 
tester line (ey,DVAP-P58S). Therefore, we selected lines that enhanced the 
degeneration in the eye and the lethality linked to DVAP-P58S, and these stocks 









Figure 13. Genetic suppressors of DVAP-linked neurodegeneration in the eye.            
(A) Stereo microscope images of control (ey-Gal4/+), ey,DVAP-P58S (ey-
GAL4,DVAP-P58S/+) and ey,DVAP-P58S/DIAPG2326 (ey-GAL4,DVAP-P58S/ 
DIAPG2326) adult fly eyes. Scale bar = 50 um. (B) Quantification of the eye surface 
area of adults flies. The population average size (red line) in the co-expression of 
DVAP-P58S and the representative suppressor EP line is drastically increased 
(P<0.001, One-way ANOVA) to levels closer to wild type, suppressing the 
degenerative phenotype of the tester line. (C) List of suppressor misexpression lines 
detected in the screen. Each point represents the average surface area from one 
experiment, normalised to the size of its control ey,DVAP-P58S eye. Average of 
three independent experiments is displayed as a red line. Significant suppression of 




After the analysis of almost 1200 lines, we obtained 97 lines with a potential 
modification effect. With these candidate modifiers we started an exhaustive 
validation round of assays (detailed in the next section) to discard additional false 
positive lines. These analyses include a more specific test for enhancer lines, genetic 
controls of P-element insertions and phenotypic analysis of the modifier lines 
without the DVAP-P58S expression. After these validation assays, we completed a 
final list with 85 confirmed modifiers. In the Tables 5 and 6 are reported the 
complete lists of validated modifiers together with the average percentage of 
modification, name of the allele used and molecular activities associated, according 
to the PANTHER classification system (Mi et al., 2013). Table 7 describes the 
modification effect of each independent experiment, and the statistical difference 
compared to their controls. Also, variation between the three replicas was analysed 
using a one sample t-test, comparing their average to the hypothetical value of 
modification (no modification effect, value = 0). The average of all the independent 
triplicates was significantly different than the hypothetical value. This list of 71 
suppressors and 14 enhancers indicates a successful approach in the search of 




Gene Name - 
Suppressors 
Gene 




Sup Protein class Biological process Cellular component 
Hormone receptor-like 
in 39 Hr39 P{EPgy2}Hr39
EY04579 20152 90.55 Hormone receptor 
regulation of transcription, DNA-dependent  
female meiosis chromosome segregation  
ecdysone-mediated induction of cell autophagic cell death  
activation of cysteine-type endopeptidase activity involved in 
apoptotic process  
spermathecum morphogenesis   
regulation of gene silencing  
steroid hormone mediated signaling pathway   
regulation of transcription, DNA-dependent  
male courtship behavior, veined wing generated song production  
nucleus 
Inhibitor of apoptosis 
2 Iap2 P{EP}Iap2
G2326 26986 79.62 Protease inhibitor 
sensory organ development  
defense response to Gram-negative bacterium 
endopeptidase activity involved in apoptotic process 
negative regulation of apoptotic process 
peptidoglycan recognition protein signaling pathway 





Sgt P{EPgy2}EY02712 15587 79.12 Chaperone neuromuscular synaptic transmission - 
CG5118 CG5118 P{EPgy2} 
CG5118EY18569 16541 76.58 - - - 
Spaghetti Spag P{EPgy2}spagEY11196 20274 75.79 Chaperone 
cell proliferation   
imaginal disc growth  
imaginal disc development   
imaginal disc fusion, thorax closure  
- 
Type III alcohol 
dehydrogenase T3dh P{EPgy2}T3dh
EY09338 17559 74.65 Dehydrogenase oxidation-reduction process   - 
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Abrupt ab P{EPgy2}abEY09709 16949 74.02 Nucleic acid binding 
sensory organ development  
synaptic target recognition  
muscle attachment   
axon choice point recognition  
dendrite morphogenesis  
neuron development   
muscle organ development  
border follicle cell migration  
mushroom body development  
nucleus   
Rap GTPase 
activating protein 1 RapGAP1 P{EPgy2}
EY01137 15062 73.59 G-protein modulator 
inter-male aggressive behavior 
activation of Rap GTPase activity 
regulation of small GTPase mediated signal transduction 
germ plasm 
Rhomboid rho P{EP}rhoEP3704 17276 72.15 Serine-protease 
brain development   
learning or memory   
cytokinesis  
epidermal growth factor receptor signaling pathway   
salivary gland development  
axonogenesis  
behavioral response to ethanol   
negative regulation of gene expression  




integral to membrane 
apical part of cell 
Upf3 Upf3 P{EPgy2}Upf3EY03241 16558 69.62 Nucleic acid binding nuclear-transcribed mRNA catabolic process, nonsense-decay  - 
Klarsicht klar P{EP}EP3104EP3104 6413 68.83 Hydrolase 
microtubule-based movement 
nuclear migration 
lipid particle transport along microtubule 
compound eye morphogenesis 
cellular membrane organization 
lipid transport  
organelle localization 










CG12299 CG12299 P{EPgy2} 
CG12299EY01579 15520 68.45 
KRAB box 
transcription factor - - 
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Leak lea P{EP}leaEP2582 17071 67.86 Receptor 
axon guidance   
ventral cord development   
tracheal outgrowth, open tracheal system   
neuron migration   
positive regulation of cell-cell adhesion   
cardioblast cell fate specification  
mushroom body development   
central complex development  
gonad development   
synaptic target recognition   
plasma membrane  
axon   
CG5734 CG5734 P{EPgy2} 
CG5734EY05560 15456 67.76 
Phosphatidyl inositol 
binding - - 
Acyl-CoA synthetase  
long-chain Acsl P{EPgy2}Acsl
EY07112 19860 66.87 Ligase 
positive regulation of sequestering of triglyceride 
axon guidance 
nervous system development 
synaptic transmission  
segmentation  
neurogenesis   
long-chain fatty acid metabolic process  
lipid particle  
cytoplasm   
endoplasmic 
reticulum  
Actin 42A Act42A P{Epgy2} 
Act42AEY05608 15460 66.67 Motor protein 
cytoskeleton organization  
phagocytosis   
mitotic cytokinesis  
actin filament   
microtubule 
associated complex  
Tejas tej P{Epgy2}tejEY20088 22361 66.19 Signal transduction karyosome formation  
negative regulation of transposition  P granule   
CG15630 CG15630 P{Epgy2}EY20668 22414 66.18 Cell adhesion family - - 
Inositol 1,4,5-
triphosphate kinase 1 IP3K1 
P{Mae-UAS.6.11} 
IP3K1UY530 6769 65.77 Kinase response to oxidative stress  cytoplasm  
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Costa cos P{Epgy2}cosEY08735 19759 65.64 Motor protein 
ovarian follicle cell development  
positive regulation of hh target transcription factor activity   
negative regulation of transcription factor import into nucleus  
microtubule-based movement  
regulation of proteolysis  
smoothened signaling pathway  
imaginal disc-derived wing morphogenesis  
regulation of protein stability  
negative regulation of sequence-specific DNA binding transcription 
factor activity  
cytoplasmic sequestering of transcription factor   
cytoplasm  
kinesin complex  
microtubule 
associated complex  
Hedgehog signaling 
complex   
plasma membrane  
vesicle membrane  
CG13204 CG13204 P{Epgy2} 
CG13204EY11838 21076 65.03 Nucleic acid binding - - 
Retinal degeneration 
B beta rdgBβ P{EP}rdgBβ






P{Epgy2}    
Su(var)2-10EY01453 19642 64.25 Ligase 
chromosome condensation  
imaginal disc growth  
hemopoiesis   
regulation of JAK-STAT cascade  
regulation of protein catabolic process  
compound eye development  
chromosome organization   
neurogenesis  
mitotic G2 DNA damage checkpoint 
positive regulation of innate immune response   
cytoplasm   
nuclear lamina   
nucleoplasm  
nucleus   
polytene 
chromosome  
14-3-3ζ 14-3-3ζ P{Epgy2}        14-
3-3ζEY06147 19919 63.42 Chaperone 
Ras protein signal transduction   
activation of tryptophan 5-monooxygenase activity   
olfactory learning   
chromosome segregation   
mitotic cell cycle, embryonic   
learning or memory  
cell proliferation  
protein folding  
compound eye photoreceptor cell differentiation   
thermosensory behavior  
nucleus  
germline ring canal  
microtubule 
associated complex  
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Vacuolar protein 
sorting 35 Vps35 
P{Epgy2} 
Vps35EY14200 20913 63.20 
Membrane trafficking 
protein 
vesicle-mediated transport   
endocytosis  
retrograde transport, endosome to Golgi  
protein transport   
endosome  
late endosome   
retromer complex   
Spc105-Related Spc105-R P{EP}G4635 28884 63.09 - 
mitotic spindle organization   





CG3625 CG3625 P{Epgy2} 
CG3625EY07089 16406 62.88 - - integral to membrane  
Milton milt P{Mae-UAS.6.11} 
miltLA00951 22198 62.52 
Mitochondrial 
trafficking protein 
axon transport of mitochondrion   
mitochondrion distribution  
Nebenkern assembly   
sperm mitochondrion organization  
axon transport of mitochondrion   
mitochondrion   
Signal peptide 
peptidase spp P{EP}G2086 27455 62.40 Protease 
open tracheal system development  
cellular response to unfolded protein  




Syntaxin 6 Syx6 P{Epgy2}Syx6EY14508 20941 61.91 SNARE protein 
neurotransmitter secretion  
vesicle-mediated transport  
synaptic vesicle docking involved in exocytosis  
Golgi vesicle transport  
plasma membrane    
SNARE complex  
Silent information 
regulator 2 Sir2 P{EP}Sir2
EP2300 24859 61.43 Acetylase 
histone deacetylation  
chromatin silencing  
regulation of histone acetylation  
determination of adult lifespan  
response to nutrient  
regulation of apoptotic process  
behavioral response to ethanol  
regulation of transcription, DNA-dependent  
positive regulation of feeding behavior  
cytoplasm  
nucleus   
nucleoplasm   
Female sterile (2) 
Ketel Fs(2)Ket 
P{EPgy2} 
Fs(2)KetEY06666 15967 60.73 Transporter 
mitosis  
chorion-containing eggshell formation |  
protein import into nucleus  
actin filament organization   
regulation of cell shape   






Lethal (2) k05819 l(2)k05819 P{EPgy2}EY03384 20150 60.55 - - - 




Hippo hpo P{EP}hpoG3315 27105 58.58 Kinase 
protein phosphorylation  
apoptotic process  
cell proliferation  
response to ionizing radiation  
negative regulation of neuron apoptotic process   
stem cell proliferation  
retinal cell programmed cell death  
eye development  
organ growth  
negative regulation of transcription, DNA-dependent  
- 
CG10809 CG10809 P{EP}CG10809G4564 27161 58.17 - - - 
Ras which interacts 
with calmodulin Ric P{EP}Ric
G2693 27003 58.10 Small GTPase 
response to oxidative stress 
response to starvation  
response to heat 
response to osmotic stress 
small GTPase mediated signal transduction  
GTP catabolic process 
plasma membrane 
Quaking related 58E-3 qkr58E-3 P{EPgy2}     
qkr58E-3EY02038 15086 57.68 Transcription factor 
apoptotic process  
regulation of alternative mRNA splicing, via spliceosome  
nucleus  
nuclear speck  
Vesicle-associated 
membrane protein 7 Vamp7 P{EP}Vamp7
G7738 28488 57.56 SNARE protein 
intracellular protein transport 
autophagic vacuole maturation  
vesicle fusion  
endosome to lysosome transport   
autophagic vacuole fusion 
plasma membrane  
integral to membrane   
late endosome 
membrane  
SNARE complex  
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Cyclin-dependent 
kinase 4 Cdk4 P{EPgy2}Cdk4
EY09330 19891 57.55 Kinase 
protein phosphorylation  
cell proliferation   
regulation of cell growth   
mitochondrion organization   
JAK-STAT cascade  
blastoderm segmentation   
open tracheal system development 
regulation of cell cycle  
mitotic cell cycle   
- 
CG18870 CG18870 P{EPgy2} 
CG18870EY06926 15981 57.14 - - - 
Secreted Wg-
interacting molecule Swim 
P{EPgy2} 
SwimEY09931 17622 56.49 Protease 
positive regulation of Wnt receptor signaling pathway     
immune response   
proteolysis   
chorion  
extracellular space  
CG4896 CG4896 P{EPgy2} 
CG4896EY01431 19814 55.85 - - - 
CG9643 CCG9643 P{EPgy2} 
CG9643EY07345 16815 55.72 Methyltransferase - - 
Polycomblike Pcl P{EPgy2}PclEY08457 19876 55.49 - 
transcription, DNA-templated 
multicellular organismal development 
chromatin modification 
neurogenesis 
defense response to fungus 
chromosome 
nucleus 
CG8520 CG8520 P{EPgy2} 
CG8520EY09481 17573 55.43 Hydrolase - - 
Disc proliferation 
abnormal dpa P{EPgy2}dpa
EY04015 15922 54.86 DNA helicase DNA replication   
mitotic spindle organization   
nucleus   
MCM complex  




Olf186-F olf186-F P{EPgy2} 
olf186-FEY01467 20119 54.67 Signaling molecule 
positive regulation of NFAT protein import into nucleus   
positive regulation of calcium ion transport  
nervous system development   
store-operated calcium entry   
integral to membrane   
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Autophagy-specific 
gene 7 Atg7 P{EPgy2}Sec6
EY10058 17635 54.22 Transfer protein 
ligase 
regulation of autophagy  
macroautophagy  
larval midgut cell programmed cell death  
determination of adult lifespan  
regulation of defense response to virus  
positive regulation of macroautophagy   
cellular response to starvation  
oogenesis   
cytoplasm  
CG13192 CG13192 P{EPgy2} 
CG13192EY07746 17400 54.20 
G-protein coupled 





CG4502EY07938 17415 53.95 Ligase - - 
Cullin-2 Cul-2 P{EPgy2}Cul-2EY09124 19883 52.79 Ubiquitin-protein 
ligase 
neurogenesis  
growth of a germarium-derived egg chamber   
regulation of synaptic growth at neuromuscular junction  
ubiquitin-dependent protein catabolic process  
nuclear ubiquitin  
ubiquitin ligase 
complex   
CG10492 CG10492 P{EPgy2} 
CG10492EY10125 17640 52.75 - - - 
Croquemort crq P{EPgy2}crqEY14489 20939 52.71 Receptor 
phagocytosis  
phagocytosis, engulfment  
defense response  
immune response  
autophagic cell death  
apoptotic process  
macrophage activation   
salivary gland cell autophagic cell death  
cell adhesion  
 plasma membrane   
membrane  
CG11125 CG11125 P{EP}CG11125G18969 26951 52.37 - - - 
Auxillin Aux P{EP}auxG6787 30174 51.85 Transcription factor 
protein phosphorylation  
synaptic vesicle uncoating  
Notch signaling pathway  
compound eye morphogenesis  
sperm individualization  
protein phosphorylation  
Golgi stack  
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Rab5 Rab5 P{EPgy2}Rab5EY10619 20193 51.73 Membrane trafficking  
regulatory protein 
chromatin organization   
mitosis  
endocytosis  
negative regulation of cell proliferation   
endosomal vesicle fusion   
axonogenesis   
protein transport  
Rab protein signal transduction   
vesicle-mediated transport   
Notch receptor processing  
early endosome  
lipid particle  
synapse  
neuronal cell body  
vesicle  
Syntaxin 7 Syx7 P{EP}Syx7G6457 28476 50.75 SNARE protein 
neurotransmitter secretion  
vesicle-mediated transport 
synaptic vesicle docking involved in exocytosis 
negative regulation of cell proliferation  
positive regulation of endocytosis 
endosomal vesicle fusion 
pupariation 
multicellular organism growth  






Protein 1 HSPC300 P{EP}HSPC300
G19021 26953 50.54 - 
regulation of cell shape  
central nervous system morphogenesis  
regulation of synaptic growth at neuromuscular junction 
positive regulation of filopodium assembly 
positive regulation of lamellipodium assembly 
- 
Trap1 Trap1 P{EPgy2} 
Trap1EY10238 19974 50.43 Chaperone 
protein folding  
response to oxidative stress  
lipid particle   
mitochondrion  
Draper drpr P{EP}drprEP522 17175 50.41 Receptor/signaling 
molecule 
cell adhesion  
larval locomotory behavior 
phagocytosis 
cell competition in a multicellular organism  
apoptotic cell clearance  
salivary gland cell autophagic cell death 
neuron remodeling 
wing disc dorsal/ventral pattern formation  
defense response to bacterium  




Kismet kis P{EPgy2}kisEY12846 21391 49.16 DNA helicase 
determination of adult lifespan  
segment specification  
antimicrobial humoral response   
axon guidance   
positive regulation of organ growth  
negative regulation of transcription, DNA-dependent  
short-term memory   
locomotion   
neuron remodeling  
peroxisome organization   
nucleus   
microtubule 
associated complex  
Hiiragi hrg P{EPgy2}hrgEY10340 17668 49.15 Adenylyltransferase mRNA polyadenylation   nucleus   
A kinase anchor 
protein 200 Akap200 P{EP}Akap200
EP2254 17037 48.14 Kinase 
protein localization   
negative regulation of Ras protein signal transduction   
autophagic cell death   
salivary gland cell autophagic cell death   
behavioral response to ethanol  
regulation of establishment of planar polarity  
lipid particle 
Cyclin B CycB P{EPgy2}CycBEY08217 19870 45.23 Kinase activator 
cytokinesis  
mitotic chromosome movement towards spindle pole  
mitotic cytokinesis  
attachment of spindle microtubules to kinetochore   
embryonic development via the syncytial blastoderm   
G2/M transition of mitotic cell cycle   
cellular process  
response to DNA damage stimulus  
regulation of chromatin binding   
regulation of cyclin-dependent serine/threonine kinase activity  
pole plasm   
chromosome  





complex   
spindle midzone  
nucleus   
Src oncogene at 42A Src42A P{EPgy2} 
Src42AEY08937 19763 44.66 
Transmembrane 
receptor 
tricarboxylic acid cycle 
protein phosphorylation 
transmembrane receptor protein tyrosine kinase signaling pathway 
JNK cascade 
multicellular organismal development 
axon guidance 
open tracheal system development 
regulation of cell proliferation 
apoptotic cell clearance 






beta 5 Prosβ5 P{EPgy2}EY00934 14870 43.98 Proteasome 
centrosome organization  
mitotic spindle organization  
mitotic spindle elongation  
cell proliferation  
neurogenesis  
proteolysis involved in cellular protein catabolic process  
proteasomal ubiquitin-dependent protein catabolic process   
proteasome core 
complex  
Coronin coro P{EP}coroGE15547 26894 43.51 Non-motor actin 
binding 
defense response to fungus 
actin cytoskeleton organization 
adult somatic muscle development 
actin cytoskeleton 
mitotic spindle 
Connector enhancer of 
ksr cnk P{EPgy2}cnk
EY06675 20160 40.89 Kinase modulator 
signal transduction   
Ras protein signal transduction   
compound eye photoreceptor cell differentiation  
imaginal disc-derived wing morphogenesis  
anterior/posterior axis specification, embryo   
torso signaling pathway  
tracheal outgrowth, open tracheal system  
imaginal disc-derived wing vein morphogenesis  
apical part of cell   
cytoplasm   
plasma membrane   
cell-cell adherens 
junction  
Lightoid ltd P{EPgy2}ltdEY07166 20166 30.51 GTPase activity 
ommochrome biosynthetic process  
learning or memory  
olfactory learning  
eye pigment precursor transport   
protein transport  
Rab protein signal transduction  
vesicle-mediated transport   
compound eye pigmentation   
regulation of lipid storage  
regulation of autophagy  
synapse  
recycling endosome  
vesicle  
lysosome 
autophagic vacuole  
 
Table 5. List of suppressors of DVAP-P58S-associated toxicity in the eye. For each modifier gene found in the screen, the average modification 
effect is displayed after three independent experiments, performed at 30ºC. Statistical analysis of each experiment is detailed in Table 7. Stock ID 
represents the Bloomington Drosophila stock center annotation for the line carrying the specific Allele. Protein class was obtained from the 




Gene Name - 
Enhancers 
Gene 




Protein class Biological process Cellular component 
Eye Let 
Scabrous sca P{EPgy2}EY00639 20095 57.14 41.18 Signaling 
molecule 
chaeta morphogenesis   
nervous system development   
female meiosis chromosome segregation   
ommatidial rotation   
nervous system development   
lateral inhibition  
regulation of R8 cell spacing in compound eye  
compound eye development  
imaginal disc-derived wing margin morphogenesis   
response to alcohol 
fibrinogen complex  
extracellular region   
Myocyte-specific 
enhancer factor 2 
Mef2 P{EP}Mef2EP2002a 17230 40.80 58.77 Transcription 
factor 
transcription from RNA polymerase II promoter 
mesoderm development 
regulation of transcription, DNA-dependent 
heart development 
muscle fiber development 
myoblast fusion 
locomotor rhythm 





biogenesis factor 10 Pex10 P{EP}Pex10
G5094 27176 24.59 53.24 Transporter 
peroxisome organization 
spermatid development 
primary spermatocyte growth 
male meiosis cytokinesis 
spermatocyte division 
protein import into peroxisome matrix 
protein import into peroxisome membrane 
very long-chain fatty acid catabolic process 
peroxisome organization 
integral to peroxisomal membrane 
peroxisome 
Smooth sm P{EPgy2}smEY07191 19727 23.01 20.30 Splicing factor 
adult feeding behavior   
axon guidance   
determination of adult lifespan  
ribonucleoprotein complex  
CG9153 CG9153 P{EP}CG9153G5486 27181 22.60 47.63 Ubiquitin-
protein ligase 
protein ubiquitination involved in ubiquitin-dependent 





carrier homolog 1 Mtch P{EP}Mtch
G8642 27981 20.49 46.35 Mitochondrial 
carrier protein - mitochondrion 




Mdh1EY08761 16435 18.04 29.28 Dehydrogenase 
lateral inhibition  
cellular carbohydrate metabolic process  
malate metabolic process  
cytoplasm  






lolaEY10040 27480 17.37 40.28 
Nucleic acid 
binding 
axon guidance   
antimicrobial humoral response  
brain morphogenesis   
startle response  
locomotion involved in locomotory behavior   
inter-male aggressive behavior    
nurse cell apoptotic process 
regulation of transcription, DNA-dependent                                                    
neurogenesis 
gonad development   
nucleus  
Dynamin associated 
protein 160 Dap160 P{EP}Dap160





synaptic growth at neuromuscular junction 
synaptic vesicle endocytosis 
positive regulation of protein kinase activity 
positive regulation of neuroblast proliferation 








G3500 27111 13.45 41.18 RNA binding 
protein alanyl-tRNA aminoacylation  cytoplasm   
Dreadlocks dock P{EPgy2}EY08327 19871 12.87 24.47 Signaling 
molecule 
axon guidance 
insulin receptor signaling pathway   
axonogenesis  
regulation of insulin receptor signaling pathway  
myoblast fusion  
cytoplasm 
CG30456 CG30456 P{EP}EP2185 17237 12.25 52.06 Signaling 
molecule 
imaginal disc-derived leg morphogenesis 
positive regulation of Rho protein signal transduction - 
Calcium-binding 
protein 1 CaBP1 
P{EPgy2} 
CaBP1EY12345 20346 11.06 34.99 Isomerase 
cell redox homeostasis  
glycerol ether metabolic process  
positive regulation of apoptotic cell clearance  
lipid particle  




Table 6. List of enhancers of DVAP-P58S-associated toxicity in the eye. For each modifier gene found in the screen, the average modification effect 
is displayed after three independent experiments, performed at 28ºC. Statistical analysis of each experiment is detailed in Table 7. In addition, lethality 
changes were measured in triplicate for these enhancers. Stock ID represents the Bloomington Drosophila stock center annotation for the line carrying 




Suppressors R1 P S R2 P S R3 P S OST (P) 
Hr39 87.67 < 0.0001 *** 93.61 < 0.0001 *** 90.38 < 0.0001 *** 0.0004 
Diap2 75.25 < 0.0001 *** 68.31 < 0.0001 *** 95.31 < 0.0001 *** 0.0102 
Sgt 86.72 < 0.0001 *** 72.72 < 0.0001 *** 77.91 < 0.0001 *** 0.0027 
CG5118 81.93 < 0.0001 *** 72.69 < 0.0001 *** 75.13 < 0.0001 *** 0.0013 
Spag 80.11 < 0.0001 *** 78.72 < 0.0001 *** 68.53 < 0.0001 *** 0.0023 
T3dh 82.51 < 0.0001 *** 72.53 < 0.0001 *** 68.91 < 0.0001 *** 0.003 
Abrupt 78.84 < 0.0001 *** 77.05 < 0.0001 *** 66.16 < 0.0001 *** 0.0029 
RapGap1 63.79 < 0.0001 *** 80.56 < 0.0001 *** 76.41 < 0.0001 *** 0.0047 
Rhomboid 65.83 < 0.0001 *** 77.21 < 0.0001 *** 73.4 < 0.0001 *** 0.0021 
CG3625 72.06 < 0.0001 *** 70.01 < 0.0001 *** 46.57 0.0006 *** 0.0165 
CG12299 63.52 < 0.0001 *** 72.25 < 0.0001 *** 69.59 < 0.0001 *** 0.0014 
upf3 69.02 < 0.0001 *** 83.9 < 0.0001 *** 55.95 < 0.0001 *** 0.0132 
Klar 65.04 < 0.0001 *** 58.16 < 0.0001 *** 83.28 < 0.0001 *** 0.0117 
leak 66.19 < 0.0001 *** 70.88 < 0.0001 *** 66.5 < 0.0001 *** 0.0005 
CG5734 81.92 < 0.0001 *** 69.42 < 0.0001 *** 51.93 < 0.0001 *** 0.0161 
Acsl 64.2 < 0.0001 *** 68.41 < 0.0001 *** 67.99 < 0.0001 *** 0.0004 
Act42 65.86 < 0.0001 *** 75.41 < 0.0001 *** 58.75 < 0.0001 *** 0.0052 
Tejas 71.52 < 0.0001 *** 70.11 < 0.0001 *** 56.95 < 0.0001 *** 0.0049 
IP3K1 63.82 < 0.0001 *** 63.15 < 0.0001 *** 70.34 < 0.0001 *** 0.0012 
Cos 77.29 < 0.0001 *** 58.43 < 0.0001 *** 61.19 < 0.0001 *** 0.0079 
CG13204 66.01 < 0.0001 *** 75 < 0.0001 *** 54.09 < 0.0001 *** 0.0086 
RdgBβ 55.49 0.0001 *** 84.3 < 0.0001 *** 53.32 < 0.0001 *** 0.0232 
Su(Var)2-10 67.01 < 0.0001 *** 69.7 < 0.0001 *** 56.03 < 0.0001 *** 0.0042 
14.3.3ζ 77.46 < 0.0001 *** 49.41 < 0.0001 *** 63.4 < 0.0001 *** 0.0159 
Vps35 66.33 < 0.0001 *** 65.89 < 0.0001 *** 57.39 < 0.0001 *** 0.0021 
CG15630 70.37 < 0.0001 *** 62.65 < 0.0001 *** 65.51 < 0.0001 *** 0.0012 
Spp 56.64 < 0.0001 *** 54.32 0.0005 *** 76.23 < 0.0001 *** 0.0122 
milt 68.72 < 0.0001 *** 48.24 < 0.0001 *** 70.6 < 0.0001 *** 0.0129 
Syx6 63.58 < 0.0001 *** 57.88 < 0.0001 *** 64.28 < 0.0001 *** 0.0011 
Sir2 69.02 < 0.0001 *** 60.61 0.0002 *** 54.67 < 0.0001 *** 0.0046 
CG1599 43.61 0.0002 *** 61.56 < 0.0001 *** 67.52 0.0002 *** 0.0152 
Fs(2)Ket 56.75 < 0.0001 *** 64.07 < 0.0001 *** 61.36 < 0.0001 *** 0.0012 
l(2)k05819 57.01 < 0.0001 *** 53.57 < 0.0001 *** 71.08 < 0.0001 *** 0.0077 
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Hippo 48.52 < 0.0001 *** 69.34 < 0.0001 *** 57.89 0.0002 *** 0.0104 
CG10809 53.15 < 0.0001 *** 75.2 < 0.0001 *** 46.16 < 0.0001 *** 0.0219 
Ric 56.72 < 0.0001 *** 60.42 < 0.0001 *** 57.17 < 0.0001 *** 0.0004 
Spc105R 69.28 < 0.0001 *** 63.50 < 0.0001 *** 56.46 < 0.0001 *** 0.0034 
qkr58E-3 54.56 0.0001 *** 70.01 < 0.0001 *** 48.48 < 0.0001 *** 0.0121 
Cdk4 65.42 < 0.0001 *** 54.06 < 0.0001 *** 53.17 < 0.0001 *** 0.0047 
CG18870 62.22 < 0.0001 *** 57.29 0.0001 *** 51.91 < 0.0001 *** 0.0027 
Swim 49.22 < 0.0001 *** 60.38 < 0.0001 *** 59.86 < 0.0001 *** 0.0041 
CG9643 58.52 < 0.0001 *** 63.18 < 0.0001 *** 45.47 0.0008 *** 0.0089 
CG4896 51.75 < 0.0001 *** 65.17 < 0.0001 *** 50.62 < 0.0001 *** 0.0069 
Pcl 63.84 < 0.0001 *** 50.61 < 0.0001 *** 52.02 < 0.0001 *** 0.0057 
CG8520 60.83 < 0.0001 *** 52.12 < 0.0001 *** 53.35 < 0.0001 *** 0.0024 
hrg 55.89 < 0.0001 *** 49.97 < 0.0001 *** 41.59 < 0.0001 *** 0.007 
DPA 54.51 < 0.0001 *** 48.4 < 0.0001 *** 61.67 < 0.0001 *** 0.0049 
Ero1L 57.88 < 0.0001 *** 50.66 < 0.0001 *** 55.95 < 0.0001 *** 0.0015 
Olf186-F 74.52 < 0.0001 *** 45.42 < 0.0001 *** 44.07 < 0.0001 *** 0.0315 
Atg7 62.61 < 0.0001 *** 48.42 < 0.0001 *** 51.64 < 0.0001 *** 0.0062 
CG13192 50.84 < 0.0001 *** 59.91 < 0.0001 *** 51.85 < 0.0001 *** 0.0028 
CG4502 55.84 < 0.0001 *** 57.35 < 0.0001 *** 48.65 < 0.0001 *** 0.0025 
Cul-2 55.71 < 0.0001 *** 46.38 < 0.0001 *** 56.29 < 0.0001 *** 0.0037 
CG10492 40.12 0.0015 ** 52.15 < 0.0001 *** 65.99 < 0.0001 *** 0.0195 
Crq 61.47 < 0.0001 *** 50.21 < 0.0001 *** 46.44 0.0005 *** 0.0073 
CG11125 58.51 < 0.0001 *** 44.11 < 0.0001 *** 54.5 < 0.0001 *** 0.0066 
Aux 68.63 < 0.0001 *** 45.26 < 0.0001 *** 41.66 0.0014 ** 0.0256 
Rab5 50.01 < 0.0001 *** 62.15 < 0.0001 *** 43.03 < 0.0001 *** 0.0115 
Akap200 61.81 < 0.0001 *** 42.95 < 0.0001 *** 39.67 < 0.0001 *** 0.0199 
Syx7 50.61 < 0.0001 *** 52.07 < 0.0001 *** 49.57 < 0.0001 *** 0.0002 
HSPC300 50.8 < 0.0001 *** 50.51 < 0.0001 *** 50.32 < 0.0001 *** < 0.0001 
Trap1 71.12 < 0.0001 *** 42.51 0.0117 * 37.65 0.0005 *** 0.0403 
Draper 48.36 0.0010 ** 49.01 0.0002 *** 53.87 < 0.0001 *** 0.0012 
Kis 69.23 < 0.0001 *** 38.76 0.0418 * 37.63 0.0001 *** 0.0395 
Eno 56.46 < 0.0001 *** 67.36 < 0.0001 *** 53.41 < 0.0001 *** 0.0051 
CycB 49.21 < 0.0001 *** 41.61 < 0.0001 *** 44.86 < 0.0001 *** 0.0024 
Src42A 60.79 < 0.0001 *** 36.93 0.0007 *** 36.25 < 0.0001 *** 0.0311 





Table 7. Statistical analysis of the modifying effect of DVAP-P58S interacting 
genes. Independent experiments were quantified and compared to their control using 
a two-tailed student t-test. All replicas for the 85 modifiers were significantly 
different than observed control values. This difference is stronger for the case of the 
suppressor lines. In the case of enhancer lines, modification results were also 
supported with a decrease in the viability of these lines. R1,R2,R3 = Replica 1, 2 and 
3. P = P-value for the Student t-test. S represents the significance level of each test. 










Coro 48.22 0.0002 *** 45.08 0.0019 ** 37.22 0.0055 ** 0.0056 
cnk 50.24 < 0.0001 *** 36.98 < 0.0001 *** 35.46 0.0003 *** 0.0129 
Ltd 27.17 0.0002 *** 36.95 < 0.0001 *** 27.41 0.0008 *** 0.011 
Enhancers R1 P S R2 P S R3 P S OST (P) 
Pex10 22.15 < 0.0001 *** 31.44 0.0002 *** 20.17 0.0001 *** 0.0194 
Dap160 11.63 0.0224 * 12.28 0.0005 *** 20.21 < 0.0001 *** 0.0334 
Mef2 23.74 < 0.0001 *** 56.03 < 0.0001 *** 42.63 < 0.0001 *** 0.0489 
9153 29.32 0.0018 ** 19.16 0.0001 *** 19.33 < 0.0001 *** 0.0214 
30456 14.97 < 0.0001 *** 10.29 0.0171 * 11.5 0.0002 *** 0.0128 
Mtch 16.62 0.0005 *** 29.75 < 0.0001 *** 15.11 0.0075 ** 0.0478 
Dock 14.52 < 0.0001 *** 12.05 0.0005 *** 12.04 0.0314 * 0.0041 
sca 65.83 < 0.0001 *** 50.45 < 0.0001 *** 55.15 < 0.0001 *** 0.0039 
Sm 27.08 < 0.0001 *** 32.04 < 0.0001 *** 10.18 0.0037 ** 0.0402 
7324 20.95 < 0.0001 *** 16.75 0.0009 *** 22.51 0.0003 *** 0.0011 
Mdh1 23.24 0.0079 ** 17.39 0.0002 *** 13.5 0.0035 ** 0.0073 
CaBP1 9.62 0.0028 ** 11.26 0.002 ** 12.31 0.0314 * 0.0439 
lola 24.49 0.0051 ** 16.11 0.0003 *** 11.52 0.0026 ** 0.0296 
Aat-Ala 10.17 0.004 ** 12.63 0.002 ** 17.55 0.0453 * 0.011 
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4.7 Genetic validations of the DVAP-P58S-neurodegeneration 
modifier lines 
 
4.7.1 Enhancer lines were confirmed at a lower temperature 
 
As previously discussed, selection of experimental temperature at 30ºC improves the 
search of suppressors but affected the detection of enhancers. UAS-GAL4 system 
has been a key genetic tool in Drosophila studies especially for its flexibility in 
modulating the expression of a transgene of interest. We characterised in the 
previous chapter a less dramatic eye phenotype when mutant DVAP allele was 
expressed at 28ºC. Therefore, we used this difference to confirm the enhancer effect 
of selected stocks. We repeated the crosses at this lower temperature and quantified 
the significant reduction of eye surface area. 
 
 Originally, 26 lines were selected as potential enhancers at 30ºC, after a 
decrease in the eye size and a reduction of the expected number of eclosed flies. 
Most lines (19 stocks) maintained this modification even at 28 ºC (Figure 14A), At 
this lower temperature, the crosses were performed in triplicate and consequently, 
the eye size and viability was quantified (Figure 14C). Seven lines (stocks with 
insertions in genes egl, alc, lilli, Capu, CG9318, gbb and cdc14) were discarded after 
this step because their phenotype was not significantly different than controls. The 
confirmed positive modifiers were now tested for the next set of validations assays, 
altogether with the suppressor lines. 
 
4.7.2 Identication of false positive modifying effects after exhibiting 
neurodegeneration independently of DVAP-P58S expression 
 
Expression of DVAP-P58S in the eye has been already linked to neurodegeneration 
(Forrest et al., 2013) and our search for modifiers in this screen is based on the 
genetic interaction that other genes may present with DVAP. Changes in eye size 
observed in crosses with lines overexpressing a specific target gene are an indication  
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Figure 14. Genetic enhancers of DVAP-linked neurodegeneration in the eye.           
(A) Stereo microscope images of control (ey-Gal4/+), ey,DVAP-P58S (ey-
GAL4,DVAP-P58S/+) and ey,DVAP-P58S/CaBP1EY12345 (ey-GAL4,DVAP-P58S/ 
CaBP1EY12345) adult fly eyes. Scale bar = 50 um. (B) Quantification of the eye surface 
area of adult flies expressing the previous alleles. Co-expression of DVAP-P58S and 
the P-element insertion in the eye reduced even more the population average size 
(red line), enhancing the degenerative phenotype of the ALS model. (C) List of 
enhancers found in the primary screen, showing reduction in eye size (red) and 
viability (black) normalised to their control (ey-Gal4,DVAP-P58S/+). The plot 
represents the average of three independent experiments performed at 28ºC. Increase 
in DVAP-P58S- linked neurodegeneration and viability was found in 14 
misexpression lines. Scale Bar = 50 um. *** P < 0.001 (One-way ANOVA). 
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that DVAP toxicity mechanism is affected by this overexpressed gene. However we 
must consider the option that the new gene may have an effect in the eye by its own, 
meaning that overexpression of this gene can increase or reduce the eye size, 
independently of DVAP-P58S expression. To address this question, we crossed all 
the potential modifier lines with the ey-GAL4 driver (not recombined with DVAP-
P58S). We expected an eye size comparable to controls, and any change in the eye 
size meant a DVAP-independent effect. 
 
 From the remaining 90 stocks, most of them consistently showed the same eye 
size than control flies ey-GAL4/+ (representative examples shown in Figure 15). 
Only in 5 cases, we observed neurodegeneration in these crosses. The lines carrying 
insertion in genes wee, wech, debra, CG10444 and elF3-S9 were discarded from 
further analysis. The remaining 85 lines were tested and validated in the next 
analyses.  
 
4.7.3 The excision of the P-elements suggested that the phenotype 
was linked to the insertion 
 
The basis of the screen is the use of misexpression lines carrying a P-Element 
inserted in a specific site of the genome. If the transgenic promoter of the element is 
altering the expression of a target gene, any modification phenotype of these lines 
should be caused exclusively by this P-Element insertion. Therefore, we can assume 
that removing this element, we should restore the original DVAP mutant phenotype 
from the initial cross. To test this hypothesis, we analysed four lines using a classic 
genetic strategy based on the excision of the P-element. 
 
 P-elements used in this study contain in their structure a 31-bp terminal 
inverted repeat and an 11-bp subterminal inverted repeat sequences (O'Hare & 
Rubin, 1983). These regions may become target of transposition and recombination 
from different genetic elements. A transgenic line carrying one of these elements, the 
P{∆2-3} line, was characterised as an stable recombinase source (Robertson et al., 
1988). It could mobilise at high frequencies different elements in the genome but at  
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Figure 15. Genetic modification of DVAP-P58S phenotype is specific to its 
interaction with modifier lines. Representative suppressor (A) and enhancer (B) 
lines displaying its phenotype at 30ºC and 28ºC respectively. (C) Their effect in 
DVAP-P58S neurodegeneration was specific to the interaction, as the alleles failed to 
show an increase or reduction of the eye size after crossing the original 
misexpression lines with the ey-GAL4 driver alone. Scale bar = 50 um. 
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the same time, it was stable and was not affected by its own activity. This line, 
lacking the 2-3 intron of the P-element transposase and therefore, missing the 66kDa 
repressor form of the protein, became an important tool to create new deletion lines 
and improve transformation techniques to move elements around the genome 
(Robertson et al., 1988).  
 
 If we remove the P-element from modifier lines, we should lose their effect in 
the ey,DVAP-P58S line. We tested this hypothesis in the lines over expressing the 
genes DIAP2, HSPC300, Rdgbß and Rhomboid. Males from the initial offspring, 
carrying the P-element and the transposase source in trans, were independently 
crossed with virgin females with trackable markers. This process was performed in 
100 different crosses, considering the low probability of the excision event. The 
selected offspring from these crosses following the correct markers, were tested with 
the ALS model ey-GAL4,DVAP-P58S to observe the loss of suppression phenotype. 
No more than 2 positive excised lines were obtained from the original crosses. They 
showed a clear loss of the modification effect when compared to controls and the 
original misexpression stock (representative example in Figure 16). This phenotype, 
altogether with the marker trail observed in the genetic scheme, suggest us that the 
phenotype of these lines was exclusively caused by the P-element insertion. We can 
not confirm with this experiment however, that the suppression effect was caused by 
an insertion in the expected reported gene. The possibility of an insertion in another 
unknown gene can not be discarded with this technique. A better alternative would 
imply the confirmation of the effect with an independently generated overexpression 
allele of the same studied gene. For this reason, this classic genetic process was 
tested only in these initial 4 lines after obtaining the confirmation of our proposed 
hypothesis. However, we cannot discard the idea of using this technique as a 
potential source of mutants and new alleles for selected modifiers if we need further 






Figure 16. P-element excision from the modifier line recovers original DVAP-
P58S phenotype in the eye. (A) Stereo microscope images of adult fly eyes of 
controls (ey-Gal4/+), ey,DVAP-P58S/Diap2G2326 (ey-GAL4,DVAP-P58S/DIAPG2326) and 
ey,DVAP-P58S/Diap2G2326∆EP (ey-GAL4,DVAP-P58S/Diap2G2326∆EP) line created by 
the excision of the P{EP} (see results for details). Suppression in eye size toxicity of 
DVAP-P58S-expressing flies is lost without the presence of the EP element, 
confirming the specificity of this technique. (B) Quantification of eye surface area of 
flies carrying these alleles shows a return to original ey,DVAP-P58S eye size after 





4.7.4 Exact location of the element insertion was confirmed using 
plasmid rescue 
 
Besides the collaborative effort to generate misexpression collections, also has been 
instrumental the posterior analysis and characterisation of each stock performed by 
the Drosophila community and the Gene Disruption project (Bellen et al., 2004). 
These analyses include not only phenotypes and affected genes, but also importantly, 
the exact location of each element insertion. This key information to understand and 
predict gene expression should be normally reliable. However with scenarios like 
stock mislabeling or P-element mobilization under the presence of a transposase 
source becomes relevant to double-check the reported information. 
 
 For this purpose, we confirmed the exact location of the element insertion 
using the plasmid rescue technique. This approach allowed us to calculate the exact 
position of the genomic region containing the P-Element and the target neighbours 
affected gene, by cloning this genomic segment and comparing the size of the 
fragment with the sequence information reported in FlyBase. From the three used 
collection, only the P{EP} carries the complete cassette needed for this purpose 
(Figure 11A, details in Chapter 2.4). This cassette includes a bacterial origin of 
replication for its maintenance in prokaryotic cells, kanamycin resistance as a 
bacterial marker for the plasmid purification, and an EcoRI site, which will be used 
as the first end of the purified restriction fragment. The second EcoRI site is located 
in the target gene, and the distance from the first site will determine the size of the 
purified fragment. This size of this restriction fragment is then analysed in a DNA 
electrophoresis and compared with the predicted size of the fragment obtained by the 
sequenced genomic region available in FlyBase. 
 
 From the list of modifier genes, 17 of the 27 modifiers available from the 
P{EP} collection were used in this study. DNA was extracted and processed for all 
these stocks and cloning and following restriction analysis confirmed the reported 
location in all of them. Results from 10 representative lines are presented in Figure 









Plasmid size            
(bp) 
Inhibitor of apoptosis 2 Iap2 26986 7138 
Ras which interacts with calmodulin Ric 27003 8979 
Peroxisome biogenesis factor 10 Pex10 27176 3887 
Retinal degeneration B beta Rdgbβ 27975 3667 
Syntaxin Interacting Protein 1 HSPC300 26953 7074 
Syntaxin 7 Syx7 28476 9120 
Myocyte-specific enhancer factor 2 Mef2 17230 3779 
Klarsicht klar 6413 5641 
Auxillin Aux 30174 6919 
CG9153 CG9153 27181 4455 
Ero1-like protein Ero1L 29300 3885 
Draper drpr 17175 3724 
CG30456 CG30456 17237 6151 
Signal peptide peptidase Spp 27455 5116 
Mitochondrial carrier homolog 1 Mtch 27981 5162 
Coronin Coro 26984 6875 
Dynamin associated protein 160 Dap160 19582 8208 
Figure 17. Plasmid rescue analysis of DVAP-P58S genetic modifiers (A) 
Determination of the rescued plasmid size from ten representative P{EP} lines. Each 
DNA fragment purified after the plasmid rescue protocol was digested with EcoRI 
and compared with the DNA ladder (1 kb DNA ladder, New England Biolabs). (B) 
Seventeen analysed P{EP} stocks and the size of the predicted purified plasmids 
obtained from their genome. Plasmid size was calculated using the bioinformatic tool 




obtain this result at least three clones per line were analysed, and where differences 
in size were observed, further analysis showed that clones with larger fragments 
correspond to EcoRI restriction sites in other location of the target gene. A most 
definitive confirmation of these results can be obtained sequencing the cloned 
fragments and compare them with the Drosophila genome sequence. However, we 
did not find major discrepancies between the predicted fragment sizes and the cloned 
fragments analysed, making the DNA sequencing dispensable. 
 
 This analysis included a selection from only one of the three collections 
studied, but the positive results proved correct and reliable the information reported 
in FlyBase, with no lines showing major discrepancies. For the other two collections, 
lacking the cassette necessary for cloning, other techniques such as inverse PCR are 
available to prove the same concept. However we decide to focus in next assays after 
confirming the information already reported in the databases for the total of analysed 
lines. These results were obtained together with the honour students Alistair Rocke 
and Mohammed Al-kharfan.   
 
4.7.5 Independent alleles for the DVAP modifiers strongly validated 
the original result observed with misexpression lines 
 
Having tested all the potential modifier lines under different validation assays, we 
were able to filter based on relevant controls obtaining a set of 85 potential modifiers 
of the DVAP toxicity (Tables 5 and 6). However, another crucial validation is to 
analyse whether the gene misexpressed in the modifier stock is the real causative for 
this phenotype. For this purpose, we aimed to test an independent allele for each of 
these 85 genes and corroborate with these new stocks the real effect of the former 
ones.  
 
 This stage is far from straightforward, if we consider the different types of 
alleles available, but especially the lack of solid overexpressing alternatives in the 
public stock centers. Considering that mostly our stocks corresponded to 
misexpression lines that overexpress target genes, the most direct independent alleles 
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are transgenic overexpression lines carrying an upstream activator sequence (UAS). 
However, largely these lines are not publicly available or even not constructed 
because some of these genes have not been fully studied yet. We tried to contact 
several groups from the Drosophila community, and were able to obtain 
overexpressing lines for a minor part of our set of modifiers. For this reason we 
decided to explore other available stocks and test as an alternative to the 
overexpression, other EP lines affecting the same genes but not tested initially. 
 
 Considering both alternatives, we found 14 lines, covering less than the 20% of 
our genes. We used as a third option, RNAi lines that down-regulate the expression 
of target genes. In the last years, most Drosophila genome has been covered with 
these stocks, available publicly in centers in Kyoto (NIG-FLY), Harvard (Exelixis), 
Vienna (VDRC) and Bloomington (TRiP collection). With the last two collections 
we could cover mostly our potential modifiers, testing the hypothesis that if the 
overexpression of target genes modifies the neurodegeneration phenotype associated 
with DVAP-P58S, the down regulation of the same genes should produce the 
opposite phenotype, altering eye size and viability in the inverse direction.  
 
 Lines acquired for this validation assay (Table 8) were tested under the same 
conditions as original stocks, and same parameters (eye size, viability) were 
measured in an identical way. For downregulation lines of original suppressor-
overexpressing genes, the crosses against the model expressing ey-Gal4,DVAP-P58S 
were performed at 28ºC to expect an enhancer effect with the new allele. Also, for 
loss-of-function lines, it was considered a positive confirmation if the independent 
allele affected either eye size or ratio of viable adult flies; covering in this way any 
minor effect that could be missed under a more strict condition. After this analysis, 
we found 48 of 60 RNAi lines that were consistent with our original observation 
using misexpression lines. Specifically, 39 suppressor genes were confirmed by an 
RNAi line that has an enhancement effect in DVAP-P58S-linked eye phenotype, and 
7 enhancer genes were confirmed by the suppressor effect of their RNAi lines. 
Additionally we were lucky to obtain from Prof. David Gilder an antibody that 
specifically recognises the modifier Syx7. Initially, we observed a suppression of the 
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Validation of modifiers with a suppressor effect by using RNAi alleles 
Gene name Gene symbol Stock ID Validation % Enhancement 
Disc proliferation abnormal dpa v44484 Eye + Lethality 36.45 ; 44.56 
Rab5 Rab5 t34832 Eye + Lethality 27.53 ; 78.97 
Acyl-CoA synthetase long-chain Acsl v3222 Eye + Lethality 24.33 ; 37.55 
Actin 42A Act42A v12456 Eye + Lethality 38.63 ; 39.26 
Kismet kis v46685 Eye + Lethality 14.31 ; 62.46 
Milton milt v41508 Lethality 33.88 
Vesicle-associated membrane protein 7 Vamp7 v13316 Lethality 39.27 
Croquemort crq v45883 Lethality 31.79 
Small glu-rich tetratricopeptide protein sgt v22002 Lethality 39.26 
CG3625 CG3625 v40855 Lethality 48.16 
Hormone receptor-like in 39 Hr39 v37694 Lethality 19.18 
CG13192 CG13192 v32157 Lethality 38.41 
Lethal (2) k05819 l(2)k05819 v13555 Lethality 36.74 
CG10809 CG10809 v38407 Lethality 38.75 
CG5734 CG5734 v43798 Lethality 34.05 
CG10492 CG10492 v12356 Lethality 32.82 
CG12299 CG12299 v102146 Lethality 16.95 
Quaking related 58E-3 qkr58E-3 v26242 Lethality 27.17 
Lightoid ltd v104348 Lethality 25.54 
14-3-3ζ 14-3-3ζ v48724 Lethality 36.33 
Ero1-like protein Ero1L v51169 Lethality 39.29 
CG11125 CG11125 v18413 Lethality 46.71 
Cyclin B CycB v43772 Lethality 11.77 
Signal peptide peptidase spp v7247 Lethality 39.27 
Leak lea v11823 Lethality 13.52 
Autophagy-specific gene 7 Atg7 v27432 Lethality 39.28 
Suppressor of variegation 2-10 Su(var)2-10 v30709 Lethality 18.59 
Hiiragi hrg v42283 Lethality 36.48 
Upf3 Upf3 v31444 Lethality 30.71 
Secreted Wg-interacting molecule swim v6617 Lethality 38.42 
CG18870 CG18870 v3471 Lethality 34.51 
Src oncogene at 42A Src42A v17643 Lethality 28.55 
CG13204 CG13204 t31913 Lethality 14.28 
CG8520 CG8520 v36546 Lethality 19.41 
Spaghetti spag v31253 Lethality 31.59 
Cyclin-dependent kinase 4 Cdk4 v40576 Lethality 50.23 
Proteasome subunit beta 5 Prosβ5 v38659 Lethality 100.00 
Spc105-Related Spc105-R t35466 Lethality 100.00 
Vacuolar protein sorting 35 Vps35 v22180 Eye 17.53 
 
Validation of modifiers with an enhancer effect by RNAi lines 
Gene name Gene symbol Stock ID Validation %Suppression 
CG30456 CG30456 v21186 Eye 41.38 
Scabrous sca v44527 Eye 65.51 
Smooth sm v28117 Eye 27.84 
Dreadlocks dock v37524 Eye  60.97 
Calcium-binding protein 1 CaBP1 v43148 Eye 55.11 
Myocyte-specific enhancer factor 2 Mef2 v15550 Eye 38.19 
CG9153 CG9153 t37220 Eye 43.57 
 
Validation of modifiers with a suppressor effect caused by a loss–of-function 
Gene name Gene symbol Stock ID Validation %Suppression 
Syntaxin Interacting Protein 1 
HSPC300 t35051 Eye 46.34 
Hippo hpo t27661 Eye 90.73 
Klarsicht klar Klar YG3 Eye 62.89 
 
Validation of modifiers with a suppressor effect by an overexpressing allele 
Gene name  Gene symbol Allele Validation %Suppression 
Inhibitor of apoptosis 2 Iap2 UAS-DIAP2 Eye 71.08 
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Ras which interacts with calmodulin Ric UAS-Ric Eye 57.44 
Silent information regulator 2 
Sir2 UAS-Sir2 Eye 77.32 
Rhomboid rho UAS-Rho Eye 69.77 
Draper drpr UAS-Drp Eye 50.81 
Retinal degeneration B beta rdgBβ P{EP}rdgBβEP2360 Eye 84.30 
A kinase anchor protein 200 Akap200 P{EPgy2}Akap200EY01150 Eye 61.81 
Polycomblike Pcl P{EP}PclGE15295 Eye 50.60 
 
Validation of modifiers with a suppressor effect by a loss-of-function allele 
Gene name Gene symbol Allele Validation %Enhancement 
Costa cos  P{lacW}cosk16101 Eye + Lethality 26.62 ; 48.82 
Rap GTPase activating protein 1 RapGAP1 P{Mae-
UAS.6.11}RapGAP1LA00889 
Eye + Lethality 24.12 ; 34.15 
Type III alcohol dehydrogenase T3dh Mi{ET1}T3dhMB09825 Lethality 40.86 
 
Validation of modifiers with a enhancer effect by an loss-of-function allele 
Gene name Gene symbol Allele Validation %Suppression 
Alanyl-tRNA synthetase Aats-ala P{EPgy2}Aats-alaEY01137b Eye 73.59 
Dynamin associated protein 160 Dap160 Dap160∆1 Eye 66.82 
 
Validation of modifiers with a suppressor effect by immuno-staining  
Gene name Antibody Tissue Reference 
Syntaxin 7 rabbit anti-syx7 Brains - eye discs Lu and Bilder, 2005 
 
Unconfirmed modifiers 
Gene Name Gene symbol Stock ID 
Coronin coro v44671 
Inositol 1,4,5-triph kinase 1 IP3K1 t35296 
Enolase eno t26300 
Auxillin aux v16182 
Trap1 Trap1 v108300 
Connector enhancer of ksr cnk v107746 
Cullin-2 Cul-2  v19297 
Malate dehyrogenase Mdh1 v27398 
Longitudinals lacking lola v12573 
Syntaxin 6 Syx6 v1501 
Mitochondrial carrier homolog 1 Mtch t16644 
Peroxisome biogenesis factor 10 Pex10 v46613 
CG7324 CG7324 v31063 
CG15630 CG15630 v37842 
Female sterile (2) Ketel Fs(2)ket v22348 
Ub-conjugating enzyme E2Q-like CG4502 v34855 
CG4896 CG4896 v26652 
Tejas tej v24181 
Olf186-F Olf186-F v12221 
Abrupt ab v41005 
CG9643 CG9643 v24081 
CG5118 CG5118 v34963 
 
Table 8. Independent alleles used for validation of modifiers.                          
Original modification effect of each gene was confirmed using an independent line 
that affects its expression either by up- or down-regulation. Each subtable indicates 
which kind of line was used and their final effect in the modifiers. Confirmation 
effect was observed in eye size or lethality ratios, and their modification degree was 
quantified and normalised to their control flies (ey-Gal4,DVAP-P58S/+). 62 of the 
85 modifiers were confirmed with these independent lines and an extra line (Syx7) 
was confirmed using immunostaining assays. However, the negative 22 lines cannot 
be discarded as they include unavailable lines or potential weak lines unable to 
confirm the original effect. 
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DVAP-P58S neurodegenerative phenotype in the eye when we down-regulated the 
expression of Syx7. This implies that in a damaged DVAP-P58S tissue, the 
expression of Syx7 might be up-regulated. We stained DVAP-P58S tissue and 
indeed, observed an up-regulation of the signal specific for Syx7 compared to 
controls (Figure 18), validating in this way the original loss of function allele. 
Together, positive independent alleles from the 4 approaches (63 of 85 lines, 74% of 
the total) provide us the strongest genetic confirmation of our results and at the same 
time, validate the ALS model and our project as a valid way to search novel 
interactors of the mutant DVAP allele. Indeed, we can be confident about these 63 
genes confirmed, but we do not have enough arguments to discard the remaining 22 
lines. Some of the non-validated lines may not be dose-dependent in opposite 
directions, and they may lack a phenotype when down-regulated but still present the 
modifier phenotype when overexpressed. Conversely, the tested RNAi alleles 
generated only a weak hypomorph that only partially inactivates the target gene, 
missing the expected phenotype. Moreover, these negative results include lines not 
tested due to lack of an independent allele or problems in the stock when they were 
shipped from the stock centres. We can not discard that these lines may present a 
positive confirmation if we are able to test them against the ALS model or we are 
able to test other independent alleles. 
 
 Taken together, these assays supply us strong evidence about the initial screen 
and validate these genes as bonafide candidates for DVAP-P58S modifiers. Most 
importantly, these time-consuming assays are often avoided or disregarded in 
previously reported genetic screens, where basically most efforts of these studies are 
focused on a specific modifier (Franciscovich et al., 2008; Couthois et al., 2011; 
Wang et al., 2013). In our case, we can propose a stronger set of modifiers, which 
potentially can lead to the study of different ways of action of DVAP-P58S toxicity. 
We consider this fact, together with the functional nature of the screen, as a strong 
advantage of our project compared to others attempts done in the research of ALS. 
Also, this gives us confidence to continue with a secondary screen and the 











Figure 18. Syntaxin 7/Avalanche is up-regulated in DVAP-P58S eye imaginal 
discs. Control (A) and DVAP-P58S expressing eye imaginal discs (ey-GAL4,DVAP-
P58S/+) (B) immuno-stained with anti-DVAP and anti-Avl antibodies. Both proteins 
are homogenously distributed throughout the cytoplasm, however Avl appears up-
regulated in DVAP-P58S expressing cells and as part of the DVAP-positive large 


















Chapter 5: DVAP-P58S 
genetic interactors modify viability 















To correlate the previously validated DVAP-P58S genetic modifiers with common 
hallmarks of ALS, we studied their phenotype when expressed in the nervous system 
under the control of elav-GAL4 driver. For this, we looked for changes in lethality 
and motor performance defects in flies co-expressing DVAP-P58S and the 
misexpressed alleles. These two extra readouts helped us to filter even more our 
potential candidate genes and validate the results obtained in the primary screen.  
 
5.2 Lethality screen 
 
The data presented so far indicate that DVAP-P58S expression in the eye causes a 
significant neurodegeneration. This phenotype was used to obtain novel DVAP-P58S 
genetic interactors that can provide us clues to understand ALS pathomechanism. In 
humans, disease’s hallmarks are mostly related to loss of motor activity due to death 
of motor neurones. Even though we obtained bona fide DVAP candidates looking at 
the Drosophila eye, we asked whether we could see the same modification effects in 
the rest of the nervous system. With this, we tried to mimic some of the most 
important symptoms of patients with ALS, validating the modifier genes in a 
disease-related context. 
 
 We already reported in the chapter 3.7 a characterisation of the expression of 
DVAP mutant allele in the whole nervous system under the control of elav-GAL4 
driver. We observed an increase in lethality of flies expressing DVAP-P58S 
compared to control. Additionally, for the first time we presented a progressive loss 
in the motor performance of DVAP-P58S-expressing surviving flies that leads to a 
total paralysis in temperature-dependent time range (Figure 4). Over the last years, 
lethality screens have been used to find genes able to modify toxic activities from 
relevant proteins (Zhang et al., 1999, Graham et al., 2011, Bates et al., 2014). These 
screens are based on the hypothesis that neurodegeneration can be suppressed or 
enhanced by coexpression of the toxic protein and genetic modifiers. With these 
studies, several genes have been found and the assay has been validated as a strong 
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way to find the modifiers. Therefore, we planned to use a lethality assay as a 
secondary screen for the DVAP-genetic interactors found in the previous chapter and 
strengthen their potential effect in ALS pathogenesis.  
 
 A line carrying both elav-GAL4 driver and DVAP-P58S allele was constructed 
for this assay (elav-GAL4/elav-GAL4; DVAP-P58S/CyO-GFP). Virgin females from 
this line were crossed with males from the same misexpression lines used in the 
primary screen. These 85 lines shown significant modification effect in the eye and 
were already validated by different assays. Embryos were laid for 48 hours at room 
temperature to then increase DVAP-P58S expression transferring them at 28ºC. This 
temperature was selected after initial optimisation as the point where DVAP-P58S 
presented a difference in viability with controls and flies displayed a clear motor 
performance curve, point to be discussed later. Parental flies from the crosses were 
transferred to another vial to create a replica of the cross and then removed after two 
days laying at room temperature.  
 
 A degree of variability can be observed in two different crosses. Factors 
affecting the food such as cooking, dryness or humidity can alter offspring number 
and phenotypes. For this reason is desirable to obtain an internal control, which is 
obtained from the same vial than the experimental cross. We selected this option for 
our assays comparing the experimental flies expressing DVAP-P58S and normal 
wings (elav-GAL4/+;DVAP-P58S/P{EP}) with the control flies obtained from the 
same cross carrying the dominant marker Cy (elav-GAL4/+; P{EP}/CyO-GFP). 
Therefore, the offspring was collected and classified in two groups according their 
wing phenotype. These groups were counted and the viability ratio was calculated as 
the difference with the controls (details in Materials & Methods).  
 
 After testing each modifier in three independent experiments, 47 of 85 
modifiers presented a strong modification effect, with a normalised viability larger 
than 0.5 times the values from control flies. In figure 19, a two-axis plot correlates 
the normalized viability of each modifier with their effect in the DVAP-P58S-
induced neurodegeneration in the eye observed in the primary genetic screen. Forty-  
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Figure 19. Secondary lethality screen. Two-axis plot expressing the correlation 
between eye size modification (X axis) and viability modification (Y axis) for 82 
lines found in the primary screen. Each point represents the average of three 
independent experiments for both axes. Values were normalised by comparing with 
their control (DVAP-P58S, in green). Most modifiers are confirmed suppressors 
(blue) but there is a small group of modifiers that did not show the same phenotype 
in both assays (black). 
125 
one lines that were suppressors of DVAP-neurodegeneration in the eye were able to 
decrease the DVAP-linked lethality when co-expressed in the nervous system. Five 
genetic modifiers that enhanced the eye phenotype were able to reduce even more 
the number of flies co-expressing both genes. Only one of the 47 lines (19727 - 
Smooth) presented the modification effect in the opposite direction than the original 
screen. Even considering that these results could support the previous analyses, 
unfortunately they can not confirm them and can not be used as an independent 
assay. The small difference between the percentage of expected and observed flies, 
plus the number of repetitions (n=3) made that less than half of these positive results 
were statistically significant (19 of 46, two-way Student’s T-test, p<0.05, results in 
Table 9), indicating not the degree of modification but only how spread the averages 
were. The tendency observed for most of them could potentially support as an extra 
readout the modification effects obtained originally in the eye. However further 
analyses are needed to confidently use these data. A strong alternative could be a 
rescue of a fully penetrant DVAP-linked lethality after an increase of temperature, 
but in this case we preferred to perform this experiment at the same temperature than 
the motor performance assay, using the same flies for both experiments. 
 
 From the original 85 lines, three stocks showed complete pupae lethality at the 
tested temperature. Lines overexpressing the genes Rhomboid, Leak and Src42 
crossed with the line elav;DVAP-P58S were lethal at different stages of larval 
development and were unable to produce a significant number of viable adults. 
When these three lines were crossed with the driver elav-Gal4 on its own, also 
showed decrease in viability in a similar way. This means that they already presented 
a phenotype, and DVAP co-expression only could make that phenotype stronger. 
Probably, the observed lethality can be caused for different reasons and the study of 
these genes could be possible at lower temperatures. However, we did not try other 
conditions in this study as we focused on the main group of positive modifiers, 
avoiding further optimisation for specific genes. We cannot discard however, the 





 P1 P2 P3 Avr M1 M2 M3 Avr Signif 
Vps35 85.71 117.86 148.65 117.41 0.529 2.030 2.820 1.793  
Fs2Ket 113.43 116.67 107.87 112.65 1.896 1.656 1.310 1.620 ** 
RapGap1 101.18 114.29 115.00 110.16 1.042 1.728 1.840 1.537 ** 
Ero1L 118.03 105.88 107.69 110.54 1.919 1.212 1.359 1.497 ** 
Cdk4 107.69 121.05 98.04 108.93 1.338 2.272 0.866 1.492 * 
Pcl 155.77 80.00 111.94 115.90 2.841 0.213 1.394 1.482  
Spp 99.03 113.89 108.57 107.16 0.935 1.778 1.437 1.383 ** 
18870 78.95 126.76 100.00 101.90 0.250 2.544 1.000 1.265  
CG1599 87.50 95.00 136.84 106.45 0.292 0.803 2.450 1.182  
Hr39 109.68 96.10 100.00 101.93 1.645 0.862 1.000 1.169 * 
5734 119.05 94.00 95.35 102.80 2.143 0.637 0.721 1.167  
IP3K1 116.28 97.96 92.06 102.10 1.904 0.882 0.703 1.163 * 
Sm 131.25 98.51 114.29 114.68 2.375 0.946 0.104 1.142  
Rab5 93.10 109.09 104.70 102.30 0.772 1.463 1.170 1.135 ** 
cnk 107.60 109.33 88.57 101.84 1.456 1.560 0.309 1.108 * 
Akap200 117.24 106.67 81.82 101.91 1.977 1.403 -0.091 1.096  
Hippo 110.20 102.44 92.31 101.65 1.578 1.136 0.573 1.095  
Olf186-F 110.68 108.33 85.11 101.37 1.381 1.504 0.345 1.076  
CG11125 88.24 108.75 92.60 96.53 0.581 1.598 0.733 0.971  
upf3 86.05 102.33 103.03 97.13 0.503 1.141 1.182 0.942  
ab 129.23 78.65 89.29 99.06 2.656 -0.290 0.357 0.908  
RdgBb 89.36 83.08 113.33 95.26 0.409 0.441 1.769 0.873  
Syx6 100.00 98.11 94.38 97.50 1.000 0.938 0.676 0.871 * 
spag 85.71 87.23 111.63 94.86 0.491 0.229 1.698 0.806  
hrg 95.40 92.31 100.00 95.90 0.836 0.535 1.000 0.790 * 
10809 93.33 100.00 89.60 94.31 0.738 1.000 0.625 0.787 ** 
milt 89.58 97.06 100.00 95.55 0.542 0.809 1.000 0.783 * 
tej 128.68 80.60 80.00 96.43 2.721 -0.172 -0.200 0.783  
l(2)k05819 85.00 98.92 97.39 93.77 0.465 0.945 0.854 0.755 * 
Cul-2 76.47 91.67 105.56 91.23 0.161 0.672 1.219 0.684  
Sir2 94.03 96.15 87.27 92.49 0.666 0.795 0.580 0.680 * 
klar 88.06 75.41 107.50 90.32 0.606 -0.082 1.425 0.650  
Swim 100.00 92.73 84.06 92.26 1.000 0.561 0.372 0.644  
acsl 92.00 101.23 83.54 92.26 0.520 1.049 0.352 0.640  
4502 83.52 97.74 93.18 91.48 0.413 0.885 0.618 0.639  
5118 93.96 76.19 99.10 89.75 0.785 0.156 0.956 0.632  
Ric 100.00 94.74 77.27 90.67 1.000 0.696 0.150 0.615  
DPA 83.95 112.05 88.89 94.96 -0.070 1.451 0.359 0.580  
prosB5 87.41 87.88 88.89 88.06 0.551 0.523 0.563 0.546 *** 
T3dh 95.10 93.33 87.50 91.98 0.674 0.660 0.300 0.545 * 
Aux 82.05 82.76 95.00 86.60 0.293 0.431 0.835 0.520 * 
Su(Var)2-10 73.61 97.92 106.12 92.55 -0.759 0.908 1.398 0.516  
3625 88.89 75.93 105.56 90.12 0.604 -0.455 1.333 0.494  
Cos 61.40 112.00 106.93 93.44 -1.573 1.528 1.451 0.468  
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sca 79.37 90.20 101.75 90.44 -0.376 0.614 1.069 0.436  
crq 84.62 90.32 96.51 90.48 0.077 0.452 0.761 0.430  
qkr58E-3 91.57 90.67 83.17 88.47 0.531 0.651 0.029 0.404  
Spc105R 82.00 81.32 93.33 85.55 0.362 0.086 0.759 0.403  
Kis 81.60 87.50 87.10 85.40 0.344 0.363 0.432 0.380 * 
12299 95.08 71.43 90.37 85.63 0.705 -0.018 0.422 0.370  
13192 81.18 83.61 77.14 80.64 0.329 0.459 0.246 0.345 ** 
Dap160 90.91 78.00 87.18 85.36 0.394 0.220 0.373 0.329  
Mtch 77.42 72.73 102.70 84.28 -0.279 0.100 1.156 0.326  
Mdh1 93.62 83.01 73.33 83.32 0.773 0.253 -0.050 0.325  
Sgt 95.65 76.00 89.86 87.17 0.739 -0.385 0.620 0.325  
10492 78.20 84.21 94.87 85.76 0.223 0.046 0.692 0.320  
9643 83.33 81.48 89.36 84.73 0.406 0.057 0.404 0.289  
Diap2 90.53 85.71 83.82 86.69 0.220 0.529 0.110 0.286  
Atg7 83.33 83.08 80.00 82.14 0.344 0.199 0.278 0.274 * 
13204 69.47 81.75 98.08 83.10 -0.088 -0.103 0.885 0.231  
Draper 65.19 92.86 101.18 86.41 -0.973 0.412 1.065 0.168  
Aat-Ala 80.00 81.72 88.89 83.54 -0.367 0.280 0.563 0.159  
eno 96.35 65.12 74.70 78.72 0.757 -0.373 0.004 0.129  
Syx7 79.17 83.72 98.41 87.10 -0.958 0.359 0.938 0.113  
lola 83.76 70.59 62.16 72.17 0.421 0.029 -0.249 0.067  
4896 75.44 97.96 66.67 80.02 -0.484 0.878 -0.203 0.064  
HSPC300 106.25 72.00 69.74 82.66 1.347 -0.586 -0.664 0.032  
Ltd 85.37 77.55 80.99 81.30 0.171 -0.144 -0.064 -0.012  
CycB 95.45 51.16 74.42 73.68 0.850 -0.923 -0.007 -0.027  
Trap1 84.56 80.70 61.33 75.53 0.450 -0.114 -0.447 -0.037  
15630 61.54 87.27 78.40 75.72 -0.371 0.352 -0.212 -0.077  
CaBP1 75.00 76.92 70.40 74.11 -0.416 0.091 -0.165 -0.163  
Coro 80.88 60.43 71.43 70.91 0.322 -0.935 0.057 -0.185  
14.3.3z 85.71 82.42 63.64 77.26 0.206 0.227 -1.181 -0.249  
Act42 72.73 63.83 67.92 68.16 -0.291 -0.305 -0.158 -0.251  
8520 53.66 81.82 78.95 71.47 -0.652 -0.099 -0.263 -0.338  
7324 81.36 63.01 85.71 76.69 -0.118 -1.219 0.137 -0.400  
CG30456 91.14 76.69 51.85 73.23 0.686 -0.140 -2.291 -0.582  
dock 46.15 66.67 59.50 57.44 -1.549 -0.630 -0.462 -0.880 * 
CG9153 67.53 74.42 28.57 56.84 -1.165 -0.366 -1.578 -1.036  
Pex10 62.34 80.00 36.36 59.57 -1.259 -0.333 -1.800 -1.131  
Mef2 30.91 78.08 57.95 55.65 -3.606 0.137 -0.656 -1.375  
Table 9. Viability ratios observed in DVAP-P58S flies co-expressing the 
modifier alleles. P, Percentage of flies observed, normalised by the number of flies 
expected for each cross. M, Modification ratio expressed by the difference between 
observed and expected percentage P and controls C, (P-C)/(100-C). Significance 
level calculated after unpaired, two-tailed Student’s t-test for P1, P2 and P3 and their 
controls. From 82 tested modifiers, 49 showed a viability modification consistent 
with the primary screen, but only 20 of these were statistically significant 
although.*** p<0.001, ** p<0.01, * p<0.05. 
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5.3 Motor performance assay 
 
In the previous section we observed a modification in the lethality when 
misexpression lines were crossed with flies expressing DVAP-P58S in the nervous 
system. We tested the offspring from these crosses to analyse whether they displayed 
as well neurodegenerative phenotype over time. Previously, we observed that the 
expression of DVAP-P58S in the nervous system produced a late-onset progressive 
motor dysfunction that was dependent on the temperature of the system (Figure 7). 
Expression of the gene at higher temperatures resulted in a shorter time-curve with a 
steep decrease in the climbing ability, which made difficult to observe any 
modification with another genetic interactor. The same assay performed at lower 
temperatures produced a time-curve twice as long and with a slower decline in the 
motor performance and an increased variability between points. For these reasons, 
we determined the optimal temperature as 28ºC, where we obtained a conveniently 
short time-curve but with enough space to observe phenotypic changes. 
 
 The climbing assay has been used in previous genetic screens in Drosophila 
(Miller et al., 2012; Kaltenbach et al., 2007). They can provide a strong phenotype 
that is related specifically with neurodegeneration and at the same time, can be used 
at large scale to search for modifiers. In our case we tested the 82 modifiers (not 
including the lethal lines Rho, Leak and Src42) to search for modification in the 
DVAP-P58S-induced motor performance decline. For this purpose, sets of 10 flies 
were challenged each two days to see whether they were able to climb 8 centimeters 
in 15 seconds. The average of 10 trials was compared to the performance of controls 
and time points were analysed statistically using two-way ANOVA.  
 
 From the 82 DVAP genetic interactors tested, 58 showed a significant 
modification in at least one point of the curve, which confirmed the same 
modification effect observed in the primary screen. According their degree of 
significance, suppressor lines were grouped in strong (showing modification effect in 
most part of the time curve), intermediate (with a significance difference with 
controls in two time points) and weak modifiers (showing modification in one time 
129 
point). From the 50 confirmed suppressors, 30 showed a strong effect, 14 an 
intermediate and 6 a weak one. In the case of the enhancers, the modification of the 8 
positive lines was observed only at the beginning of the curve, as the performance of 
the control elav;DVAP-P58S was at minimum levels after 8 days and an enhancing 
of this phenotype was no longer possible. The group of 24 negative results includes 
15 lines that did not show any difference compared to the control and 9 lines that 
displayed a slight opposite effect to that exhibited by the phenotype in the eye 
neurodegeneration, indicating that a more complex interaction may be present 
between DVAP-P58S and these modifiers. Table 10 presents statistical classification 
of the modifier lines and Figure 20 individual results of each modifier tested. 
 
 After the analysis of these results, different aspects can be mentioned. 
Considering that allele- and dose-dependent effects may be present in some of the 
negative results, further optimisation of the conditions can lead to an increase of the 
number of confirmed lines. Just as in the case of the validation with independent 
alleles, we can not discard however, the negative results as real DVAP interactors. 
Another possibility is a different interaction of the modifiers in the nervous system 
and imaginal discs, where their specific relation with DVAP is yet to be elucidated. 
Nevertheless, it is remarkable the important group of genes confirmed by all means, 
even if we do not consider the supporting results from the viability assay. Starting 
from 1183 misexpression stocks, we isolated 85 potential modifiers and at least half 
of them also were validated by two independent assays (Figure 21). This group of 
genes not only validates our project but also increases the potential mechanisms and 
pathways associated with DVAP pathomechanism. As previously mentioned, a 
further study of each one of these genes is mandatory to understand their function in 
DVAP biology and their link with current gaps in the ALS study. However, as an 
initial step, the current list of genetic modifiers is a promising start to further analyse 
their connection with known information, not only by bioinformatic analyses but also 







Suppressors - Strong effect TP1 TP2 TP3 TP4 TP5 Overall 
Cyclin B *** *** *** *** - 1.000 
Ras which interacts with calmodulin *** *** *** *** - 1.000 
Inhibitor of apoptosis 2 *** *** *** ** - 0.917 
CG4896 *** *** *** *** ns 0.800 
Hippo ** *** *** *** *** 0.933 
CG5734 ns *** *** *** *** 0.800 
Small glu-rich tetratricopeptide 
protein 
ns *** *** ** * 0.600 
Lightoid *** *** *** ns - 0.750 
Tejas ** *** *** *** ns 0.733 
Secreted Wg-interacting molecule ** *** *** *** ns 0.733 
Abrupt ns *** *** ** - 0.667 
CG10492 *** *** *** * ns 0.667 
CG13204 *** *** *** * ns 0.667 
Auxillin ns *** *** *** ns 0.600 
Klarsicht * *** *** * ns 0.533 
CG15630 *** *** *** ns ns 0.600 
Croquemort *** *** *** ns ns 0.600 
Olf186-F ns * *** *** ** 0.600 
Vesicle-associated membrane protein 
7 
ns *** *** *** ns 0.600 
CG5118 ns *** *** *** ns 0.600 
Proteasome subunit beta 5 ns ** *** *** * 0.600 
Hiiragi ns *** *** *** ns 0.600 
Cyclin-dependent kinase 4 *** *** ns *** ns 0.600 
Acyl-CoA synthetase long-chain ns *** *** ns ** 0.533 
Disc proliferation abnormal ns * *** *** * 0.533 
Draper *** *** ns ns - 0.500 
Enolase ns *** *** ns - 0.500 
CG18870 ns ** *** ** ns 0.470 
A kinase anchor protein 200 * *** * ns - 0.420 
Actin 42A ns * *** ** ns 0.400 
Suppressors - Intermediate effect TP1 TP2 TP3 TP4 TP5 Overall 
Connector enhancer of ksr ns *** *** ns ns 0.400 
CG13192 (**) *** *** ns ns 0.400 
Female sterile (2) Ketel ns ns *** *** ns 0.400 
Vacuolar protein sorting 35 ns ns *** *** ns 0.400 
Milton ns *** *** ns ns 0.400 
Inositol 1,4,5-triphosphate kinase 1 ns ns *** *** ns 0.400 
Syntaxin interacting protein 1 ns ns ns *** *** 0.400 
CG9643 ns *** *** ns ns 0.400 
Upf3 ns *** *** ns ns 0.400 
CG11125 ns ** ns *** * 0.400 
CG8520 (***) ns *** ns * 0.267 
Trap1 ns ns * *** ns 0.267 
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Ero1L ns * *** ns ns 0.267 
Quaking related 58E-3 ns * *** ns ns 0.267 
Suppressors - Weak effect TP1 TP2 TP3 TP4 TP5 Overall 
Syntaxin 6 ** * * ns ns 0.267 
Spc105-related ns ns *** ns ns 0.200 
Autophagy-specific gene 7 ns * * ns - 0.170 
Signal peptide peptidase ns *** ns ns - 0.250 
Type III alcohol dehydrogenase ns *** ns ns - 0.250 
lethal (2) k05819 ns ns ** ns ns 0.133 
Enhancers TP1 TP2 TP3 TP4 TP5 Overall 
Myocyte-specific enhancer factor 2 *** *** ns ns - 0.500 
CG9153 *** *** ns ns - 0.500 
scabrous *** * * ns ns 0.333 
longitudinals lacking ns *** ns ns - 0.250 
Smooth *** *** *** ns ns 0.600 
Malate dehyrogenase ns ns *** *** ns 0.400 
Dreadlocks (**) *** *** ns ns 0.400 
Alanyl-tRNA synthetase ns *** * ns ns 0.270 
 Suppressors - No effect TP1 TP2 TP3 TP4 TP5 Overall 
Suppressor of variegation 2-10 ns ** ns ns - 0.167 
Retinal degeneration B beta ns ns *** ns ns 0.200 
CG10809 ns ns ** ns ns 0.130 
Costa ns ** ns ns ns 0.130 
Rab5 ns ns ns ns ns 0.000 
Cullin-2 ns ns ns ns ns 0.000 
spaghetti ns ns ns ns ns 0.000 
Polycomblike ns ns ns ns ns 0.000 
CG3625 ns ns ns ns ns 0.000 
Suppressors - Opposite effect TP1 TP2 TP3 TP4 TP5 Overall 
Rap GTPase activating protein 1 ns * (**) ns ns 0.070 
Hormone receptor-like in 39 (***) (***) ns ns ns 0.000 
kismet ns ns (***) (***) ns 0.000 
Syntaxin 7 (***) (***) ns ns ns 0.000 
14-3-3ζ ns ns ns ns ns 0.000 
Coronin ns (***) (*) ns ns 0.000 
CG12299 ns ns ns (***) ns 0.000 
Ub-conjugating enzyme E2Q-like ns ns (***) ns ns 0.000 
Silent information regulator 2 (***) ns ns ns - 0.000 
Enhancers – No effect TP1 TP2 TP3 TP4 TP5 Overall 
Dynamin associated protein 160 (***) (***) (***) (***) - 0.000 
Peroxisome biogenesis factor 10 ns ns ns ns - 0.000 
CG30456 ns ns * ns ns 0.070 
calcium-binding protein 1 ns *** ns ns ns 0.200 
Mitochondrial carrier homolog 1 * ns ns ns - 0.083 






Table 10. Motor performance assay tested on the DVAP-P58S genetic modifiers.  
TP, Time point tested. Overall column express relative significance level though out 
the different time points. Strong modifiers are significantly different from controls at 
most part of the curve. Intermediate lines show two points significantly different 
from the control and weak modifiers include alleles which are significantly different 
in at least one time point but with a curve closer to the one observed in controls. A 
group of modifiers presented an opposite effect to the one observed in the primary 
screen; their significance level is presented in brackets. 58 modifiers discovered in 
our primary screen were confirmed using this assay. *** p<0.001, ** p<0.01, * 

















































Figure 20. Motor performance behaviour of each of the DVAP-P58S genetic 
modifiers. Climbing assay was performed in flies co-expressing in the nervous 
system DVAP-P58S and each one of the genetic modifiers. Modification output in 
this assay was classified as suppressors showing a strong (A), intermediate (B) or 
weak modification effect (C), enhancers (D) and lines that did not present any effect 
compared to controls or did not confirm the effect observed in the primary eye screen 
(E). Each experimental line (black line) is compared to the tester line (red line: (elav-
GAL4/+; DVAP-P58S/+) and to the control (blue line: elav-GAL4;+/+). *** P < 

































Figure 21. Summary scheme of screens and validations results. The number of 
positive modifiers is displayed for each of the independent allele (yellow), viability 
(red) and climbing assays (blue). Intersection between two circles represents the 
number of lines that showed positive modification in those two readouts. From an 
initial set of 85 modifiers, 23 were confirmed also by these three methods (white 
box, right). Considering the two stronger methods, 42 bona fide modifiers of DVAP-

















Chapter 6: Bioinformatic 














6.1 Introduction  
 
The aim of the following analyses was to further characterise the confirmed list of 
genetic modifiers using different bioinformatic approaches. We searched for 
predicted and known functions of each modifier gene, potential interactions between 
them and DVAP, and if these connections were translated into human orthologs of 
the modifiers. In-silico analyses are a central component of previously published 
genetic screens and with these approaches, we were able to connect DVAP-P58S-
toxicity modifiers with relevant functional pathways. 
 
6.2 Human orthologs and functional categories were found for most 
of the modifying genes 
 
A central step in our analysis is to understand the nature of each modifier and its 
function in the cell. In theory, if different researchers try several unrelated 
approaches to study and classify the function of genes, a disorganised amount of 
divergent data would be potentially useless. To address this problem, the Gene 
Ontology consortium was created to provide a controlled vocabulary of terms to 
describe functions and characteristics of each gene (Ashburner et al., 2000). These 
GeneOntology (GO) terms are grouped in three categories: Biological process, 
describes the protein’s biological activity or the pathways where it is involved; 
Molecular function, referred to the biochemical nature of the protein and Cellular 
component, or the specific location of the protein inside the cell (Robinson et al., 
2004) 
 
 After this publication, several approaches have applied this data source to 
address different questions in a practical way. To study the specific gene function 
and protein family classification, we used the classification data base PANTHER 
(Protein ANalysis THrough Evolutionary Relationships), part of the GeneOntology 
consortium (Table 5 and 6). Through this database, we associated protein categories 
to each modifier gene according the function they are performing in the cell. Only 12 
modifiers (13.3%) are not linked with a protein function, primarily corresponding to 
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non-studied Computed Genes (CG lines). Although some information regarding 
these genes is available and can potentially link them to relevant functional 
pathways, the specific nature of the proteins still remains unknown. From these 
categories, the presence of trafficking and SNARE proteins highlight as one the most 
represented groups. Also we could find an important number of kinases, which 
potentially can be target of chemical modulation for potential therapeutic 
approaches.  
 
 PANTHER also informs the best available human ortholog of the confirmed 
DVAP-P58S-neurodegeneration modifiers. However, several other tools have been 
developed over the last years to predict ortholog genes based in different approaches 
such as phylogeny, sequence similarity or protein-protein interaction (Hu et al., 
2011). The use of different algorithms can be difficult to handle and the specificity of 
the results can be hard to compare between all the approaches. To avoid that, we 
used DRSC Integrative Ortholog Prediction Tool (DIOPT), an approach that 
integrates all these several prediction tools and predicts the best ortholog based on 
the number of independent algorithms that yielded the same result (Hu et al., 2011). 
In this case, we obtained a score showing the number of positive algorithms for that 
specific ortholog (Table 11). From the 85 modifiers, 77 exhibit a significant human 
ortholog found in at least two of the ten different algorithms. Overall these lines 
display a human version according most tested algorithms, giving us a strong support 
of the possible function of the modifiers in humans and expanding the available 
studies that characterise these genes. For this approach however, we took into 
consideration only the best human ortholog for each Drosophila gene according this 
software. Bearing in mind that more than one paralog can be found in humans for 
one Drosophila gene, the selection of only one of them under DIOPT’s parameters 
can represent an incomplete picture of the genetic networks. However, for the 
following analyses the presence of this only ortholog could provide enough 
information to the relation of VAPB and its genetic modifiers. Most importantly, the 
presence of a human ortholog indicates that our data obtained in Drosophila can be 
translated into a mechanism of ALS in humans. 
 
148 











Hormone receptor-like in 39 Hr39 NR6A1 2 
nuclear receptor subfamily 6, group A 
member 1 
2649 
Inhibitor of apoptosis 2 Iap2 BIRC2 9 baculoviral IAP repeat containing 2  329 
Small glutamine-rich 
tetratricopeptide           
containing protein 
Sgt SGTB 10 
small glutamine-rich tetratricopeptide repeat 
(TPR)-containing, alpha 
6449 
CG5118 CG5118 - - - - 
Spaghetti Spag RPAP3 10 RNA polymerase II associated protein 3 79657 
Type III alcohol dehydrogenase T3dh ADHFE1 10 alcohol dehydrogenase, iron containing, 1  137872 
Abrupt ab - - - 9278 
Rap GTPase activating protein 1 RapGAP1 RAP1GAP2 6 RAP1 GTPase activating protein 2 23108 
Rhomboid rho RHBDL3 5 rhomboid veinlet-like 3 162494 
CG3625 CG3625 AIG1 10 androgen-induced 1 51390 
CG12299 CG12299 ZNF366 3 zinc finger protein 366  167465 
Upf3 Upf3 UPF3B 10 
UPF3 regulator of nonsense transcripts 
 homolog B 
65109 
Klarsicht klar - - - - 
Leak lea ROBO1 5 roundabout 1 6091 
CG5734 CG5734 SNX17 10 sorting nexin 17 9784 
Acyl-CoA synthetase      long-
chain 
Acsl ACSL3 9 
acyl-CoA synthetase long-chain family  
member 3 
2181 
Actin 42A Act42A ACTB 6 actin, beta 60 
Tejas tej TDRD5 3 tudor domain containing 5 1635 
Inositol 1,4,5-triphosphate 
kinase 1 
IP3K1 ITPKA 2 Inositol-trisphosphate 3-kinase A 3706 
Costa cos KIF7 4 Kinesin family member 7 374654 
CG13204 CG13204 - - - - 
Retinal degeneration B β rdgBβ PITPNC1 9 
phosphatidylinositol transfer protein 
 cytoplasmic 1  
26207 
Suppressor of variegation   2-
10 
Su(var)2-10 PIAS1 9 protein inhibitor of activated STAT, 1 8554 
14-3-3ζ 14-3-3ζ YWHAZ 9 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta  
7534 
Vacuolar protein sorting 35 Vps35 VPS35 10 vacuolar protein sorting 35 homolog 55737 
Spc105-Related Spc105R - - - - 
CG15630 CG15630 NCAM1 2 neural cell adhesion 1 4684 
Signal peptide peptidase spp HM13 9 histocompatibility (minor) 13 81502 
Milton milt TRAK1 10 trafficking protein, kinesin binding 1 22906 
Syntaxin 6 Syx6 STX6 10 Syntaxin 6 10228 
Silent information regulator2 Sir2 SIRT1 8 sirtuin 1 23411 
Vesicle-associated membrane 
protein 7 
Vamp7 VAMP7 9 vesicle-associated membrane protein 7  6845 
Female sterile (2) Ketel Fs(2)Ket KPNB1 10 karyopherin (importin) beta 1 3837 
lethal (2) k05819 l(2)k05819 KIAA0195 9 KIAA0195 9772 
Hippo hpo STK3 9 serine/threonine kinase 3 6788 
CG10809 CG10809 ANKRD54 6 ankyrin repeat domain 54  129138 
Ras which interacts with 
calmodulin 
Ric RIT2 9 Ras-like without CAAX 2 6014 
quaking related 58E-3 qkr58E-3 KHDRBS1 4 
KH domain containing, RNA binding, signal 
transduction associated 1  
10657 
Cyclin-dependent kinase 4 Cdk4 CDK6 9 cyclin-dependent kinase 6 1021 
CG18870 CG18870 - - - - 
Secreted Wg-interacting 
molecule 
Swim TINAGL1 9 tubule-interstitial nephritis antigen-like  64129 
CG9643 CG9643 METTL10 6 methyltransferase like 10 399818 
CG4896 CG4896 RBM5 8 RNA binding motif protein 5 10181 
Polycomblike Pcl MTF2 8 
Metal response element binding transcription 
factor 2 
22823 
CG8520 CG8520 LACE1 10 lactation elevated 1  246269 
hiiragi hrg PAPOLG 8 poly(A) polymerase gamma 64895 
disc proliferation abnormal dpa MCM4 9 
minichromosome maintenance       complex 
component 4 
4173 
Ero1-like protein Ero1L ERO1LB 7 ERO1-like beta 56605 
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Human Gene Name 
Human 
Gene ID 
olf186-F olf186-F ORAI1 10 
ORAI calcium release-activated      calcium 
modulator 1  
84876 
Autophagy-specific gene 7 Atg7 ATG7 10 autophagy related 7  10533 
CG13192 CG13192 GNB1L 9 





CG4502 UBE2QL1 7 
ubiquitin-conjugating enzyme  
E2Q family-like 1  
134111 
Cullin-2 Cul-2 CUL2 10 cullin 2 8453 
CG10492 CG10492 ZCCHC2 2 zinc finger, CCHC domain containing 2 54877 
Croquemort crq SCARB1 3 scavenger receptor class B, member 1 949 
CG11125 CG11125 ENKD1 7 enkurin domain containing 1 84080 
Auxilin Aux GAK 10 cyclin G associated kinase 2580 
Rab5 Rab5 RAB5A 9 RAB5A, member RAS oncogene family 5868 
A kinase anchor protein 200 Akap200 - - - 65108 
Syntaxin 7 Syx7 STX7 9 syntaxin 7  8417 
Syntaxin interacting           
protein 1 
HSPC300 BRK1 6 
BRICK1, SCAR/WAVE actin-nucleating 
complex subunit 
55845 
Trap1 Trap1 TRAP1 10 TNF receptor-associated protein 1 10131 
Draper drpr MEGF11 9 multiple EGF-like-domains 11 84467 
kismet kis CHD7 9 
chromodomain helicase DNA                 
binding protein 6 
55636 
Enolase Eno ENO1 9 enolase 1, (alpha)  2023 
Cyclin B CycB CCNB1 6 cyclin B1  891 
Src oncogene at 42A Src42A FRK 9 Fyn-related kinase 2444 
Proteasome subunit beta 5 Prosβ5 PSMB5 10 
proteasome (prosome, macropain)  
subunit beta, type, 5 
5693 
Coronin coro CORO1C 8 coronin, actin binding protein, 1C 23603 
connector enhancer of ksr cnk CNKSR2 7 
connector enhancer of kinase  suppressor of 
Ras 2  
22866 
Lightoid ltd RAB32 6 member RAS oncogene family 32  10981 
Enhancers 
scabrous sca FGA 2 fibrinogen alpha chain 2243 
Smooth sm HNRPL 8 heterogeneous nuclear ribonucleoprotein L 3191 
longitudinals lacking lola - - - - 
Myocyte-specific             
enhancer factor 2 
Mef2 MEF2A 7 myocyte enhancer factor 2A  4205 
CG7324 CG7324 TBC1D9 8 TBC1 domain family, member 9 23158 
Mitochondrial carrier homolog 1 Mtch MTCH2 10 mitochondrial carrier 2  23788 
Peroxisome biogenesis factor 10 Pex10 PEX10 10 peroxisomal biogenesis factor 10  5192 
calcium-binding protein 1 CaBP1 PDIA6 10 
protein disulfide isomerase  
family A, member 6  
10130 
Dynamin associated          
protein 160 
Dap160 ITSN1 9 intersectin 1 (SH3 domain protein)  6453 
Malate dehyrogenase Mdh1 MDH1 10 malate dehydrogenase 1, NAD (soluble)  4190 
Alanyl-tRNA synthetase Aats-ala AARS 10 alanyl-tRNA synthetase  16 
CG9153 CG9153 HERC4 9 
HECT and RLD domain containing  
E3 ubiquitin protein ligase 4 
26091 
Dreadlocks dock NCK1 10 NCK adaptor protein 1  4690 
CG30456 CG30456 PLEKHG4 2 
pleckstrin homology domain containing, family 
G, member 4 
25894 
 





6.3 GeneOntology terms enrichment associates DVAP toxicity with 
cell death, vesicle recycling and other biological process 
 
Over the last years, several genomic and proteomic studies in Drosophila have 
provided data that link genes to functional pathways and highlight interactions 
between proteins. To generate hypotheses regarding potential functions of the 
confirmed modifiers, we used two different approaches. The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) is a NIH-based 
database that provides a comprehensive set of tools to analyse and integrate 
GeneOntology terms (Huang et al., 2008). Through DAVID, we were able to 
discover enriched functional groups and GO terms, starting from a gene set. 
GeneMANIA on the other hand is another tool based on the GeneOntology 
consortium (Warde-Farley et al., 2010). This tool collects 60 Drosophila data sets 
from other databases (BioGRID, Gene Expression Omnibus, Pathways Commons 
and I2D) to create connections between fly genes using their gene functions and 
reported interactions, determining the most enriched categories in a specific data set. 
Firstly we studied the most enriched functional categories using DAVID.  
 
 We analysed the 85 DVAP-P58S-toxicity modifiers with this database and 
found 41 significant, non-redundant GeneOntology (GO) functional categories, 
including 3 Molecular Function terms and only 2 Cell Compartment term: Lipid 
Particle and Endosome. Interestingly, the best ranked, non-redundant categories are 
related with Vesicle metabolism, signaling and development (Figure 22). When this 
analysis was performed with GeneMANIA, similar results were obtained, with the 
same most enriched categories reported. Notably the most enriched annotation 
cluster, an analysis used to filter out redundant terms, also predicts Endosome and 
Cell signaling as the most important category found in the screen. Relevant genes 
part of this group are the vacuolar protein sorting Vps35, syntaxins Syx6 and Syx7, 






Figure 22. Functional categories overrepresented in the genetic modifiers list. 
GeneOntology terms associated with all the genes found in the screen were analysed 
with the bioinformatic database DAVID. A total of 41 significantly enriched terms 
were found with a significance cutoff of 0.05, where the significance is expressed as 
the -log10 (P values). Numbers in white represent the number of genes in each 
specific category. Most enriched categories are related to vesicle trafficking, lipids 




6.4 Gene network analyses reveal known interaction between the 
modifiers and predict potential involved pathways  
 
A comprehensive gene network was built with all the DVAP-P58S-modifier genes, 
based on the co-localisation, physical, genetic and predicted interaction Drosophila 
datasets integrated in the GeneMANIA database and visualized with the software 
Cytoscape (Shannon et al., 2003) (Figure 23). Only a small group of significant 
interactions linked DVAP with its genetic modifiers. Nevertheless, important 
previously reported links were found, associating genes with significant GO 
functions and DVAP. These interactions can potentially lead to describe the way the 
modifiers can alter DVAP-induced neurodegeneration. 
 
 By further exploring this gene network, we observed that seven of the 
modifiers physically interact with DVAP. This group of genes (CG7324, Syx7, 
Ero1L, Rab5, CG5118, rho and Spp) shows a stronger evidence of a potential 
interaction with DVAP, considering that we are now adding a second connection 
with the genetic interaction found in the screen. 
 
 To confirm the results observed in this gene network and at the same time, 
predict novel genes that can potentially interact with the modifier genes and DVAP, 
we used as a parallel approach STRING. This is another database that predicts and 
report protein interactions, based on high-throughput experiments and genomic 
context (Jensen et al., 2009). In the created network, DVAP appears connected with 
Autophagy, vesicle recycling and Cell proliferation clusters, including several 
predicted new interactors. Other significant clusters involve Proteasome activity, 









Figure 23. Interaction network of DVAP-P58S modifier genes. All the                    
DVAP-genetic modifiers were connected using previously reported Drosophila data 
sets with GeneMANIA. Genetic modifiers were connected using previous available 
co-localisation (blue), physical (red), genetic (green) or predicted (orange) 
interaction data. In the network, DVAP (yellow circle) corresponds to a node already 
connected to some of its modifiers. A group of 13 modifiers do not present 
previously reported interaction information. Strength of the interaction was 
automatically weighted by the software and it is graphically displayed with different 














Figure 24. Interaction network of DVAP-neurodegeneration modifier 
genes and predicted candidate interactors. Interaction network based on 
high-throughput Drosophila data sets collected by the database STRING. 
Interactions between DVAP-modifier proteins and predicted interactors are 
displayed as components of this network. These connections gather predicted 
and observed modifiers in relevant protein clusters, including Notch (red 







6.5 Ingenuity pathway analysis suggests that functions and 
interactions of DVAP genetic modifiers are conserved in humans 
 
These bioinformatic analyses of Drosophila modifiers gave us several new paths to 
understand DVAP-linked toxicity. To further explore the implications of these 
connections among genes but in a higher context, we used Ingenuity Pathway 
Analysis (IPA). This software is based on previously reported data of human proteins 
and the way they associate to diseases, mechanisms and functions. In this way, the 
relation between our modifier set and disease-related pathways was studied with 
more detail and supporting information. From the original 85 Drosophila modifiers, 
77 human orthologs were found (Table 11) and were used to the IPA analysis. 
 
 Functional categories analysis provided the most enriched pathways found in 
the screen and the genes that are part of them. Significance level and number of 
subcategories involved are also displayed in the Table 12. Consistent with what we 
observed in the Drosophila bioinformatic analyses, the most enriched pathways are 
related to Cell death, assembly and organization, with specific relevance of Fusion of 
vesicles, endosomes and lysosomes, as well as apoptosis and autophagosomes. Also 
are mentioned as significant categories Protein trafficking, Cell growth and 
Development. 
 
 To gather further information about our genes and pathways, we looked for 
predicted upstream regulators of our modifiers and their pathways. Significant 
transcription factors as TP53, FOS and several kinase inhibitors and chemicals drugs 
are predicted as potential modifiers of the DVAP-genetic interactors. Interestingly, 
SOD1, another ALS-causative gene, is an upstream regulator of four DVAP 
modifiers and its human ortholog, VAPB (Table 13). These factors can potentially 
affect DVAP relation with its modifiers but it is an important starting point to test 
novel pharmaceutical targets to affect VAPB toxicity and ALS pathogenesis. 
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Functional Category Sub P-value 
range 
Molecules NM 
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Table 12. Ingenuity pathway analysis enriched functional categories for DVAP 
modifiers human orthologs. Sub column displays the number of subcategories 
included in the main functional category. Significance level of each of these 
subcategories is between the values presented in P-value range column. Number of 
modifier human ortholog (NM) reflects the number found in all the significant 

















Upstream Regulator Molecule Type P-value Target molecules 
IL31 other 1.10E-05 CCNB1,CDK6,MCM4 
miR-181a-5p (and other 
miRNAs w/seed 
ACAUUCA) 




panobinostat chemical drug 1.08E-04 CCNB1,CDK6,YWHAZ 
IND S7 
chemical - kinase 
inhibitor 
1.21E-04 ACTB,ENO1,HNRNPL 





chemical - kinase 
inhibitor 
1.35E-04 ACTB,ENO1,HNRNPL 
miR-421-3p (and other 
w/seed UCAACAG) 
mature microRNA 2.23E-04 
ACSL3,CDK6,CHD7,CORO1C,FRK,PAPOLG, 
UBE2QL1,VAMP7 
SMOC2 other 2.43E-04 CCNB1,MCM4 
desmopressin biologic drug 2.66E-04 ACTB,ENO1,STX7,YWHAZ 
T3-TR-RXR complex 3.82E-04 ENO1,FGA,SCARB1 
SOD1 enzyme 4.28E-04 ACTB,GAK,PSMB5,SIRT1,VAPB 
miR-190a-5p (and other 
w/seed GAUAUGU) 
mature microRNA 7.33E-04 ATG7,CHD7,MEF2A,PAPOLG,VAPB 
BAX transporter 7.70E-04 BIRC2,CCNB1,PDIA6 
NDUFA13 enzyme 8.92E-04 CCNB1,MCM4 
miR-204-5p  mature microRNA 8.99E-04 
ATG7,BIRC2,CORO1C,KHDRBS1,RAP1GAP2, 
ROBO1,SIRT1,VAPB,YWHAZ 
picropodophyllin chemical drug 1.04E-03 CCNB1,CDK6 
asiatic acid chemical reagent 1.04E-03 CCNB1,SIRT1 
KITLG growth factor 1.11E-03 ACTB,FRK,KPNB1,ORAI1,PSMB5 
D-glucose 






chemical - endogenous 
non-mammalian 
1.54E-03 CDK6,SCARB1 
FOS transcription regulator 1.55E-03 ENO1,FGA,GAK,PIAS1,STK3,VAMP7,YWHAZ 
IND S1 chemical - kinase 
inhibitor 
2.59E-03 ACTB,ENO1 
nocodazole chemical reagent 3.07E-03 CCNB1,KHDRBS1,STK3 
Table 13. Significant upstream regulators of DVAP modifiers human orthologs 
predicted by Ingenuity Pathway Analysis.  
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 ALS is a complex disorder that shares symptoms and mutations with other 
neurodegenerative diseases. If VAPB-interactors affect the function of the protein in 
ALS, we may think that they may also be involved in other disorders as well. To 
study this idea, we searched in the public databases OMIM and GWAS for the 
connection between human alleles and genetic disorders. Interestingly, seventeen 
genes are already associated with different disorders (Table 14). Among these, 
neurodegenerative diseases are an important group with mutations found in 
Parkinson’s disease, multiple sclerosis and spinocerebellar ataxia 31. Curiously, 
AARS, the human ortholog of Aats-ala, has been associated with Charcot-Marie-
Tooth disease, a disease that extensively overlaps with ALS phenotypes. These 
overlapping genes can represent a currently unknown link between ALS and other 
diseases, especially for the ones that have been associated previously with patients 
carrying both disorders.  
 
 Finally, human orthologs of the DVAP genetic modifiers were analysed with 
supporting information to create functional networks between them. The genes were 
processed with the highest stringency, using only non-predicted, experimental and 
direct interaction between them, excluding signaling and indirect interactions. This 
map (Figure 25) shows interaction between 32 of the human orthologs including 
some well-connected nodes. YWHAZ, the ortholog of 14-3-3ζ, works as a central 
node of a cluster that connects VAPB with STK3, human version of Hippo. This link 
could work as a central way to understand the connection of VAPB with the rest of 
its genetic modifiers. Other functions associated with this cluster include lipid 
metabolism and RAS signaling pathway. Also well connected we can find proteins 
related with vesicles and endocytosis, in the central network (RIT2, RAB5A, ITSN1) 













UPF3B Upf3 Mental retardation, X-linked, syndromic 14 300676 OMIM 
ACTB Act42A 








Joubert syndrome 12 







PIAS1 Su(Var)2-10 Major depressive disorder - GWAS 










VPS35 Vps35 Parkinson disease 17 614203 OMIM 
KPNB Fs(2)Ket Multiple sclerosis - GWAS 









Natural killer cell and glucocorticoid deficiency 
with DNA repair defect 
 
609981 OMIM 
GAK Aux Parkinson’s disease - GWAS 
CHD7 Kis CHARGE syndrome 214800 OMIM 
ENO1 eno 
Autism spectrum disorder                                 








FGA sca Amyloidosis, hereditary renal 105200 OMIM 
PEX10 Pex10 
Peroxisome biogenesis disorder 1A 
Peroxisome biogenesis disorder 2B 







AARS Aats-ala Charcot-Marie-Tooth disease, axonal, type 2N 613287 OMIM 
PLEKHG4 CG9153 Spinocerebellar ataxia 31 117210 OMIM 
 
Table 14. Genetic disorders associated with the human orthologs of the DVAP-







Figure 25. Ingenuity Pathway Analysis of DVAP-neurodegeneration modifiers 
human orthologs. Previously reported interactions between human ortholog of the 
DVAP-neurodegeneration modifiers found in the screen. Links include direct, 
indirect and self-interactions. DVAP human ortholog, VAPB, is part of the network 
via interaction with STK3, the human ortholog of Hippo. These proteins are part of a 
cluster with the protein YWHAZ as a central node. The vesicle related proteins 










 To expand the number of orthologs connected to VAPB and its network, we 
manually inserted the protein in the modifier list and then, it was connected to the 
rest of proteins using the “Shortest path” algorithm from IPA. Most nodes from the 
network were now connected using known interactions with predicted, non-DVAP-
modifier proteins (Figure 26, yellow nodes). With this method, we increased in 13 
the number of connected modifiers to a total of 45 nodes (green nodes). VAPB is 
now associated with the Vesicles cluster in a stronger way, via its interaction with 
STX proteins. Interestingly, other modifiers are also connected to VAPB through the 
central neurodegeneration-related proteins SOD1, HTT and SNCA. 
 
 These analyses gave us additional clues to understand the data obtained from 
the screen. Enrichment of functional clusters like cell death, lipid particle and vesicle 











Figure 26. Expanded interaction network of DVAP-neurodegeneration 
modifiers human orthologs and predicted interactors. Interaction network 
connecting DVAP genetic modifiers and its human ortholog, VAPB. This protein is 
connected through known interactions with proteins not found in the screen (yellow 
molecules) but predicted as link with the genetic modifiers (green molecules) using 
the Shortest path algorithm. Several functional categories cluster together and are 


















Chapter 7: Endosomal transport 
modifies DVAP-P58S  















Having found and validated a novel group of DVAP genetic interactors, we were 
able to understand their connection using bioinformatic approaches. Among these 
functional categories we observed that endocytosis was one of the most represented 
in the genetic screen. Therefore, we plan to confirm the relation of this process with 
DVAP neurodegeneration studying specific endocytic genes. If our screen and the 
bioinformatic analysis were correct, we will be able to successfully observe 
modification of DVAP toxicity in vivo with the novel genetic modifier Rab5 and 
other related predicted interacting genes. Finally, we will check whether this 
modification is also conserved in humans. 
 
7.2 Vesicle metabolism and endocytosis have been previously 
associated with neurodegeneration 
 
The data presented so far have indicated that an important group of DVAP genetic 
modifiers is involved in vesicle metabolism and endocytosis. These processes, 
central in cell biology and neurodevelopment, are strictly regulated by complex 
endosomal system (Yap & Winckler, 2012). After the initial internalisation of 
molecules, via clathrin-dependent or -independent mechanisms, cargo molecules are 
stored, degraded or recycled. This process is crucial in all the cell types, but in 
neurons is even more specialised, considering the addition of polarisation in the 
endosome movement and an increased differentiation in endocytosis stages (Howe & 
Mobley, 2004). Therefore, endosomes in neurons regulate various central processes 
such as retrograde neurotrophic signaling, axonal pathfinding during development, 
synaptic vesicle recycling and synaptic plasticity (Yap & Winckler, 2012). 
Malfunction of any endocytic stage leads to a wide range of disorders, including 




 Previously, vesicle metabolism and endocytosis have been associated with 
other neurodegenerative diseases, some of them showing commonalities with ALS. 
In 2008, Liang and colleagues (Liang et al., 2008) found that vesicle related genes 
modified α-syn toxicity. One of these genes, ENT3, was a conserved clathrin adapter 
suggesting that protein transport to vacuoles to initiate degradation may be involved 
in the Parkinson’s pathomechanism. Another example was provided by Dimitriadi 
and colleagues (Dimitriadi et al., 2010) with the finding of common proteins in C. 
elegans and D. melanogaster as modifiers of SMN. These proteins were linked to 
endocytosis and synaptic vesicle release, functions enriched in our screen. Last year, 
MacLeod and cols (MacLeod et al., 2013) elegantly proved that the common 
mechanism between Parkinson’s disease causative genes LRRK2 and PARK16 
implicated retromer and lysosomal pathways. They showed that two central proteins 
in this process were RAB7L1 and VPS35. Interestingly these two proteins were 
found in our screen as DVAP-P58S-induced toxicity modifiers.  
 
7.3 Vps35, Syx7, Ric and Rab5 are amongst the vesicle-associated 
genes found as DVAP-P58S modifiers 
 
The genetic screen presented in the previous chapters revealed genes associated with 
vesicle metabolism; however this is the first time that they are connected to DVAP-
linked neurodegeneration or ALS. From the 85 identified modifiers, 13 were 
functionally connected to vesicle fusion and recycling (Figure 27A). The interaction 
network of these proteins is highly connected as expected and DVAP also appear to 
be part of the cluster. Known physical interaction was found between DVAP and 
Ero1L, Syx7 and Rab5. On the other hand, Ric co-expresses with DVAP and co-
localisation with DVAP was found in five of these proteins: Ric, Ltd, Syx6, Dap160 
and Aux. However, all these data are taken from large scale Drosophila studies and 
no functional interaction has mostly been described so far between these genes and 
either DVAP or ALS pathogenesis. Some of these genes although, can be linked to 
DVAP through other known DVAP-interactors like OSBP (Rocha et al., 2009) or 






Figure 27. DVAP genetic interactors are associated with vesicle traffic. (A) 
Reported interactions between DVAP genetic interactors based on Drosophila 
databases compiled by GeneMANIA. DVAP presents known interactions with 7 of 
the 13 proteins that form the well-connected network using co-expression (purple), 
co-localisation (blue), physical (red) and genetic interaction data (green). (B) 
Diagram displaying the functional connection between some of the human orthologs 
associated with vesicle recycling (yellow nodes). Links represent known interactions 
between the proteins, including known VAPB interactors such as OSBPL1A. Vesicle 





 From the 13 genes, 7 were in the group of 42 high-confidence modifiers 
confirmed by an independent allele and motor performance assay: Sgt, Vps35, Ltd, 
Act42A, Vamp7, Ero1L and Ric. The last three were also confirmed by the viability 
assay. These 7 genes are suppressors of DVAP-mediated toxicity and interestingly, 
all of them are connected to other modifiers or to pathways relevant to DVAP or 
ALS. Vps35 is a central component of the retromer complex and controls trafficking 
between endosome and Golgi. Its loss causes mislocalisation of endocytic proteins 
and defects in neuromuscular junction (Korolchuk et al., 2007) and as previously 
mentioned, is connected with Parkinson’s mechanism. In this same process but in 
opposite direction, are also involved other two modifiers, the syntaxin 6 and 7. The 
first one regulates trafficking from trans-Golgi network (TGN) to early endosomes 
and syntaxin 7 connects early and late endosome. The correct balance between 
concentrations of these proteins ensures an accurate distribution of the cargo 
molecules in the cell (Jung et al., 2012). Interestingly, Syx6 and Syx7 are 
suppressors but the tested lines were loss of function for these genes. This means that 
the same effect is observed with the down-regulation of the anterograde transport and 
with the up-regulation of the reverse trafficking, suggesting that these three proteins 
can be involved in DVAP-toxicity in a mechanism involving transport from vesicles 
to Golgi. 
 
 On the other hand, Ras-related protein interacting with calmodulin, Ric, is the 
only Drosophila member of Rit subfamily of Ras-related small GTPases (Wes et al., 
1996). Ric regulates the p38-Akt pathway, proteins previously associated with 
VAPB in oxidative stress and growth control. At the same time, CG9153 is an 
uncharacterized DVAP modifier and its human ortholog is Herc4, an ubiquitin ligase 
with a Guanine nucleotide Exchange Factor (GEF) domain. This protein is the 
common ancestor of a family involved in vesicular transport and the same GEF 
domain (RCC-1-like, RLD) is found in another gene causative of ALS, alsin. As 
downstream effectors of alsin stand out the Ras-related protein Rab5 and syntaxin 7 
(Hadano et al., 2007; Morrison et al., 2008), both found in our modifier genes set. 
The linkage between Alsin and DVAP through these endocytic genes could be 
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relevant to understand both pathomechanism and explain possible common 
molecular pathways between these two disease variants. 
 
7.4 DVAP-P58S mediated aggregates disrupts Rab5 wild type 
localisation in Drosophila nervous system 
 
Rab5 was one of the 13 vesicle-related genes found as a strong modifier in 3 of 4 
possible readouts, failing to show a significant suppression effect only in the 
climbing assay. This small GTPase is involved in clathrin-mediated endocytosis 
from the membrane to the early endosome pool (Cavalli et al., 2001) regulating 
important cellular processes such as postsynaptic trafficking and autophagy (Dou et 
al., 2013; Brown et al., 2005). As part of early endosomes, Rab5 concentration is 
recruited by an increased amount of the phosphoinosite PI3P (Zoncu et al., 2009). 
Maturation to late endosome involves a molecular exchange from Rab5 to Rab7, 
activity probably controlled by Rab proteins and phosphoinositides levels (Yap & 
Winckler, 2012). 
 
 Protein aggregation is a common hallmark for most neurodegenerative 
diseases. In our group we also showed that DVAP-P58S forms aggregates that 
sequester the wild type form of the protein, triggering cell death (Chai et al., 2008). 
Rab5 also has been associated with protein aggregates, decreasing the toxicity levels 
of aggregates formed by disease-related proteins such as huntingtin (Ravikumar et 
al., 2008), amyloid  (Li et al., 2012) and α-synuclein (Sancenon et al., 2012). For 
this reason we wanted to study the relation between Rab5 and DVAP protein 
aggregation.  
 
 So far, we have shown that Rab5 down-regulation is involved in DVAP-P58S 
toxicity and its overexpression can suppress the neurodegeneration. To understand 
what happens with Rab5 in DVAP mutants and whether the protein is mislocalised, 
we dissected eye imaginal discs from flies expressing DVAP-P58S and stained them 
with Rab5-specific antibodies. In controls, both proteins showed a clear distribution, 





Figure 28. Rab5 colocalises with DVAP-P58S-induced aggregates. Representative 
confocal images from CTRL (ey-Gal4/+) and ey,DVAP-P58S (ey-GAL4,DVAP-
P58S/+) eye imaginal discs stained with DVAP and Rab5 antibodies. In controls, 
both proteins showed a clear staining in the cell contour, but the aggregate formation 
caused by the overexpression of DVAP-P58S dramatically sequesters Rab5 protein. 




 However in DVAP mutant imaginal discs, Rab5 and especially DVAP lost 
their localisation forming protein aggregates that contain both mutant and wild type 
forms of the protein, as we have previously reported (Chen et al., 2010). 
Interestingly, Rab5 presents an irregular, granular distribution and is sequestered into 
DVAP-P58S-mediated aggregates (Figure 28B), suggesting that the depletion from 
wild type structures and loss of its function is caused by the formation of DVAP-
P58S aggregates. This interesting finding can be further supported with a better 
characterization of the exact location of these proteins. The addition of nuclear 
(DAPI), ER (Boca), Golgi (GM130) or membrane specific markers (HRP) could 
clarify furthermore the exact nature of Rab5 and DVAP interaction. Additionally, the 
comparison on the effect between DVAP-P58S and DVAP-WT over Rab5 
localisation could provide more evidence to the proposed loss-of-function 
mechanism. 
 
7.5 Overexpression of the endolysosomal markers Rab7 and Rab11 
also suppress DVAP-P58S linked neurodegeneration 
  
The initial analysis of this chapter detailed 13 genetic interactors of DVAP that were 
associated with vesicle recycling. However, the most enriched vesicle-related 
functional category was endosome, a central structure for the vesicle trafficking. 
When we isolated the genes associated with this category and study their connection 
to predicted genes, we were able to make several important observations. Firstly, 
most genes and their connections are conserved between Drosophila and humans 
(Figure 29). This not only supports the idea that this process has a central role inside 
the cell, but also validates the search for novel disease-related pathways in 
Drosophila. Secondly, we observed that some predicted interactors are also 
conserved in both networks. Interestingly, connected to Rab5 and Vps35 we observe 
the presence of Rab7. This protein is another endosome-related GTPase that in its 
mutant form produces axonal degeneration and can cause Charcot-Marie-Tooth 
(CMT) disease, which is highly reminiscent to ALS and its hallmarks (McCray et al., 
2010). For instance, FIG4/SAC3, another vesicle-related ALS-causative gene also is 




Figure 29. Rab7 is a predicted interactor of DVAP. (A) Interaction network 
between Drosophila DVAP modifiers that belong to functional categories associated 
with endocytosis (black nodes). The network can be strengthened with the addition 
of predicted interactors not found in the genetic screen (Gray nodes). (B) Interaction 
network between human orthologs of DVAP modifiers using the Grow feature of 
IPA. Predicted interactors in this network (yellow nodes) present previously reported 
interactions with the molecules found in the screen. Interestingly, Rab7 appears 
strongly connected in both network as a potential DVAP interactor through its 
interaction with the DVAP modifiers Vps35 and Rab5 (black arrows). 
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a physical interaction between this protein and DVAP in Drosophila, supporting a 
previously proposed mechanism linking both proteins in the regulation of 
microtubule trafficking of late endosomes (Rocha et al., 2009).  
 
 To study whether Rab7 displays the same phenotype as the other vesicle-
related DVAP genetic interactors found in the screen, we tested different Rab7 
alleles to search for toxicity modification effect. Transgenic flies expressing a 
disease-causing mutation (L129F, Figure 30A) and a dominant negative allele 
(T22N) did not have any significant effect in DVAP toxicity, as they maintain the 
eye size of the ey,DVAP-P58S line (Figure 31). Interestingly, the overexpression of 
the wild type Rab7 version or an engineered constitutively active form (Q67L) 
showed a significant suppression of the DVAP neurodegeneration in the eye (Figure 
30B,C), suggesting that the balance of DVAP and Rab7 activity can be important 
also for late endocytic vesicles and not only in early nucleation stages as Rab5 and 
other vesicle-related modifiers indicated. This effect was also confirmed in the 
nervous system, as the overexpression of Rab7 and its constitutively active form 
suppress DVAP-P58S lethality and motor performance defects (Figure 30D).   
  
 To confirm even more the implication of this pathway in DVAP-P58S-
mediated neurodegeneration, we went one step further in the molecules associated 
with the formation of endosomes. Rab11 is the final step of the machinery that also 
involves Rab5 and Rab7. Rab11 is involved in the recycling of endosome back to 
plasma membranes, regulating the balance between these molecules (Bastin and 
Heximer, 2013). If we observed an important effect of Rab5 and Rab7 in DVAP 
toxicity, we should expect a similar effect with Rab11. Indeed, we observed a 
significant suppression of DVAP-P58S-mediated neurodegeneration in the eye upon 
Rab11 overexpression (Figure 32). In conclusion, we were able to support previously 
reported DVAP interaction with our model and strengthen the relation between 







Figure 30. Suppression of DVAP neurodegeneration by upregulation of Rab7.    
(A) Genetic structure of Drosophila Rab7 gene. Two mutations associated with 
Charcot-Marie-Tooth disease and the dominant negative and constitutively active 
alleles were tested. (B) Light microscopy images of control flies (ey-GAL4/+) and 
flies expressing DVAP-P58S protein under the regulation of ey-GAL4 driver (ey-










) A significant suppression is observed for both alleles. (C) Quantification 
of the eye size of the crosses performed. Both up-regulated alleles presented a 
significant suppression compared with the ALS model. (D) DVAP-P58S-induced 
motor performance defect is suppressed by the overexpression of Rab7 in the 
nervous system, and in a lower degree by its constitutively active form. Scale Bar = 
50 um. *** P < 0.001, ** P < 0.01, * P < 0.05 (One-way ANOVA in C, Two-way 








Figure 31. Down-regulation of Rab7 does not affect DVAP neurodegeneration.    
(A) Light microscopy images of control (ey-GAL4/+) and flies expressing DVAP-
P58S protein under the regulation of ey-Gal4 driver (ey-GAL4,DVAP-P58S/+), and 










. (B) Quantification of the eye size of the crosses 









Figure 32. Suppression of DVAP neurodegeneration by upregulation of Rab11.    
(A) Light microscopy images of control (ey-GAL4/+) and flies expressing DVAP-
P58S protein under the regulation of ey-Gal4 driver (ey-GAL4,DVAP-P58S/+), and 
Rab11 overexpressing allele (ey-GAL4,DVAP-P58S/UAS-Rab11). (B) Quantification 
of the eye size of the crosses performed reveals a significant suppression of the 
DVAP-P58S phenotype in the eye by the overexpression of Rab11.  Scale Bar = 50 







7.6 Rab5 mislocalisation in DVAP-P58S-expressing tissue is 
conserved in humans 
 
In this genetic screen, we identified vesicle-related genes capable to modify DVAP-
P58S-mediated neurodegeneration. Some of these genes were previously linked to 
DVAP in Drosophila and we observed in-silico that these connections were 
conserved in humans. To confirm this last observation and link DVAP-modifiers 
with ALS phenotypes in patients, we studied the levels and distribution of the 
endocytosis-related protein RAB5A in tissues from ALS patients. This is the ultimate 
assay to validate the genes found in Drosophila and their potential relevance in the 
pathomechanism of ALS. Previous screens have validated in this way their results, 
showing that use of genetic approach in smaller organisms can be a great way to find 
novel genes involved in human neurodegenerative diseases (Neumann et al., 2006; 
Couthouis et al., 2011). 
 
 Human post-mortem spinal cord tissue was used to do immunohistochemistry 
using an antibody specific to the human protein RAB5A. When we analysed tissue 
from healthy control individuals, RAB5A seems to distribute in the contour of 
circular structures, possibly related to vesicles and endosome (Figure 33). However, 
when we analysed tissues from two representative patients with ALS, RAB5A 
distribution in neurons lost the previous organization and looks to be part of multiple 
abnormal protein aggregates (Results provided by Dr. Colin Smith, Centre for 
Clinical Brain Sciences, University of Edinburgh). This result confirmed the 
aggregation observed in Drosophila tissue but more importantly, suggest that loss-
of-function and aggregation of endocytic proteins could be linked to ALS 
pathogenesis. Taken together, our data identify potential novel ALS causative genes 
and their related pathways can lead to a better understanding of the mechanisms 















Figure 33. RAB5A mislocalises and aggregates in spinal cord neurons of 
patients with ALS. Representative images of immunohistochemistry of Control 
tissue and two different ALS patients tissue stained for RAB5A, displaying a change 
in the distribution of the protein. In Control individuals, RAB5A presents a defined 
circular staining but in tissue from two patients with ALS, an up-regulation and a 
dense aggregate-like structure is observed altogether with the lack of ring structures. 








































8.1 Overview of the project 
 
Only over the last two decades, research in the neurodegenerative field has showed 
an increased development. Major characterisation of several degenerative diseases 
has improved the chances of finding therapies and cures for a great number of 
patients. ALS is not outside this group, with an impressive amount of scientific 
growth since the discovery of TARDBP as causative gene in 2008 (reviewed in 
Robberecht & Phillips, 2013; Renton et al., 2014). This fact however, brings as a 
drawback an increasing amount of data that try to explain the whole disease without 
understanding the basic mechanisms of it yet. Moreover, the lack of success in 
several models and therapeutic trials, has led to a challenging point where it is 
difficult to move forward (Genc and Ozdinler, 2014). We thought that instead keep 
trying to understand the mechanism of the disease with the current knowledge, we 
needed to expand our available data and hence, explore known and novel pathways 
in a better way. This is useful to fill the gaps that could potentially merge two 
apparently dissimilar processes in a clearer one. More importantly, with the novel 
molecules found in this screen we are now able to study mechanisms that previously 
were not associated with ALS pathomechanism. Moreover, these novel molecules 
will potentially lead us to comprehend as well, more cases of ALS patients with a 
sporadic origin. 
 
 From this perspective, we could observe that our proposal of finding novel 
genetic interactors of the ALS-causative gene DVAP was mostly achieved. Selection 
of a high amount of parameters to perform a genome-wide screen is not always 
exempt of risks and failures. For this reason, we initially tested different parameters 
and decided a specific set of conditions to obtain in a clear way genetic modifiers of 
DVAP-induced neurodegeneration in the eye. We also covered with extra assays the 
more complicated search for enhancers of the DVAP-linked phenotype. Therefore, 
we started the screen with the aim to search for significant modifiers, minimising the 
risks of potential false hits. The initial discovery of 85 potential DVAP genetic 
interactors, and their subsequent validation and confirmation through a series of 
assays, confirmed the success of the selection of parameters and suggest that we are 
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now in a better position to understand the disease. At the same time, we can support 
the use of our Drosophila ALS model based on the expression of the mutant allele 
DVAP-P58S, for the search of genes using genome-wide screens. The combination 
of this model with classical Drosophila genetic techniques successfully achieved 
what has been also reported in other genetic screens that searched genes associated 
with neurodegenerative diseases over the last years (Park et al., 2014; MacLeod et 
al., 2013; Miller et al., 2012). 
 
 Another positive aspect of the outcome of this project is the favourable 
prospect to carry on with the use of this ALS model. A group of modifiers can 
hypothetically be the target of studies to modulate their activities. Up- or down-
regulation of the activity of these proteins can lead to potential therapeutic tests to 
suppress toxicity. At the same time, changes in the activity of kinases or proteins 
related with lipid metabolism can be assessed with the same consistent phenotypes 
used in this study, such as the neurodegeneration in the eye of the ALS model. 
Further biochemical characterization of these novel molecules opens a real 
possibility to understand the mechanisms associated with the disease. 
  
8.2 Endocytosis up-regulation suppress DVAP-P58S-induced 
neurodegeneration 
 
To fulfill completely the purpose of the project and find the genes involved in the 
ALS pathomechanism, is mandatory further characterisation of each one of the 
proposed genetic interactors. We selected genes linked to vesicle metabolism and 
endocytosis as an initial stage to validate the project and move forward in the 
understanding of the disease. Luckily, we were able to not only confirm the 
biological relevance of one of these proteins, Rab5, but to expand our search to other 
related Rab proteins as well. This finding provides a step forward to the relation 
between this molecular process and neurodegeneration, which hopefully can open 
novel researches in this direction. However, this also implies that similar biological 
assays can be used to further validate other genes found in the genetic screen. The 
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potential validation of other pathways will provide a bigger picture of the DVAP 
biology in the cell. 
 
 Rab5, an important endocytic component found in the screen, is a protein that 
is critical for early endosome fusion along the endocytic pathway. The native Rab5 
protein is present in endosomes at synaptic terminals as well as in cell bodies 
(Wucherpfennig et al., 2003). Both Rab5 constitutively active (CA) and dominant 
negative (DN) mutations affect Rab5 protein localisation, forming aggregates and 
less punctate signal than the wild-type in photoreceptor cells. Rab5-CA still 
colocalises with wild-type but DN looks more disperse, moving away from original 
early endosomes (Zhang et al., 2007). In the present study, we confirmed the relation 
between Rab5 and DVAP using two different approaches. Overexpression of Rab5 
was able to suppress the DVAP-P58S associated neurodegeneration in the 
Drosophila eye. Also, we observed a mislocalisation and aggregation of Rab5 in 
tissue from flies expressing the ALS-linked DVAP allele. These observations 
suggest a strong interaction between both proteins. Thus, a main consequence of 
DVAP aggregation and loss-of-function could be related with the loss-of-function of 
Rab5 and with this, deregulation of the normal endocytic balance. DVAP-P58S-
induced aggregates capture Rab5-WT protein and decrease its available levels. 
Therefore it makes sense that with the increase of available protein overexpressing 
the Rab5-WT allele, we were able to suppress the toxicity. It still remains unknown 
whether this suppression is due to a return to normal levels of early endosomes or 
whether this increase would also remove the DVAP-induced protein aggregates, 
improving the response to protein aggregation in the cell. The confirmation of RAB5 
mislocalisation phenotype in tissue from patients with ALS validates our proposed 
model and methodology, but more importantly suggests that this effect is a 
conserved VAPB-related phenotype.  
 
 The functioning of the endocytic trafficking is based on the highly coordinated 
spatial distribution and directionality of the vesicles. These aspects are regulated by 
different factors including the concentration and composition of phosphoinositides, 
and the sequential assembly of specific regulatory proteins or markers, such as the             
184 
Rab-GTPases (Krauss and Haucke, 2011). Bioinformatically we were able to predict 
marker proteins involved in this process. Rab7 appears as the next step after Rab5 
early endosome control. Present as a marker for late endosomes, Rab7 continues the 
recycling process inside the cell (Burd, 2011). Rab11 is the final step of the 
endocytic control and marker of recycling endosomes (Yap and Wickner, 2012). 
Therefore, the experimental confirmation of the Rab5 suppression effect with the 
overexpression alleles of Rab7 and Rab11 was highly important. Additionally, the 
identification in this study of other late endosome and lysosome markers, such as 
VAMP7 and Syntaxin 7, underlines the involvement of this last endocytic step in 
VAPB-linked toxicity. This last point is highly significant considering the function 
of late endosomes as crossroad with autophagy and protein degradation mechanisms 
(Scott et al., 2014), which also may play an important role in DVAP toxicity. 
 
 Another regulator of the coordinated endocytic trafficking is the concentration 
and composition of phosphoinositides, which can create different compartments and 
finally determine the fate of each structure and cargos (Yap and Wickner, 2012). We 
already associated phosphoinositides misregulation and DVAP neurodegeneration 
(Forrest et al., 2013). Therefore, the connection between DVAP-mediated 
phosphoinositide regulation and Rab protein activity acquire a central relevance with 
the observed neurodegeneration. It would be interesting to study the possibility that 
DVAP control of membrane dynamics is due to its interaction with more endocytic 
proteins, working as a central scaffold protein, or whether its lipid regulation is 
sufficient to affect membranes and the homeostasis of endosomes. Rocha et al. 
proposed a model where VAPB controls late endosome positioning by motor 
proteins in a cholesterol-dependent process (Rocha et al., 2009). This supports the 
function of VAPB yeast homologue, Scs2, as a tethering protein in the formation of 
multi contact sites (MCS) between ER and plasma membrane (Manford et al., 2012). 
A disruption in the MCSs between endosomes and ER can be a potential scenario in 
DVAP-P58S neurons due to the lack of tethering function of this protein. An 
increase in the amount of Rab proteins available may compensate that loss of 
function and may facilitate MCSs formation to recover normal trafficking. 
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 The link proposed here between ALS and endocytosis is not a minor one. Even 
though previous studies tried to explore this connection (Kasperaviciute et al., 2007), 
we did not know major links between ALS and endocytosis. However this year, Farg 
et al. associated Rab proteins to C9orf72 patients, proposing that this novel causative 
gene is a regulator of several steps in the endosomal trafficking (Farg et al., 2014). 
Here, we can now link endocytosis and the levels of Rab proteins in the DVAP-
linked neurodegeneration, suggesting a VAPB role facilitating vesicular trafficking. 
More important is the fact that DVAP works as key protein that, despite being 
previously ignored as central cause of the disease’s mechanism, is proven as central 
node for processes that now emerge as relevant for the disease.  
 
8.3 RAS signaling pathway is the most represented mechanism 
amongst the DVAP genetic modifiers 
 
From the whole set of genetic modifiers found in this study, probably the best 
connected each other were the molecules associated with RAS signaling pathway. 
This superfamily of proteins plays a role in almost every cellular process, sharing as 
a biochemical activity the hydrolysis and binding of GTP (Colicelli, 2004). The 
activated state of these proteins is caused by the binding of GTP that increases the 
affinity of RAS proteins to their downstream effectors. The hydrolysis of GTP or its 
exchange for a GDP molecule inactivates the proteins, differentially signaling in this 
way several processes. GTP exchange and protein activation can be accelerated by 
the removal of GDP molecules by the Guanine nucleotide exchange factors (GEFs) 
(Chardin et al., 1993). In the opposite way, RAS proteins can be inactivated by the 
hydrolysis of bound GTP performed by the GTPase activating proteins (GAPs) 
(McCormick, 1998). With this complex network, several signaling pathways are 
down- or up-regulated, affecting the activity of an impressive amount of downstream 
targets and regulating in this way cellular homeostasis (Colicelli, 2004). 
 
 The superfamily is formed by at least ten different subfamilies, some of them 
represented in our genetic screen. RAS subfamily include the first identified 
member, rat sarcoma (RAS) (Harvey, 1964), which is up-regulated in different 
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tumour cells and therefore, has been associated with cancer, growth and cell 
differentiation. RAS associated with brain proteins (RABs) is another subfamily 
previously discussed as central outcome of our assays, with an important control in 
endocytosis and vesicle metabolism. This one is the largest family with 71 members, 
due in part to an important number of expansions and duplications, if we consider 
that the number of members from humans is the double than in Drosophila 
(Colicelli, 2004). RHO (Ras homolog) is a third subfamily associated with cancer 
and cytoskeletan remodeling (Sahai and Marshall, 2002; Fransson et al., 2003), 
which include different Rho proteins and the motility regulator Rac1. Interestingly, 
the downstream target of Rac1 is Alsin, another ALS causative gene (Yang et al., 
2001). The Rac1-mediated relocalisation of Alsin from the cytoplasm to the 
membrane appears to be the most affected process damaged by ALS-linked 
mutations (Otomo et al., 2011). Furthermore, the downstream target of Alsin is 
RAB5, protein that in turn is an upstream regulator of STX7 (Hadano et al., 2007; 
Morrison et al., 2008). Both of them are DVAP genetic modifiers found in our 
genetic screen. The impairment in the interaction between Rac1 and Alsin would 
lead to a lack of activation of Rab5 that would translate in a deficiency of the 
endocytic balances, idea already discussed in the previous section. Indeed, this was 
observed by Otomo et al., when Alsin mutants failed to be localised by Rac1-
induced macropinosomes, which lead to a loss of function of Rab5 affecting its role 
in endocytosis and autophagy. This relocalisation failure also may be caused by a 
lower affinity of the Alsin mutant protein to the macropinosomal-enriched lipid 
molecules PI3P and PI4P (Otomo et al., 2011). Alsin presents three GEFs signaling 
motifs, including RCC1-like domain (RLD) which is also present in HERC ubiquitin 
ligases (Hochrainer et al., 2005). We found in the screen CG9153, the Drosophila 
homolog of HERC4, supporting even more the involvement of this pathway. The 
connection between RAS pathways and endocytosis, with ALS-linked mutations in 
VAPB has not been associated yet and could provide novel insights into ALS 
pathogenesis. 
 
 Another DVAP-interactor found in the screen is “Ras interacts with 
calmodulin”, Ric. This protein is a member of the Rit subfamily of Ras small 
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GTPases, which other members are Rin and Rit (Wes et al., 1996). In contrast to 
other RAS subfamilies, Rit proteins are not well understood and even though they 
are connected to major MAPK cascades, their exact function is not completely 
characterized (Shi et al., 2013). However, it is known that the MAPK p38 works as a 
downstream target of Ric, in an anti-apoptotic pathway that also involves Akt, mTor, 
Mef2 and Atg1 (Cai et al., 2011; Bitting & Armstrong, 2013). The suppression of 
DVAP-P58S neurodegeneration caused by the overexpression of Ric suggests that a 
delay in apoptotic responses could protect the cell from protein aggregation or novel 
unknown mechanisms caused by DVAP mutant allele. Furthermore, we found in the 
screen RapGAP1 (Chen et al., 1997), a GAP protein that inactivates RAP and RAS 
proteins, and potentially can be also one of the currently unidentified GAP proteins 
for Ric (Shao et al., 1999; Shi et al., 2013). The fact that we observed suppression by 
a loss of function allele of this protein supports the previous hypothesis. Also, it links 
the RAS signaling with other functional process unveiled in the screen such as 
vesicle trafficking and apoptosis. The relation between Akt and DVAP is known but 
not yet understood (Rao et al., 2012); perhaps the regulation of RAS proteins is the 
link between that previously reported data. 
 
 Other two genes found in the screen are the oncogene Src42 and the kinase 
modulator Cnk. This last protein is involved in the RAS pathway modulating 
antagonistically RAF, the first identified RAS effector (Van Aelst et al., 1993). Cnk 
is essential to RAF activation due to two N-terminal domains, but also presents a 
short C-terminal element, the RAF-inhibitory region (RIR) that avoid the normal 
signaling from RAF to MEK independently of RAS activation (Douziech et al., 
2003). The effect of this region can be suppressed although, by a binding activity of 
Src42 over the C-terminal region of Cnk. The binding of Src42 returns the MAPK 
signaling and therefore, the activation of the initial cascade. Thus, Cnk mediates 
RAF activity from the interaction with signals from RAS and Src42, preventing 
signaling leakage to MEK (Laberge et al., 2005; Douziech et al., 2003). Once again, 
it seems that an overall activation of the RAS pathway is linked with a suppression 
of DVAP-induced neurodegeneration. In this case, we observed that both Src42 and 
Cnk are suppressors with an overexpression allele, which suggests an overall 
188 
downregulation of RAF and its downstream effectors MEK and ERK in cells 
expressing DVAP-P58S. This also implies that in neurodegenerative cells, the RAF 
repressive effect over MST2 is silenced, which would lead to an increase in 
apoptosis. Altough recently was shown that a coordinated balance in the 
phosphorylation state of MST and RAF can switch between apoptosis and cell 
proliferation (Romano et al., 2014). Interestingly, we found in our screen that the 
MST2 ortholog hippo is upregulated in DVAP-P58S neurons, leading to an increase 
in apoptosis as another potential trigger in neurodegeneration. Therefore, DVAP 
regulation of RAS pathways could play a key role in the strict balance between cell 
proliferation and neurodegeneration increase through apoptosis. 
 
 Recently, other studies have linked RAS pathways to neurodegeneration. 
Down-regulation of RAS-MAPK-MSK1 pathway can decrease the levels of ATXN1, 
the causative gene of spinocerebellar ataxia type 1 (SCA1). This down-regulation, 
which can be mimicked pharmaceutically, lead to a suppression of the phenotypes 
associated with the disease (Park et al., 2013). Similar results were obtained in a 
screen for modifiers of huntingtin, the causative gene of Huntington’s disease. 
Down-regulation of the RRAS pathway and its central protein related RAS viral (r-
ras) oncogene homolog, suppress expanded huntingtin-associated neurodegeneration 
(Miller et al., 2012). Both studies were genetic screens that used among other 
systems, Drosophila as a fast way to find important unappreciated pathways. In our 
study, again we obtain similar results that strongly support the use of the model for 
this kind of studies. In our case, further characterisation of DVAP interactions with 
RAS-related proteins could elucidate the mechanisms involved in neurodegeneration 
and other cellular processes affected by these interactions.  
 
 With all these details, it is interesting that in this study we were able to find out 
many genes involved in these signaling pathways. If we consider that proteins and 
regulators can be shared between pathways affecting simultaneously multiple targets 
(Boguski and McCormick, 1994), we can underline that most of the components of 
the RAS-signalling cascade are represented in the screen. We can find the initial 
steps with the Ric protein, its repressor RapGAP and then, the downstream target 
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Rab5 and potentially CG9153, which share commonalities with Alsin. Downstream 
effectors such as Src42, Mef2, Syx7 and 14-3-3ζ expand the mechanistic spectrum 
controlled potentially by DVAP. The additional evidence of the involvement of 
DVAP in endocytosis and lipid metabolism can give us clues about the specific 
function of the protein and changes associated with the ALS-linked mutations. 
 
8.4 Hippo signaling pathway is involved in ALS pathomechanism 
 
The relation between VAP proteins and cell proliferation is a novel and interesting 
research focus that could explain some of the ALS-linked phenotypes. Only recently, 
Rao et al. found an up-regulation of VAPB in metastatic breast tumor tissue that 
could be explained through a link with the modulation of the AKT pathway (Rao et 
al., 2012). For this reason, it is significantly important that from the genetic 
modifiers found in our screen, one of the most represented functional categories was 
cell death. Not only a relevant number of genes from this category were found, but 
also some of them were confirmed by all of our validation tests, strengthening their 
link to VAP biology. 
 
 One of the suppressors found in this project is Hippo, a central component in 
the control of cell proliferation. Hippo is the ortholog of human MST1 and STK3 
serine/threonine kinases (Dan et al., 2001). These human proteins have been 
identified as tumor suppressors, activating apoptosis and decreasing cell proliferation 
as a normal function (Harvey et al., 2003). Activation of apoptosis has also been 
reported with the overexpression of Hippo in Drosophila (Pantalacci et al., 2003). In 
our screen, we found that two loss-of-function lines for this gene strongly suppress 
DVAP-P58S-associated neurodegeneration in the eye and motor performance. These 
results suggest that DVAP-P58S mechanism could be linked to an activation of 
apoptosis, and the loss-of-function of Hippo could block that process, suppressing in 
this way the neurodegeneration. That would be in line with data proposed by Rao et 
al. (Rao et al., 2012), where DVAP-WT functions as an oncoprotein that activates 
the pro-survival AKT pathway. Therefore DVAP-P58S, acting through a loss-of-
function mechanism, would fail to activate pro-survival pathways and could promote 
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instead apoptosis and cell-cycle exit, just as seen with Hippo overexpression 
(Pantalacci et al., 2003). Thus, Hippo loss-of-function, as observed in our study, can 
balance the DVAP-P58S effect by decreasing its apoptotic activity. Further analyses 
in the interaction of these proteins are needed to understand this potential 
mechanism. Considering that the regulation of VAP over AKT is not known, it will 
likely need interaction with other proteins, as VAP does not present any kinase 
activity (Rao et al., 2012).  
 
 Discovered initially in Drosophila, Hippo is the central component of the 
homonymous tumour suppressor pathway (Udan et al., 2003; Pantalacci et al., 2003). 
After receive positive stimulation from different regulators including the 
Decapentaplegic and Wingless gradients, and the cytoskeleton-binding proteins 
Merlin, Expanded and Kibra, Hippo is able to bind the interactor Salvador. This 
complex phosphorylates and activates Warts, which then phosphorylates and inhibits 
the transcription activator Yorkie. This inhibition translate in the down-regulation of 
downstream targets of the pathway such as diap1, cycE, ex and bantam, leading to an 
overall control of the cell growth. A mutation in any gene upstream of Yorkie will 
lead to a constant expression of the downstream targets and an increase in the cell 
proliferation (Zhao et al., 2011). This pathway is highly conserved in humans, where 
the central components of the pathway have been linked to tumour formation and 
cancer. Interestingly, other genetic modifiers found in this study are Syx7/Avl and 
Diap2. The first one is an endocytic neoplastic tumor suppressor gene that regulates 
the same pathway (Robinson and Moberg, 2011). On the other hand, Diap2 and its 
paralog Diap1 are downstream targets of the Hippo pathway (Martin-Belomente & 
Perez-Moreno, 2011). We already reported that DIAP1 up-regulation strongly 
suppresses DVAP-P58S-linked neurodegeneration in the eye (Forrest et al., 2013), 
so this effect is now confirmed with the suppression observed with DIAP2 
overexpression. At the same time, supports the idea of DVAP-P58S causing 
neurodegeneration triggering apoptosis via the Hippo pathway. Additionally, hippo 
ortholog MST2 is a downstream target of the RAF pathway, the previously discussed 
anti-apoptotic pathway highly represented in our screen. Recently, the Hippo 
pathway was strongly associated with DVAP in a study performed by Norbert 
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Perrimon’s group, where using mass spectrometry, DVAP was identified as part of a 
high-confidence Drosophila Hippo protein-protein interaction network (Kwon et al., 
2013). Curiously in this study, vesicular trafficking, a highly enriched category from 
our screen, highlights as one of the best linked functions to the Hippo pathway.  
 
8.5 DVAP interaction with Klar and lipid droplets could, at least in 
part, explain the ALS pathomechanism 
 
VAPB and ALS have been strongly associated with lipid metabolism over the last 
years. A common factor found in ALS patients is the abnormal amount of lipids in 
the blood or dyslipidemia (Turner et al., 2009). Additionally, genes encoding 
proteins involved in lipid metabolism appear to be up-regulated in spinal cords of 
ALS patients (Malaspina et al., 2001). VAPB on the other hand, interacts with 
several lipid related proteins such as CERT, Nir2, OSBP and Sac1 (Kawano et al., 
2006, Amarilio et al., 2005, Ngo and Ridgway, 2009, Forrest et al., 2013). A strong 
factor for the interaction with VAP is the presence in some of these proteins of the 
diphenylalanine in an acidic tract (FFAT) motif. Proteins targeted to the ER and 
nuclear membrane by this signaling motif include the lipid- and VAP-interacting 
proteins CERT and OSBP (Kaiser et al., 2008, Wyles et a., 2002, Kawano et al., 
2006). Interaction between VAP and lipid transport proteins carrying FFAT-like 
motifs such as FAPP-2 supports furthermore the role of VAP in the transfer of lipids 
(Mikitova and Levine, 2012). Moreover, in 2006 Cermelli et al. purified lipid 
droplets from Drosophila embryos and using capillary liquid chromatography-
tandem mass spectroscopy, they detected that DVAP was significantly representated 
in the lipid droplet fraction (Cermelli et al., 2006). Lipid droplets store and supply 
lipids for different cellular processes such as energy metabolism and production of 
molecules derived from lipids (Pol et al., 2014). All the previous evidence provides 
more relevance to the DVAP-modifier genes found in this study, considering that 
Lipid metabolism is a significant functional cathegory, based on Ingenuity Pathway 
analysis, and Lipid Particle is the most enriched Gene Ontology term, according to 
the DAVID database.  
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 One of the components of this functional category found in our screen is 
Klarsicht, a protein that controls lipid droplets and nuclei dynamics (Elhanany-Tamir 
et al., 2012). This gene, functional ortholog of the human Nesprins, presents a 
complex structure and regulation that comprises alternative splicing and different 
promoters (Kim et al., 2013). The different isoforms share an N-terminal region that 
interacts with dynein and kinesin motors. However, the C-terminal region changes 
the different specificity of the protein for different cargos (Vu et al., 2011). The α-
isoform carries a KASH domain that regulates the interaction with the outer nuclear 
envelope. On the other hand, the β-isoform carries a LD domain that binds 
embryonic lipid droplets (Guo et al., 2005). Other 3 isoforms ( ε) are less studied 
but differ in the basic genetic structure, fact that expands even more the biology of 
the protein. In our screen, we identified as a suppressor of DVAP-P58S-toxicity the 
allele Klar
EP3104
. To confirm the effect of this gene we obtained several Drosophila 
tools from Prof. Michael Welte, a well-known expert of this protein. We were able to 
confirm that a loss-of-function effect was responsible for the neurodegenerative 
suppression in the eye and motor performance. We observed the same phenotypic 
effect with the EP line and with the loss-of-function alleles YG3 (that block the 
expression of α and β isoforms) and Klar
1 
(a truncated version of the protein that 
lacks the specific C-terminal domains and therefore, acts as a null allele (Welte et al., 
1998)). More interestingly, we detected that overexpressing the β-isoform produces 
an enhancement of the DVAP-P58S-toxicity in the eye and the rest of nervous 
system, deteriorating viability and motor performance of the tester line. These data 
suggest a strong interaction between DVAP and Klar and a potential common role of 
these proteins in ALS pathogenesis, likely mediating nuclei and lipid droplets 
dynamics.  
 
 Recently, other lipid droplet-associated proteins have been linked to motor 
neuron diseases. Mutations in the genes SPG20 and Seipin are associated with motor 
neuron disorders and misregulation of lipid droplets metabolism (Bakowska et al., 
2007; Yagi et al., 2011). Additionally, these particles are associated with other 
neurodegenerative diseases like Parkinson’s, where disease-linked mutant α-
synucleins appear to lose its normal relocalisation from cytosol to lipid droplets, 
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altering at the same time the wild type metabolism of triglycerides in this organelle 
(Cole et al., 2002). Klar-DVAP interaction can also explain changes in nuclei 
distribution that is associated with different disorders. Klar loss-of-function alleles 
produces nuclei mispositioning, an effect already involved in myopathies 
(Puckelwartz et al., 2009, Zhang et al., 2007). This suggests that Klar mutants can 
potentially be linked to other disorders as well, such as DVAP-mediated ALS. 
Further analysis of DVAP/Klar interaction, their relation with lipid droplets and 
nuclei dynamics, and their involvement in ALS-associated phenotypes would prove 
pivotal to understand the possible pathomechanism of the disease. 
 
 Klarsicht was only one of the eight proteins associated with lipid metabolism 
discovered in this study. Rdgbβ, Acsl and IP3K1 are linked to several steps of lipids 
and phosphoinositides production. As previously mentioned, the metabolism of 
phosphoinositides is already central in DVAP biology and the mechanism in which 
these genes are associated with it could clarify furthermore the currently known 
mechanism. For instance, human homologues of Acsl are associated with the 
formation of lipid droplets in the ER (ACSL3, Poppelreuther et al., 2012) and to the 
axonal transport of synaptic vesicles (ACSL4, Liu et al., 2011). On the other hand, 
Ero1L is another protein linked to lipids that works as a oxidoreductase in the ER 
and that has been associated with inositol 1,4,5-triphosphate receptor activity acting 
in the Ca
++
 release in the ER via unfolded protein response (UPR) (Li et al., 2009). 
Curiously, this protein is a known physical interactor of DVAP (Guruharsha et al., 
2009) and is involved in the DVAP-linked pathway Notch (Tien et al., 2008). Even 
though some of these data would imply a strong connection between these players, 
there is not a known mechanism to link them with the observed phenotypes. The 
participation of DVAP and these lipid-realted proteins to ALS pathomechanism is a 






8.6 DVAP-P58S modifier genes are correlated with MSP secretion 
mechanism 
 
In 2008, Tsuda et al. reported that MSP fragment of VAPB is cleaved, secreted and 
binds to Eph receptors (Tsuda et al., 2008). Using Drosophila and C. elegans they 
also showed that the presence of the ALS-linked mutation P56S suppresses the 
cleavage and promote ubiquitination and aggregation of the protein. Following 
works supported this model and associated the MSP secretion to mitochondria 
localisation (Han et al., 2012) and energy metabolism in adult survival (Han et al., 
2013). At the moment some key aspects of this theory have not been completely 
elucidated, like specificity of the biochemical assays or validation in human patients. 
However, this model exhibits some interesting notions of a possible DVAP 
pathomechanism and more interestingly, a functional relevance of the ALS-linked 
mutation. In the present study, we found a group of DVAP-toxicity modifiers that are 
related with the MSP secretion hypothesis and that could provide further clues to 
understand this mechanism. 
 
 From our screen, five modifiers codify proteins that support this hypothesis. 
We found Leak, a gene that encodes a protein associated with axon guidance and that 
is part of the receptor family Roundabout (Schimmelpfeng et al., 2001). Han 
proposed that MSP binds to the Eph receptor Lar to stabilise the mitochondria. Also, 
it can bind to Leak to block Lar activation. C. elegans VAPB mutants have 
mitochondrial defects, which are suppressed by the inactivation of Lar (Han et al., 
2012). This also may be achieved by the activation of Leak, which can explain the 
suppression of the DVAP-P58S toxicity by the overexpression of Leak that we 
observed in our screen. Additionally, the ARP2/3 complex plays a central role in the 
mitochondria stabilisation. This highly conserved complex is the key nucleator for 
the actin cytoskeleton, binding existing actin filaments to form daughter filaments. In 
this way, ARP2/3 complex regulates motility, cytokinesis and endocytosis (Rotty et 
al., 2013). Interestingly, we found that two genes involved in the actin nucleation 
process were part of the DVAP-modifier list. HSPC300 is one of the five proteins 
that support ARP2 and ARP3 proteins in the complex that initiate actin nucleation, 
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playing a reported role in axonal and NMJ architecture as well (Qurashi et al., 2007; 
Rotty et al., 2013). We also found Act42A, a gene that encodes for one of the six 
Drosophila actin isoforms (Fyrberg et al., 1981), each of them probably with a 
different specialized function (Jacinto & Baum, 2003). Curiously, the ARP2/3 
complex was originally identified as an interacting factor for Profilin, an acting-
binding protein that recently was associated with ALS after mutations in the gene 
encoding this protein were found in several ALS kindred (Machesky et al., 1994; Wu 
et al., 2012). Further studies in the interaction between DVAP with HSPC300, 
Act42A, and Leak can provide more support to the potential non-autonomous effect 
of the MSP domain. 
 
 However, possibly the most interesting modifier related with MSP secretion 
unveiled in the screen is the protease Rhomboid. Part of one of the four families of 
transmembrane proteases, rhomboid is present in all branches of life including 
endosymbiotic organelles (Urban & Dickey, 2011). It was firstly described in 
Drosophila as the activator of Spitz, a ligand of the epidermal growth factor (EGF) 
receptor (Sturtevant et al., 1993). Therefore, rhomboid plays a central role in early 
developmental stages, hydrolyzing peptide bonds inside the cell membrane (Urban et 
al., 2001). In human cells, the activity of rhomboid activity has been associated with 
cancer cells, probably related with Growth factor signaling (Etheridge et al., 2013).  
 
 The rhomboid catalytic site includes four conserved residues responsible for 
the specific serine-cleavage. Some proteins lack the catalytic domain but still 
maintain the protein structure, therefore are called rhomboid protein (no proteases) or 
iRhom, and have been associated with endoplasmic reticulum-associated degradation 
of proteins (Christova et al., 2013). In Drosophila, Rhomboid is located in the Golgi 
and initiates neighboring cell pathways cleaving Spitz. The peptide obtained from 
Spitz cleavage is then secreted to activate EGF pathway in other cells. This process 
can be a common mechanism for other proteins that could use the Rho-Spitz 
pathway to express its information in an EGF-like way (Urban & Dickey, 2011). 
Interestingly, this is highly reminiscent to the VAPB secretion proposed by Tsuda. 
Secreted MSP domain of VAPB binds to Eph receptor in the neighbour cells, 
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controlling in this way energy metabolism (Tsuda et al., 2008, Han et al., 2012). 
Despite the confirmation of this secretion and its link to a non-cell autonomous effect 
in the ALS pathogenesis (Han et al., 2013), proteases in charge of the cleavage of the 
MSP domain have not been found yet. 
 
 Rhomboid active site is positioned in the lipid bilayer of the cell membrane and 
recognises a specific sequence in the transmembrane domain of the target proteins. 
Previously it was described that a helix-destabilising residue is necessary to be part 
of the transmembrane domain, but these residues were necessary only if the sequence 
is in the transmembrane domain and not if the sequence is outside of it (Strisovsky et 
al., 2009). Considering these parameters, we can observe that VAPB aminoacid 
sequence presents a 25 residue long region in its transmembrane domain that 
potentially can be cleaved by rhomboid, fitting the proposed consensus sequence. A 
potential cleavage of VAPB in this region would lead to a release from its membrane 
localisation and fit with the secretion hypothesis. This is even more possible if we 
consider previous co-expression (Weber et al., 2008) and physical interaction data 
(Guruharsha et al., 2011) that link VAPB and Rhomboid. 
 
 The authors of the MSP hypothesis finally proposed that ALS-linked mutation 
inhibits MSP secretion, due to an increased protein accumulation and UPR activation 
that potentially decreases the amount of VAPB-MSP available to be cleaved. This 
lack of signaling in neighbour cells might affect mitochondrial localisation and 
muscular morphology of patients (Tsuda et al., 2008, Han et al., 2012).  In this 
situation, an overexpression of the protease rhomboid could increase the amount of 
secreted MSP, suppressing the VAPB-P56S-linked toxicity. Indeed, this is the 
situation observed in our screen. The result suggests that further experiments with 
these two proteins such as site-directed mutagenesis and localisation studies, could 
potentially confirm that rhomboid plays an important role in DVAP mechanism. At 
the same time, this mechanism fits with the effect of the other modifiers found in the 
screen, located all of them downstream the MSP signaling. A decrease in Lar activity 
caused by an overexpression of Leak or a change in the stability of the ARP2/3 
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complex could lead to an improved mitochondrial stabilisation and suppression of 
VAPB-linked phenotype.  
  
8.7 Ubiquitin-mediated protein clearance is confirmed as a DVAP-
linked relevant process  
 
In parallel to uncover unexpected pathways associated with DVAP pathogenesis that 
we have discussed previously, it was important for this study to find genes and 
pathways already associated with ALS and VAPB function, such as MSP-domain 
secretion and protein degradation (Tsuda et al., 2008; Lev, 2008). Together with 
autophagy, the ubiquitin-proteasome system is the main pathway to degrade non-
functional proteins in the cell (Ravid & Hochstrasser, 2008). In a normal cellular 
state, proteins must be properly folded to reach their final destination in a process 
regulated by proteins already linked to ALS (Blokhuis et al., 2013). When this 
process is not perfectly performed, proteins are normally degraded by the ubiquitin-
proteasome system (UPS). This system selectively tags proteins with an ubiquitin 
molecule, which are degraded by the proteasome. This ubiquitination process is 
mediated by three enzymatic classes: E1 activating enzymes bind and activate the 
inert ubiquitin molecule that is then transferred to an E2 ubiquitin conjugating 
enzyme. The final step is carried out by an E3 ubiquitin ligase that finally transfer the 
ubiquitin molecule from the E2 enzyme to the protein tagged for degradation (Ravid 
& Hochstrasser, 2008). When this process fails and proteins are not degraded 
immediately, the unfolded protein response (UPR) is activated. This ER-stress 
response is composed by three pathways, which central components are the 
transcription factors XBP-1 and ATF6 and the PERK kinase. These molecules 
activate chaperones and proteins involved in ER-degradation (Ron & Walter, 2007). 
Interestingly, DVAP has been previously associated with this response. The 
overexpression of VAPB-WT promotes UPR after an increased production of XBP1 
mRNA was observed in cell culture (Kanekura et al., 2006). On the other hand, the 
MSP domain of VAPB interacts and negatively modulates ATF6 activity, in a 
process that could involve membrane trafficking and ATF6 traslocation disruption 
(Gkogkas et al., 2008). 
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 In our genetic screen we found different genes involved in these processes. 
Three different genes associated with UPS’s last step were found. Cul-2 is part of the 
Cullin family of molecular scaffolds that organise RING-E3 ubiquitin ligases. 
Including hundreds of components, this family is the largest ubiquitin ligase class, 
becoming one of the most important post-translational protein regulators (Petroski & 
Deshaies, 2005). Another DVAP-modifier is Su(Var)2-10, which human ortholog is 
E3 SUMO-protein ligase PIAS1, working as well as a transcriptional co-regulator 
(Liu et al., 1998). A previously discussed gene is CG9153 that encodes the ortholog 
of HERC4. This protein carries a HECT E3-ligase domain that also binds an 
activated ubiquitin molecule to target proteins for degradation (Hochrainer et al., 
2004). Finally, the gene CG4502, a suppressor from our screen, exhibits sequence 
similarities to E2 ubiquitin ligases, as predicted by InterPro. Considering that we also 
found as a DVAP-toxicity suppressor the essential autophagy gene Atg7, which 
shows functional homology to E1 activating enzymes (Rabinowitz & White, 2010), 
it is fair to say that protein degradation genes are strongly represented in our screen, 
which supports previous findings linking this process with DVAP and ALS. 
Therefore, the potential connection between these DVAP-interactors and other 
known molecules involved in protein degradation can provide missing pieces of 
information to completely understand this pathway. 
 
8.8 Energy metabolism may play an important role in ALS 
pathogenesis 
 
SOD1 was the first gene associated with familial cases of ALS (Rosen et al., 1993). 
As a result in the last two decades, a strong linkage has been found between ALS 
cases and mitochondria. In the last years, SOD1 models have failed to support any 
consistent mechanism but also, gene penetrance in patients has decreased in this 
period, explained in part by the discovery of C9orf72 as a main cause (Robberecht & 
Phillips, 2013). In the same time frame however, increasing evidence have linked 
VAPB with mitochondria defects, suggesting that mitochondria and energy 
metabolism can still be a central feature of ALS. 
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 This fact is connected with the previously discussed MSP secretion, 
considering that VAPB affects anterograde mitochondrial movement in axons, 
increasing cytoplasmic Ca
++
 and affecting mitochondrial docking to tubulin (Morotz 
et al., 2012). Additionally, VAPB interacts with mitochondrial membrane protein 
PTPIP51 in its junction with ER, regulating the mitochondrial uptake of Ca
++ 
from 
the ER stores. ALS-linked mutation VAPB-P56S disrupts VAPB-PTPIP51 
interaction, increasing the mitochondrial uptake of Ca
++ 
(De Vos et al., 2012). The 
connection of these interactions with the mitochondrial stabilisation proposed by Han 
(Han et al., 2012), suggest an active role of VAPB in mitochondrial homeostasis.  
 
 In the present study we found novel DVAP genetic interactors that regulate 
mitochondrial metabolism. Mtch is one of the genes that enhance DVAP-P58S 
phenotype. This protein is the receptor of tBID, a BCL2 protein that promotes the 
oligomerisation of Bax in the outer membrane of the mitochondria (Zaltsman et al., 
2010). This oligomerisation is related with the mitochondria fission, release of 
cytochrome C and activation of apoptosis. Mtch loss-of-function alleles are less 
effective to recruit tBID, protecting in this way the mitochondria from fission 
(Zaltsman et al., 2010). The novel overexpression phenotype observed in our screen 
suggests that a possible activation of mitochondrial apoptosis could enhance DVAP-
P58S neurodegeneration by a still-unknown mechanism.  
 
 Important connections can be made by this protein and other apoptosis/cell 
death genes associated with this and other studies. From our set of genes, draper and 
Atg7 are related to mitochondrial shape and cell maintenance. Changes in 
mitochondrial membrane and death of this organelle require a cleaning process 
activated by these two proteins that lead to the formation of the autophagosome and 
its fusion with the lysosome (McPhee et al., 2010). VAPB-induced aggregates or 
even a loss of function of this protein at initial stages of the cleaning process would 
affect the final recycling of the dead cellular components. In our study, the 
overexpression of these two proteins suppresses the DVAP-induced toxicity, 
suggesting that a decline in the autophagy process could be related with DVAP 
effect. At the same time, they would work in an opposite direction of Mtch; an 
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increase in mitochondrial apoptosis or a decrease in autophagy would lead to a 
worsening of DVAP-induced phenotype. This would still be valid if the effect of 
mutant DVAP triggers mitochondrial death; the delay of this step or the increase of 
the recycling of cellular debris would ameliorate the toxicity in the cell. To prove 
this mechanism is not only necessary to confirm whether this effect is specifically 
due to an interaction with DVAP, but also to analyse the possible relation of other 
downstream targets of this mechanism and previously discussed pathways such as 
lipid and vesicle metabolisms.  
 
8.9 Future perspectives 
 
Throughout this project we have identified 85 novel modifiers of DVAP-P58S 
neurodegeneration. Potentially, an important number of them may be involved in 
ALS pathology and could link some of the unconnected known disease’s 
mechanisms. We have not only found these genes analysing neurodegeneration in 
Drosophila eye, but also tested changes in the motor performance and confirmed 
these results with independent alleles. These experiments lead us to propose the list 
of genes as bona fide candidates to understand ALS mechanism in a clear way and 
furthermore, to point these novel modifiers as initial steps for identifying possible 
therapeutic targets. Surely, further studies are mandatory to prove the previous 
sentence, but the encouraging results support in a good way these future analyses. 
 
 To the previous reports linking VAPB to important neurodegenerative 
processes, we can now add a consistent and relevant list of genetic interactors that 
support furthermore the role of VAPB in these processes. We can propose a potential 
mechanism where all these novel interactors support DVAP function inside the cell, 
and the loss of function of tis protein through the formation of DVAP-P58S-induced 
aggregates disrupts the vital processes that finally lead to neurodegeneration (Figure 
34). Previously discussed function of DVAP in the cell include regulation of 
endocytic traffic, lipids and nucleai dynamics, energy metabolism and cell 





Figure 34. Proposed mechanisms involved in DVAP neurodegeneration.        
(A) Molecular pathways associated to DVAP activity in a normal cellular state. The 
correct function of this protein (green) plays an important role on regulation of 
endocytic traffic, lipids and nucleai dynamics, energy metabolism and cell 
proliferation (white boxes). Genetic interactors found in the current project (yellow) 
are integral part of these pathways. (B) Protein aggregates caused by the presence of 
DVAP-P58S (red) disrupt the described pathways leading to an overall toxicity in the 
cell. Lack of endocytic particles, lipid and nucleai trafficking are related to 
neurodegeneration that is increased by the upregulation of pro-apoptotic signaling 
and failure in the energy production, mitcohondria stabilization and actin ncuelation. 
The overexpression of the DVAP-genetic interactors (yellow) could overcome at 
least one of these degenerative pathways and delay cell death. Toxicity suppression 
could be achieved decreasing the amount of DVAP-P58S aggregates formed, their 





project (yellow nodes in Figure 34) could be sufficient to restore the normal cellular 
balance previously disrupted by DVAP aggregation. However, we still need to prove 
most of these connections and confirm that the genetic interaction just found can 
determine the final output of these pathways. 
 
 Originally, this study was supposed to cover the whole genome, which includes 
additional non-tested lines from the first and third chromosome of Drosophila. A 
better characterisation of the obtained results so far led us to hold on the progress of 
the screen and analyse the relation between the novel modifiers. This point is 
relevant as this project must be continued to cover completely the spectrum of 
DVAP modifiers and in this way, fill the potential gaps in the mechanisms discussed 
before. Undoubtedly, our progress to this date is important enough to start working 
on specific genes and pathways already. However, further screening of the remaining 
764 potential overexpression lines from the analysed collections will provide a 
complete map of DVAP mechanisms in neurodegeneration. 
 
 The genetic modifiers discovered in this project are interacting with DVAP to 
modify neurodegeneration in our model. It would be relevant and equally useful to 
test these interactors with other ALS or MND causative genes. As previously 
discussed, some of these causative genes are already modeled in Drosophila, with 
similar neurodegenerative phenotypes to the DVAP-P58S model (Watson et al., 
2008; Bahadorani et al., 2013; Li et al., 2010). Therefore, it would be interesting to 
check whether DVAP-P58S modifiers also suppress the toxicity caused but 
mutations in TDP-43, SOD1, SMN, and C9orf72-based models in Drosophila. In the 
same way, with further collaboration with human ALS tissue centers, it would be 
attractive to analyse whether any of the 85 modifiers is misregulated in tissues from 
patients with ALS in the same way we observed for human RAB5. The success in 
these assays not only will advance the understanding of ALS pathomechanism, but 
also could help to explain the neurodegeneration observed in several patients with 
sporadic ALS that are not associated with any known causative gene. 
 
203 
 Another important perspective for this work involves the novel ALS-linked 
VAPB mutation V234I. Last year, in a parallel project to this screen, we were able to 
model and characterise the Drosophila version of this mutant, V260I (Sanhueza et 
al., 2013; Appendix of this study). This work yielded interesting and surprising 
results, specifically the confirmation of this mutation as a gain-of-function, as 
compared to the loss-of-function mechanism observed in DVAP-P58S. It will be 
important to observe the DVAP-V260I associated phenotypes under the effect of the 
DVAP-P58S genetic modifers found in this screen. These phenotypes include protein 
aggregation, activation of stress response and synaptic and nuclear abnormalities. 
The comparison between the modifier effects of a specific gene in the two VAPB 
mutant alleles can provide additional clues to explain the mechanism of VAPB 
neurodegeneration. 
 
 Lipid particles and metabolism became one of the most relevant functions 
found in this project. The relation between DVAP and the lipid-related protein Klar 
is being currently studied by our group. It will be necessary to confirm the levels of 
interaction between the two proteins and the way they associate in the lipid particles. 
Also it would be interesting to study their relation in the control of myonuclei and 
neuromuscular junction structure, which it seems to be highly regulated by their 
interaction. The way in which these proteins control membrane dynamics and their 
connection to vesicle recycling, could represent one of the strongest findings of this 
study. 
 
 Finally, another interesting topic found in this study is cell proliferation and 
cancer. The connection between DVAP and Hippo is a particularly interesting one, 
especially considering the biochemical nature of Hippo that makes it a perfect target 
for therapeutic studies involving activity modulation by chemicals and drugs (Pan, 
2010). The use of our ALS model in a screen that search for chemicals able to 
modulate the activity of DVAP-modifiers like Hippo, could represent a great 
opportunity to understand in a deeper way ALS pathogenesis and translate these 
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Appendix: Gain-of-function mutations in the 
ALS8 causative gene VAPB have detrimental 
















 Patients with mutations in the ALS8-causative gene VAPB were found first in 
Brazil ten years ago (Nishimura et al., 2004) and later in United Kingdom (Chen et 
al., 2010). These mutations, P56S and T46I respectively, were present in the MSP 
domain of VAPB, a highly conserved domain across the evolution (Lev et al., 2008). 
Recently, a third VAPB mutation was found in an ALS patient that also carries an 
expansion in the causative gene C9orf72 (van Blitterswijk et al., 2012). This novel 
substitution, not found in a large number of healthy subjects, was located this time in 
the conserved transmembrane domain, which plays an important structural function 
compared to the conserved VAPB-MSP domain (Appendix figure 1). No information 
was available about the genetic background and characteristics of this mutation. 
Moreover, a contradictory study refuted the proposed toxicity of the mutation (Ingre 
et al., 2013). To understand the function of this mutation and observe the phenotypes 
associated with it, we constructed a Drosophila model expressing the ortholog of this 
novel mutant in flies, DVAP-V260I. 
     
 To examine the effect of the DVAP-V260I mutation in the presynaptic 
neurons, we expressed this transgenic allele under the control of the panneural driver 
elav-GAL4. Neuromuscular junctions (NMJs) stained with the neuronal marker anti-
horseradish peroxidase antibody (α-HRP) were analysed counting the number and 
size of boutons and were compared to controls. Expression of DVAP-V260I 
produced a significant increase in the number of boutons compared to controls 
(514±3 versus 272±2, P<0.001) and a clear decrease in the size of the boutons 
(Appendix figure 2). Interestingly, this phenotype is exactly the opposite of the one 
observed in the ALS-linked mutants DVAP-P58S and DVAP-T48I, but is similar to 
the one observed in the overexpression of the wild-type form of the protein (Chai et 
al., 2008; Chen et al., 2010; Pennetta et al., 2002). For this reason we studied the 





, a stronger one. We observed similar effects in these two 
overexpressing lines, although the effect in DVAP-V260I was more severe 












Appendix figure 1. Identification of the V234I/V260I mutation on VAP proteins. 
(A) Predicted functional domains in hVAPB: a transmembrane domain (blue) at the 
C-terminus, a coil-coiled domain (brown) in the middle and a domain (green) at the 
N-terminus showing a significant homology to the nematode major sperm protein 
(MSP). The Val234 residue (indicated by an arrow) is located within the 
transmembrane domain and it has been replaced by an Isoleucine in a patient with 
ALS. (B) High degree of conservation of the transmembrane domain in VAP 
proteins from different species. (C) Sequences of human VAPB (hVAPB) protein 
and its Drosophila orthologue DVAP were aligned by using the ClustalW version 
1.82 alignment program available from EMBL–EBI. Asterisk indicates an identity 
match; colon indicates conservation between amino acids with strongly similar 
properties (scoring >0.5 in the Gonnet PAM 250 matrix) and period indicates a 
conserved substitution between amino acids with weakly similar properties (≤0.5 in 
the Gonnet PAM 250 matrix). Red boxes highlight the amino acid residues changed 
by the ALS8 causing mutations identified so far. The Drosophila protein (DVAP) 





















Appendix figure  2. Synaptic boutons are smaller, more numerous and 
clustered at NMJs expressing either DVAP-V260I or DVAP-WT transgenes. (A) 
Representative images of muscle 12 NMJs from abdominal segment 3 labeled with 
an antibody against HRP. Scale bars: 10 um. (B) Illustration of the synaptic 
overgrowth phenotype at HRP-stained NMJs of the indicated genotypes. In all panels 
arrows indicate satellite boutons. Scale bars: 10 um. (C) Quantification of the total 
number of boutons at muscles 12 and 13 of abdominal segment 3 and (D) 
quantification of satellite boutons at muscles 6/7 of the abdominal segment 3 for 











 These three lines presented in their NMJs many small boutons that bud off 
from central boutons of the synapses. This phenotype, not observed in controls, was 
previously associated with overgrowth synapses (Torroja et al., 1999; Franco et al., 
2004). Quantification of these satellite boutons in the three transgenic lines resulted 
in a significant increase compared to control NMJs (Appendix figure 2D), although 
the effect in DVAP-V260I expressing larvae was stronger (2.6 fold compared to 





, respectively). To discard that these previous phenotypes are due to 
changes in the amount of protein produced, we quantified the amount of DVAP 
present specifically in NMJs of larvae expressing the three constructs. Again, these 
alleles presented an opposite effect to DVAP-P58S and loss-of-function lines, where 
DVAP is observed in aggregates in the nerve and completely absent from the 
synapses (Appendix figure 3). Overexpression lines show a homogenous distribution 
in the NMJ, with higher concentration than controls. Interestingly, the levels in 
DVAP-V260I and DVAP-WT
1
 are similarly lower (1.7 and 1.8 fold higher than 
controls respectively) than the strong DVAP-WT
2
 line (2.2 fold higher). The milder 
phenotype observed in DVAP-WT
1 
compared to DVAP-V260I, even though they 
present a comparable amount of protein, suggests that the DVAP-V260I mutant allele 
acts as a hypermorphic allele in the production of an overgrowth synaptic phenotype. 
 
 Overgrowth phenotype in the Drosophila NMJ has been also associated with 
increase in number of satellite boutons and microtubule loop formation (Franco et 
al., 2004). Changes in microtubule architecture were studied in DVAP transgenic 
lines staining larvae NMJs with the marker for neuronal microtubule and MAP1B 
homologue, Futsch (Roos et al., 2000). The increase in the number of microtubule 
loops compared to controls was higher in the larvae expressing DVAP-V260I than in 
both lines over-expressing the wild-type allele (Appendix figure 4). The opposite 
effect observed in DVAP-P58S and loss-of-function lines, where futsch staining 
appears splayed and punctuated, is also associated with the changes in the synaptic 
boutons structure previously mentioned. This indicates that overexpression of DVAP-
V260I and DVAP-WT affects the microtubule architecture with repercussion in the 









Appendix figure 3. Synaptic levels of DVAP in different genetic contexts.                 





, (E) elav;DVAP-P58S NMJs stained with antibodies specific for 
DVAP and for anti-HRP. Scale bars: 10 um. (F) Quantification of synaptic DVAP 
intensity for the reported genotypes. DVAP fluorescence intensity is presented as a 
relative ratio of fluorescence intensity values of DVAP against those of controls. 
Note that in DVAP-P58S transgenic line aggregates are evident in the terminal part 
of the nerve (arrow in panel E) and the endogenous protein at the synapse has 
decreased to about 66±4% of the control value. Conversely, compared to controls 
DVAP levels at the synapse are significantly increased in all the other transgenic 
lines (P<0.001 in all cases). However, upregulation of DVAP levels in neurons 
expressing DVAP-V260I is comparable to that induced by the DVAP-WT
1
 transgene 
(P>0.05) and significantly lower than that associated with the strongest DVAP-WT 





















Appendix figure 4. Expression of either DVAP-V260I or DVAP-WT transgenes 
in neurons affects synaptic microtubule cytoskeleton. (A) Representative images 
of branches of NMJs of third instar elav-Gal4/+ control larvae, (B) elav;DVAP-
V260I, (C) elav;DVAP-WT
1
 and (D) elav/DVAP-WT
2
 larval NMJs labeled with 
antibodies against Futsch to show microtubule loops. Arrows in every panel indicate 
examples of Futsch loops. Scale bars: 10 um. (E) Quantitative assessment of Futsch-
positive loops at A2 and A3 muscle 4 NMJs for each indicated genotype. The highest 
increase in the percentage of boutons exhibiting looped Futsch staining (relative to 
the total number of boutons for each NMJ) was observed when DVAP-V260I was 














 To study whether DVAP overexpression also affects striated muscles, we 
expressed the alleles under the control of the muscle-specific driver BG57-GAL4. In 
controls, DVAP exhibit a signal throughout the muscle but in the three 
overexpression lines DVAP-immunopositive inclusions are observed (Appendix 
figure 5). This phenotype was confirmed with brain stainings from the same flies that 
also presented DVAP-associated inclusions (Appendix figure 6). Then, we analysed 
muscle nuclei morphology with the purpose of study whether nuclear defects are 
present in ALS as observed in Parkinson’s disease (Liu et al., 2012). Control NMJs 
present evenly spaced nuclei but in mutant lines they appear closely associated with 
tendency to form clusters (Appendix figure 5). Measurements of these samples show 
that in mutant lines, nuclei are not only closer but also longer and bigger than 
controls, indicating that DVAP overexpression affects neurons and muscles as well, 
with changes in size and positioning of nuclei. Curiously, DVAP-V260I 
overexpressing muscles presents DVAP signal predominantly inside the nucleus, a 
translocation previously associated with increased neurodegeneration in Parkinson’s 
disease (Kontopoulos et al., 2006). 
 
 Accumulation of protein aggregates has been associated in ALS and other 
diseases with upregulation of chaperone proteins and their relocation to the nucleus 
as a cellular response to stress (Vabulas et al., 2010). We observed indeed that lines 
overexpressing DVAP alleles presented an increase in the accumulation of puncta 
immunoreactive to Hsp70 compared to control striated muscles (Appendix figure 7). 
Moreover, in muscles from flies expressing DVAP-V260I, Hsp70-positive signal was 
located mostly inside the nucleus, but in the two overexpressing wild-type alleles, the 
signal still can be observed partially cytoplasmic, with a lower signal inside the 
nucleus. These data suggest that DVAP overexpression triggers stress response 
mediated by heat-shock proteins with intensity proportional to the toxicity of the 
protein.  
 
 To analyse whether all these evidence are correlated to human hallmarks of the 
disease, we studied the phenotype of adult flies overexpressing DVAP panneurally. 




Appendix figure 5. Postsynaptic expression of either DVAP-V260I or DVAP-
WT transgenes results in aggregate formation and changes in nuclear shape, 
size and positioning. (A) Third instar larval NMJs of BG57-Gal4/+ control, (B) 
BG57;DVAP-V260I, (C) BG57;DVAP-WT
1
 and (D) DVAP-WT
2
;BG57 NMJs 
expressing the indicated transgene in muscles were labeled with antibodies specific 
for DVAP and lamin. Nuclei were visualized with the nuclear specific marker TO-
PRO3. (E) Quantification of the distance, (F) circularity and (G) volume of nuclei in 
randomly selected muscles for each indicated genotype. Sectioned volume 





;BG57 (K). Scale bars: 10 







Appendix figure 6. Expression of DVAP-V260I and DVAP-WT transgenes in 
neurons leads to aggregate accumulation and disruption of nuclear architecture. 





 larval brains expressing their respective transgene 
in neurons were immunostained with antibodies specific for DVAP and Lamin. 






Appendix figure 7. Upregulation and subcellular relocalization of Hsp70 in 
striated muscles overexpressing either DVAP-V260I or DVAP-WT constructs. 
(A) NMJs of BG57-Gal4/+ control larvae and (B) BG57;DVAP-V260I, (C) 
BG57;DVAP-WT
1
 and (D) DVAP-WT
2
;BG57 larvae expressing their respective 
transgene were immunolabeled with antibodies specific for DVAP and Hsp70 while 








transgenic lines compared to controls, with a more severe effect in DVAP-V260I 
expressing flies (Appendix figure 8).  Beside this effect, eclosed flies display 
postural and locomotion defects, including droopy and held-up wings (Appendix 
figure 8B-D) and overall uncoordination that led to adult flies to die stucked to the 
food. When we analysed the eyes of adult flies expressing DVAP transgenes, 
neurodegeneration was also observed. DVAP-V260I expressing flies displayed a 
rough and smaller eye compared to controls (Appendix figure 9), phenotype also 
observed in both DVAP-WT lines but in a lower degree. This neurodegeneration was 
confirmed with stained frontal sections of the internal structure of the eye, where 
photoreceptor disruption and vacuolisation was present in the three lines. These data 
indicate that DVAP-WT triggers neurodegeneration, with a more efficient effect 
from the DVAP-V260I allele. 
  
 The novel V234I mutation found in an ALS patient is located in the 
transmembrane domain of the protein, as compared with the two previous MSP-
located VAPB mutations, P56S and T46I. This could translate in potential effects in 
important VAPB functions such as its interaction with the phosphoinositide 
phosphatase Sac1 and the ER-Golgi recycling protein YIF1A, both involved in 
dendritic and synaptic remodeling (Forrest et al., 2013; Kuijpers et al., 2013a). Here, 
we have linked the expression of DVAP-V260I to known human hallmarks but also 
to phenotypes never observed previously in the disease. Altered nuclear spacing has 
been related in other neurodegenerative diseases and myopathies before (Liu et al., 
2012; Puckelwartz et al., 2009), but here we observed for the first time its correlation 
with the overexpression of more aggressive alleles of DVAP. Even though we 
observed pyknotic nuclei, classical hallmark of apoptosis, these are not present when 
nuclear phenotypes are already visible. Furthermore, nuclear mislocalisation could 










Appendix figure 8. DVAP-V260I and DVAP-WT overexpressors display 
reduced viability and wing postural defects. (A) Eclosion rate of flies of the 
designated genotype. (B) elav-Gal4/+ control flies with a dorsal wing posture. (C) 




















Appendix figure 9. Expression of either DVAP-V260I or DVAP-WT transgenes 
in adult Drosophila eyes induce neurodegeneration. (A) Stereomicroscope images 
of ey-Gal4/+ control eyes and eyes of the indicated genotypes. (B) Frontal sections 
of control and transgenic eyes of the indicated genotypes stained with H&E. White 
arrows point to vacuoles in photoreceptors while the black arrowheads indicate areas 
of extensive tissue degeneration. (C) Quantification of the eye surface area of every 














 As previously characterised for DVAP-P58S and DVAP-T48I, the expression 
of DVAP-V260I in flies represents a solid model for the study of neurodegeneration. 
In this study, we observed three main phenotypes associated with its expression. 
Firstly, synaptic remodeling is a clear consequence of the overexpression of the three 
studied alleles with a greater effect in flies expressing DVAP-V260I. These 
phenotypes are opposite to the ones observed in DVAP-P58S, supporting the idea of 
a gain-of-function in the novel mutation. Secondly, the presence of DVAP-linked 
protein aggregates is not only observed in DVAP-P58S but also in other 
neurodegenerative diseases. This prion-like behaviour is increased with a protein 
overexpression (Eisele, 2013) and in this case, we noted that DVAP acts in this way, 
with an overexpression of the protein as sufficient stage to trigger prion-like 
aggregation of the protein. Finally, the presence of DVAP signal inside the nucleus 
of flies expressing the DVAP-V260I allele resembles what has been observed in 
Parkinson’s disease (Kontoupoulos et al., 2006). The neuroprotective effect of the 
histone deacetylase inhibitors against α-synuclein can provide innovative therapeutic 
alternative to ALS, considering that these inhibitors also decrease toxicity in ALS 
mouse models (Yoo and Ko, 2011). These three phenotypes associated with DVAP-
V260I expression support the novel gain-of-function mechanism and highlight the 
strong dose-dependence of the phenotypes. Considering the previous loss-of-function 
mechanism associated with DVAP-P58S, a double mechanism seems probable as the 
one observed in SMN (Blauw et al., 2012). This double mechanism, however, would 
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